The 2026 Post-GLP-1 Skin Laxity Forecast: Treatment Demand and Modality Shifts for Clinical Directors

8/29/2026 53,905 words 270 min read

This comprehensive report examines The 2026 Post-GLP-1 Skin Laxity Forecast: Treatment Demand and Modality Shifts for Clinical Directors through extensive research and analysis.

Key Research Takeaways

• Comprehensive Analysis: This report covers all major aspects of The 2026 Post-GLP-1 Skin Laxity Forecast: Treatment Demand and Modality Shifts for Clinical Directors

1. Executive Summary

The field of aesthetic medicine is undergoing a substantial transformation, driven by the increasing adoption of Glucagon-Like Peptide-1 (GLP-1) receptor agonist medications for weight loss. These powerful drugs, initially developed for diabetes management, have proven highly effective in promoting significant body weight reduction. While offering considerable health benefits, this rapid and substantial weight loss frequently leads to new aesthetic concerns, primarily skin laxity and volume loss. Clinical directors and aesthetic professionals must understand the scale of this demographic shift, the specific aesthetic issues presented by these patients, and the resulting changes in demand for various treatment modalities. This section provides an overview of the 2026 forecast for post-GLP-1 skin laxity treatment demand, highlighting key trends and suggesting strategic adjustments for clinical practices. The research cut-off for this report was August 29, 2026. The latest complete global procedure report from ISAPS covers 2024, with 2025 results scheduled for briefing after this report’s cut-off date ^[1] .

The Expanding Patient Population and Global Reach of GLP-1 Medications

The patient pool for GLP-1 weight loss medications is growing at a rapid rate, creating a substantial and expanding segment of individuals likely to seek aesthetic interventions. In June 2026, 11% of U.S. adults reported currently taking a GLP-1 drug for weight loss, marking a significant increase from just 3% in 2024. Furthermore, 15% of U.S. adults had used a GLP-1 medication at some point ^[2] . This near fourfold increase in current usage within two years signals a burgeoning patient base for aesthetic services. Even if only a minority of these individuals ultimately seek aesthetic care, the sheer volume of GLP-1 users suggests a considerable surge in potential demand for clinics.

This expansion is not confined to the United States; it is a global phenomenon, though access remains uneven. Novo Nordisk, a major manufacturer of GLP-1 drugs, reported that its obesity medicines reached 3.6 million people in 2025. The availability of Wegovy, one of their key products, expanded significantly from 17 countries in 2024 to 52 countries in 2025 ^[3] . This global reach indicates that aesthetic demand will emerge in more markets, typically with a delay as patients begin to experience visible facial and body volume changes following weight loss. The overall branded GLP-1 obesity medicine volume increased by 104% through November 2025, demonstrating sustained market growth ^[4] . This doubling of the underlying treatment population will support continued growth in aesthetic consultation requests.

Despite this expansion, the World Health Organization (WHO) projects that GLP-1 medicines will reach fewer than 10% of the people who could benefit from them by 2030 ^[5] . This limitation stems from factors such as manufacturing capacity, pricing, insurance coverage, and health system capabilities. As a result, post-weight-loss aesthetic demand will likely remain concentrated in countries and cities with greater access to GLP-1 medications and higher disposable incomes. Clinical directors in these regions should anticipate a continued rise in patient inquiries. For large clinic chains, leveraging country and city-specific prescription data can guide strategic expansion. Independent clinics, conversely, should base equipment purchases and service adjustments on their current consultation volume and relationships with local prescribers. Device manufacturers should avoid directly equating global obesity prevalence with the immediate aesthetic market size, as access constraints will limit the realized demand in many areas.

It is important to note that the term “Post-GLP-1” generally refers to the period following significant weight loss, rather than after stopping the medication entirely. The WHO recognizes obesity as a chronic, relapsing condition and supports long-term GLP-1 therapy ^[5] . Therefore, clinics must plan for ongoing care that spans active weight loss, weight stabilization, and maintenance phases, rather than a single intervention at the end of treatment.

Prevalence and Factors Influencing Skin Changes

Skin changes are a common consequence of substantial weight loss induced by GLP-1 medications. However, published rates of these changes vary due to differing definitions and patient populations studied. A 2026 survey of 504 GLP-1 users found that 38.7% reported experiencing skin changes ^[6] . Within this group, specific concerns included facial volume loss (10.9%), general sagging (8.3%), and jowling (7.7%) ^[6] . A separate 2026 study reported that 44% of individuals who lost 10% to 20% of their body weight experienced skin sagging ^[7] . This disparity highlights the need for precise diagnostic criteria when assessing the incidence of specific aesthetic issues.

Several factors influence the likelihood and severity of skin changes. Age, total weight lost, and the speed of weight loss are key determinants. The 2026 survey indicated a higher risk of skin changes for individuals over 55 years old and those who lost more than 20 pounds ^[6] . More than half (55.1%) of those reporting skin changes noticed them within the first five months of treatment ^[6] . This early onset of changes means that the first major wave of aesthetic consultations can begin while patients are still actively losing weight ^[9] . Baseline photography and skin assessments should therefore be implemented early in the patient journey, ideally before significant appearance changes become established.

The weight loss achieved with GLP-1 medications can be substantial. For example, semaglutide trials showed an average weight loss of 14.9% over 68 weeks, while tirzepatide demonstrated up to 20.9% over 72 weeks ^[10] . Such significant reductions can alter facial fat compartments, neck contours, breasts, arms, abdomen, thighs, and buttocks. Clinical directors should expect patients to present with concerns across several body areas rather than a single isolated complaint. For example, a Galderma report in 2025 indicated that 48% of over 1,300 medication-assisted weight-loss patients experienced significant facial changes, usually within three to six months ^[9] . Seventy-seven percent reported at least one negative change, including sagging, wrinkles, or a tired appearance ^[9] . This underscores the need for a holistic assessment and treatment approach.

The scope of the aesthetic problem extends beyond loose skin alone. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for a combination of linked issues, such as laxity, poor skin quality, and facial deflation ^[11] . This data supports an assessment methodology based on tissue problems (e.g., volume loss, skin quality, skin excess) rather than solely on individual body parts. Additionally, patients often maintain high satisfaction with the GLP-1 medication itself, even while seeking aesthetic improvements. The 504-person study revealed that 92% were satisfied with the medication, 84% reported an improved body image, and 68.5% experienced greater self-confidence ^[6] . Aesthetic care should support these health gains, not imply that weight loss was a cosmetic failure. Intake processes should record age, weight loss percentage and speed, medication stage, specific facial and body site concerns, skin quality, weight stability, nutrition, strength, and patient priorities. A three-level laxity grade (mild, moderate, or severe) can help guide treatment pathways, from device-based care to combination approaches or surgical referral.

Shifting Treatment Modalities and Combination Approaches

The demand for post-GLP-1 aesthetic care will split between non-surgical and surgical interventions. Among GLP-1 patients tracked by American Society of Plastic Surgeons (ASPS) members, 20% had already undergone plastic surgery, 39% were considering surgery, and 41% were considering a non-surgical procedure ^[12] . This indicates a clear need for capacity in both treatment tracks. Clinics focusing solely on non-invasive devices should establish formal referral pathways to plastic surgeons for severe cases.

The expected modality shift is away from fat reduction treatments and toward tissue support, tightening, and volume replacement. Hyaluronic acid fillers can address facial volume loss, while biostimulators can stimulate collagen production over time ^[8] . External radiofrequency (RF) and ultrasound technologies can offer modest tightening for mild to moderate laxity ^[13] . Surgery remains the primary treatment for significant hanging or severe excess skin ^[8] .

Clinics are already seeing a demand effect. A survey of 406 aesthetic health professionals reported a mean 137% increase in GLP-1 patients from 2023 to 2024 ^[8] . The leading concerns among these patients were midface volume loss, face and neck laxity, and loose body skin ^[8] . These surveyed clinicians typically treated a mean of 1,249 cosmetic patients per year, suggesting that the reported growth reflects active aesthetic practices ^[8] . While this strong demand signal is evident, the opt-in survey design might overstate growth compared to the full provider market.

Combination treatment plans are projected to gain market share over single treatments. A Galderma trial combining Sculptra (a biostimulator) with Restylane (a hyaluronic acid filler) reported high patient satisfaction. After nine months, 85.7% of patients felt their face looked less gaunt, and 91.4% would recommend the regimen ^[14] . This study supports the efficacy of combination care for addressing multiple concerns. However, it was company-sponsored and did not isolate the specific contribution of each product ^[14] .

Hyaluronic acid filler continues to be the primary immediate volume restoration tool. In the 406-provider survey, clinicians regarded it as the best facial treatment for an average of 47% of GLP-1 patients, particularly when midface or temple deflation was the main issue ^[8] . Biostimulators are also gaining traction; Galderma’s patient research showed that 48% expressed interest in trying a biostimulator, and 41% would consider hyaluronic acid injections ^[9] . Among surveyed clinics, 54% either offered or were considering biostimulators, while 89% offered or considered fillers ^[9] .

A practical treatment sequence typically involves initial assessment, followed by conservative structural volume correction, then collagen and skin quality treatments, and finally surface treatments. Reassessment should occur during active weight loss to adjust plans as needed. Large, early corrections should be avoided, as they may become excessive with further weight changes.

Non-Surgical Technologies and Safety Considerations

Non-invasive ultrasound and external radiofrequency treatments are expected to benefit from the demand for low-downtime care. Non-surgical skin tightening was among the five most common non-surgical procedure groups worldwide in 2024 ^[15] . The broader global market saw 20.5 million non-surgical procedures that year ^[15] , indicating a significant base of trained providers and treatment-aware consumers. A study combining focused-ultrasound with a topical regimen reported a 44% reduction in graded laxity at 12 weeks ^[13] . A separate manufacturer’s clinical study found improvement in 93% of treated upper arms after two ultrasound sessions ^[16] . These results support the use of ultrasound for mild to moderate cases but do not confirm its effectiveness for severe post-weight-loss skin, which typically requires surgical intervention ^[13] .

Conversely, radiofrequency (RF) microneedling now faces increased safety and consent scrutiny. On October 15, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication detailing reported burns, scarring, fat loss, disfigurement, and nerve damage associated with certain aesthetic uses of RF microneedling ^[17] . This warning applies specifically to needle-based RF microneedling, not all forms of RF treatment. The FDA emphasizes that RF microneedling is a medical procedure and advises patients to seek licensed providers with device-specific training. Providers are also urged to report complications ^[17] . This may shift demand toward non-needle energy devices or clinics with stronger medical oversight, although this is an inference rather than a measured sales trend. Clinical directors must differentiate between needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices in staff training and consent processes. Grouping them all under a broad “RF tightening” label can obscure critical differences in depth of penetration and associated risks.

The Role of Surgery and the Global Context

Surgery will retain a clear and critical role for patients with severe skin laxity. In the U.S., abdominoplasty procedures reached 171,064 in 2024 ^[18] . Arm lifts increased by 2%, thigh lifts by 3%, and buttock lifts by 3% from 2023 ^[18] . These figures were rising even before the full cohorts of 2025 and 2026 GLP-1 users reached stable weight. A Chinese study of post-bariatric patients found that 78.2% reported excess skin, and 37.9% desired body-contouring surgery ^[19] . While bariatric patients often experience greater weight loss than typical GLP-1 users, this study underscores the global need for surgical solutions to excess skin.

The global aesthetic procedure market is substantial, with nearly 38 million procedures performed in 2024 ^[15] . This included over 17.4 million surgical procedures and 20.5 million non-surgical procedures ^[15] , representing a 42.5% increase from 2020. Post-weight-loss care is entering an already large market with established patient acceptance and provider capacity. Interestingly, global facial fat grafting increased by 19.2% in 2024 compared to 2023, while overall face and head procedures rose by 4.3% ^[15] . In contrast, body and extremity procedures decreased by 14.8% during the same period. This suggests that the early commercial impact of GLP-1s may appear first in facial volume and skin services, with body surgery demand not yet showing the same pattern in 2024 ^[15] .

ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms (such as nausea, vomiting, abdominal pain, or constipation) are active ^[20] . This necessitates careful coordination with the prescribing physician as part of surgical planning. A 2026 West Virginia University study, which examined 373 panniculectomy patients (21.7% of whom were on GLP-1 medications), found possible differences in wound healing but no clear increase in overall surgical risk ^[21] . This finding highlights the need to avoid blanket assumptions and to conduct thorough individual patient assessments.

Commercial Considerations and Operating Model

The commercial opportunity for post-GLP-1 aesthetic care comes with specific budgetary considerations. McKinsey’s research found that approximately 60% of GLP-1 patients reduced their overall aesthetic spending, while 40% increased it ^[11] . This suggests that increased appearance concerns do not automatically translate into larger aesthetic budgets, as patients also bear costs for medication, nutrition, fitness, and clothing changes. Clinics should anticipate demand for staged treatment plans, transparent pricing, and high-value combinations, rather than expecting unlimited spending. Staged plans can address the most pressing concerns first, allowing for further care after weight stabilization and enabling patients to manage costs over time.

Trust is a critical business asset in this segment. The 2025 ASDS consumer survey indicated that 94% of consumers used ratings and review sites when selecting a provider, and nearly half considered a provider’s social media presence influential in their appointment decisions ^[22] . Therefore, clinics need to build trust through consistent before-and-after photography, clear credentials, plain language consent forms, and outcomes data separated by age, body site, and severity. Bio2 Laser Studio, for example, explicitly links external RF body and facial contouring to GLP-1 weight loss on its public pages ^[23] . They offer clear pricing structures, such as $440 for a single session, a $1,980 package for six sessions, and a $175 monthly option ^[23] . While their public pages do not provide peer-reviewed post-GLP-1 outcome data, internal tracking of results would bolster efficacy claims.

The winning operating model for clinics will be staged, transparent, and referral-based. The commercial funnel is large but segmented. ASPS members reported 837,485 patients using prescribed weight-loss medicine in 2024 ^[12] . Of these, 41% were considering non-surgical treatment, and 39% were considering surgery ^[12] . A successful service line must support both pathways rather than trying to fit every patient into the clinic’s existing equipment. Clinics should reduce messaging focused on fat reduction for patients who are already deflated. Instead, the service mix should emphasize facial structure, skin quality improvement, management of mild laxity, muscle and strength support, and surgical referral when appropriate. Severe hanging skin should not be treated with a long series of device sessions under the promise of surgical-level results.

To effectively manage this new patient population, every service line requires documented protocols for:

• Medication stage and active symptoms.
• Weight stability and nutrition screening.
• Device settings and staff credentials.
• Informed consent procedures.
• Standardized photography.
• Adverse event reporting.
• Clear referral pathways.

Claims regarding treatment outcomes should accurately describe likely degrees of improvement, rather than promising to prevent or eliminate loose skin entirely. Clinical directors should expand services in phases, diligently track their own patient outcomes, and maintain firm surgical referral limits. Purchase decisions for new equipment should be driven by local utilization data and measured results, not solely by the broader GLP-1 growth headlines.

Key Insights Summary for Clinical Directors

The rise of GLP-1 medications presents a significant opportunity and a challenge for aesthetic practices. The patient pool is growing rapidly, both domestically and internationally, albeit with uneven global access. These patients often present with multiple concerns, including facial volume loss, skin laxity, and poor skin quality, across several body areas. Age, amount of weight lost, and speed of loss influence the type and severity of skin changes.

Treatment strategies must shift from fat reduction to tissue support, volume replacement, and tightening. Combination therapies, particularly using fillers and biostimulators, are gaining prominence for facial concerns. Non-invasive external ultrasound and non-needle RF may see increased use for mild to moderate laxity, but RF microneedling faces heightened safety scrutiny from regulatory bodies. Surgical interventions remain essential for severe excess skin, necessitating clear referral protocols.

The commercial model must be transparent, offer staged treatment plans, and acknowledge patient budgetary constraints. Building trust through clear communication, standardized outcomes tracking, and strong patient education will be paramount. For example, Bio2 Laser Studio’s approach with clear pricing for external RF for GLP-1 patients highlights how smaller clinics can adapt, though validating efficacy with internal data is key ^[23] . Clinical directors must implement comprehensive intake procedures, grade laxity levels, and define clear treatment pathways, including timely surgical referrals, to effectively serve this evolving patient demographic. Tracking internal metrics such as consultation sources, weight-loss stages, treatment completion rates, patient-reported improvements, and adverse events will be crucial for guiding future service development and investment decisions.

This executive summary has provided a high-level overview of the impending shifts. The subsequent sections of this report will explore deeper into each of these areas, providing more detailed analysis and actionable strategies for clinical directors.

2. GLP-1 Treatment Adoption and Patient Pool Growth

The introduction of Glucagon-Like Peptide-1 (GLP-1) receptor agonist medications has caused a significant shift in the medical treatment of obesity and related conditions. These medications, originally developed for type 2 diabetes, have shown remarkable efficacy in supporting weight loss. This success has led to a rapid increase in their use for weight management. This section examines the current and projected growth of GLP-1 treatment adoption. It analyzes how this expansion affects the patient pool for aesthetic services, specifically in the context of post-weight loss skin changes. Understanding this patient growth is key for clinical directors to plan their service offerings, resource allocation, and patient communication strategies for the coming years.

The rise in GLP-1 use is not just a medical trend; it is also an aesthetic one. As more individuals achieve significant weight reduction, they often experience changes in their skin quality and volume. These changes create a direct demand for various aesthetic treatments. This section will provide specific data on GLP-1 adoption rates, project future growth, and detail the characteristics of this new patient group. It will also look at the global reach of these medications and the uneven access that shapes the aesthetic market.

GLP-1 Adoption Rates and Growth Trajectories

The adoption of GLP-1 medications for weight loss has shown rapid growth in recent years, particularly in the United States. This growth indicates a expanding patient base that will likely seek aesthetic treatments.

United States Adoption Rates

In the U.S., the number of adults using GLP-1 drugs for weight loss has increased significantly. A Gallup poll conducted from May 28 to June 5, 2026, found that 11% of U.S. adults reported currently taking a GLP-1 drug for weight loss. This represents a substantial rise from just 3% in 2024. The data shows a nearly fourfold increase in current use over two years ¹.

This surge in current users is further supported by statistics on past and current use. The same Gallup survey indicated that 15% of U.S. adults had used a GLP-1 drug at some point ¹. This broader figure includes individuals who may have started and stopped treatment or are in various stages of their weight loss journey. The overall number of people exposed to these medications is notable. Even if only a minority of these individuals seek aesthetic care, the potential patient base for clinics offering post-weight loss treatments is much larger than it was in 2024 ¹. This expansion extends beyond early adopters, showing that the medications are gaining broader acceptance across the population.

Global Expansion and Access Challenges

While the U.S. market has seen a rapid increase, the expansion of GLP-1 use is also global. However, access remains uneven across different regions. Novo Nordisk, a leading manufacturer of GLP-1 medications, reported that its obesity medicines reached 3.6 million people in 2025 ². The availability of Wegovy, one of its key GLP-1 drugs, expanded significantly, moving from 17 countries in 2024 to 52 countries in 2025 ². This expansion indicates a wider geographical spread for the medications. Aesthetic demand should appear in more markets over time, usually with a delay after patients begin to lose visible facial and body volume ².

Despite this expansion, the World Health Organization (WHO) projects that GLP-1 medicines will reach fewer than 10% of the people who could benefit from them by 2030 ³. This estimate highlights significant barriers to access. These barriers include manufacturing limitations, high costs, insurance coverage issues, and health system capacity constraints ³. The implication for aesthetic providers is that post-weight loss aesthetic demand will continue to be concentrated in countries and cities where GLP-1 access is greater and disposable income is higher ³.

The commercial execution of GLP-1 manufacturers further supports this growth narrative. Novo Nordisk’s annual report for 2025 indicated that obesity-care sales grew by 31% at constant exchange rates ². Furthermore, the global branded GLP-1 obesity medicine volume showed a 104% increase through November 2025, based on IQVIA data ⁴. While this growth rate slowed slightly from 119% in the prior reporting period, the underlying patient population is still doubling. This pace can support sustained growth in aesthetic consultations for years to come ⁴.

The delay in aesthetic demand following medication initiation is an important factor. Galderma’s international patient research, reported in 2025, showed that significant facial changes appeared most often three to six months after GLP-1 treatment began ⁵. This means clinics in newly opened GLP-1 markets should expect aesthetic inquiries to lag behind prescription growth ⁵. Clinical directors can use country and city prescription data to guide their expansion plans. Independent clinics should use their own consultation volume and local prescriber relationships before investing in additional equipment. Device makers should avoid treating global obesity prevalence as a direct measure of aesthetic market size, as access and conversion rates will vary significantly.

Expected Weight Loss and Its Aesthetic Impact

GLP-1 medications are designed to produce significant weight loss, which in turn leads to noticeable changes in a patient’s appearance. These changes create the need for aesthetic interventions.

Magnitude of Weight Loss

Clinical trials have demonstrated the effectiveness of GLP-1 drugs in supporting substantial weight reduction. For example, semaglutide trials showed an average weight loss of 14.9% over 68 weeks ⁶. Tirzepatide, another GLP-1 medication, showed even greater results, with participants losing up to 20.9% of their body weight over 72 weeks ⁷.

This level of weight loss is significant enough to alter facial fat compartments, neck contours, and the appearance of breasts, arms, abdomen, thighs, and buttocks ⁸. Clinical directors should expect patients to present with concerns across several affected body areas, rather than just an isolated complaint ⁸.

Common Patient-Reported Skin Changes

The rapid and substantial weight loss induced by GLP-1 medications frequently leads to skin changes. A 2026 survey of 504 GLP-1 users found that 38.7% reported experiencing skin changes ⁹. Specific concerns included:

• Facial volume loss: 10.9% of respondents ⁹
• Sagging skin: 8.3% of respondents ⁹
• Jowling: 7.7% of respondents ⁹

More than half of those who reported skin changes (55.1%) noticed these changes within the first five months of treatment ⁹. This rapid onset suggests that aesthetic consultations may occur relatively early in a patient’s weight loss journey.

Another 2026 study focused on a subgroup of 395 respondents who had lost 10% to 20% of their body weight. This study reported skin sagging in 44% of these individuals ¹⁰. The same subgroup also reported decreased facial volume at 37%, hair loss at 30%, and reduced strength at 19% ¹⁰. These figures suggest that the aesthetic service line may need to link with other services, such as nutrition counseling, resistance exercise programs, hair care, and medical management, rather than focusing solely on skin treatment ¹⁰.

It is important to note the difference in reported sagging rates between the two 2026 studies (8.3% versus 44%). These figures should not be compared directly as they used different samples, questions, and denominators ⁹. This highlights the need for careful interpretation of data and consistent methodology in future research.

Despite these appearance changes, satisfaction with GLP-1 treatment remains high. In the 504-person study, 92% were satisfied with their medication, 84% reported improved body image, and 68.5% reported greater self-confidence ⁹. This means aesthetic care should support these health gains and improvements in self-perception, rather than framing weight loss as an aesthetic problem ⁹.

Galderma’s 2025 international patient research, involving more than 1,300 medication-assisted weight loss patients, reported that 48% experienced significant facial changes. Most changes appeared within three to six months. Overall, 77% reported at least one negative change, such as sagging, wrinkles, or a tired appearance ⁵. This suggests that the first major wave of aesthetic consultations can begin while patients are still actively losing weight ⁵.

Characteristics of the GLP-1 Aesthetic Patient Pool

The growing number of GLP-1 users creates a distinct aesthetic patient pool with specific needs and expectations. Understanding these characteristics is crucial for clinical directors.

Increasing Demand and Patient Concerns

Clinics are already observing a rise in demand from GLP-1 patients. A survey of 406 aesthetic health professionals, published in 2026, reported a mean increase of 137% in GLP-1 patients from 2023 to 2024 ¹¹. These surveyed clinicians typically treated a mean of 1,249 cosmetic patients per year, indicating that the data reflects practices with active aesthetic clienteles ¹¹. This increase is a strong signal of growing demand. However, it is important to acknowledge that the opt-in survey design may overstate growth compared with the broader provider market ¹¹.

The leading concerns among GLP-1 patients seeking aesthetic care include midface volume loss, face and neck laxity, and loose body skin ¹¹. These concerns often do not appear in isolation. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for several linked issues, such as laxity, poor skin quality, and facial deflation ¹². This supports an assessment approach that considers tissue problems rather than focusing only on individual body parts ¹².

For clinical directors, this means that patient intake should thoroughly record various factors. These include age, the percentage and speed of weight loss, the current medication stage, specific areas of facial volume loss, affected body sites, overall skin quality, weight stability, nutrition, strength, and the patient’s main priorities ⁹. A three-level laxity grade – mild, moderate, or severe – can help guide decisions about device care, combination treatments, or referral for surgical options ⁹.

Budget Considerations and Spending Patterns

While GLP-1 medications create aesthetic needs, they also introduce financial considerations for patients. McKinsey’s 2025 survey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ¹³. This indicates that increased appearance concern does not always translate into a larger total aesthetic budget. Patients are also allocating funds for medication, nutrition programs, fitness activities, and clothing changes ¹³.

This budget reality implies that clinics need to offer staged plans, clear pricing, and high-value combinations of treatments, rather than expecting unlimited spending ¹³. Clinics should also consider financing options and provide clear estimates of the likely benefits for each treatment plan ¹³.

Treatment Preferences and Referral Pathways

GLP-1 patients show interest in both non-surgical and surgical aesthetic options. Among GLP-1 patients tracked by American Society of Plastic Surgeons (ASPS) members, 20% had already undergone plastic surgery related to medication-induced weight loss ¹⁴. Another 39% were considering surgery, and 41% were considering a non-surgical procedure ¹⁴. This data indicates that both treatment paths require capacity. Clinics that focus solely on devices should establish a clear, formal referral process for plastic surgeons ¹⁴.

The International Society of Aesthetic Plastic Surgery (ISAPS) global procedure report for 2024 showed nearly 38 million aesthetic procedures performed worldwide ¹⁵. This total included over 17.4 million surgical and 20.5 million non-surgical procedures ¹⁵. The overall volume was 42.5% higher than in 2020 ¹⁵. This indicates that post-weight loss care is entering an already large and expanding market with established patient acceptance and provider capacity ¹⁵.

In terms of specific surgical trends, global facial fat grafting procedures rose by 19.2% in 2024 compared to 2023, reaching about 0.9 million procedures ¹⁶. Face and head procedures increased by 4.3%, while body and extremity procedures decreased by 14.8% ¹⁶. This suggests that the early commercial impact of GLP-1 use may first appear in facial volume and skin services. Body surgery demand had not yet shown the same pattern in 2024 ¹⁶. However, U.S. abdominoplasty volume reached 171,064 procedures in 2024 ¹⁷. Other body contouring procedures like arm lifts (up 2%), thigh lifts (up 3%), and buttock lifts (up 3%) also saw increases from 2023 ¹⁷. These figures suggest that procedures designed to remove excess skin were already rising before the full cohorts of GLP-1 users from 2025 and 2026 reached stable weight ¹⁷. This indicates a pre-existing demand that GLP-1 related weight loss will further increase.

The Need for Comprehensive Care Models

The complex nature of post-GLP-1 aesthetic concerns means that clinics must adopt comprehensive and thoughtful care models. These models should address multiple issues, integrate different treatment modalities, and provide clear patient guidance.

Beyond Single-Treatment Approaches

The research indicates that patients often present with multiple concerns, making single-treatment plans less effective. Standard packages based on one device or one injection type will only serve a portion of the market ¹². Instead, combination plans are expected to gain share over single treatments.

A Galderma trial combining Sculptra with Restylane for facial concerns showed positive outcomes. After nine months, 85.7% of patients felt their face looked less gaunt, and 91.4% would recommend the regimen ¹⁸. While this company-sponsored study supports the idea of combination care, it did not isolate the contribution of each product ¹⁸. However, it illustrates the potential for integrated approaches.

A practical sequence for treatment might involve:

1. Initial assessment to understand the patient’s concerns and skin condition.
2. Conservative structural volume correction for areas like the midface or temples. Hyaluronic acid filler remains the primary immediate volume tool. A survey of 406 providers found that clinicians considered it the best facial treatment for an average of 47% of GLP-1 patients ¹¹.
3. Collagen stimulation and skin quality improvement. Biostimulators, which promote collagen formation over time, are gaining interest. In Galderma’s patient research, 48% expressed interest in trying a biostimulator, and 41% would consider hyaluronic acid injections ⁵. Among surveyed clinics, 54% offered or were considering biostimulators, and 89% offered or were considering fillers ⁵.
4. Surface treatments for texture and minor irregularities.

During active weight loss, reassessment is crucial. Clinics should avoid large early corrections that might look excessive after further weight changes ¹⁹.

The timing of treatments is also debated. A Delphi panel of 10 experts, supported by a Galderma grant, found that 70% would start poly-L-lactic acid (a biostimulator) at the same time as medication-associated weight loss ¹⁹. The panel was evenly split on fat transfer ¹⁹. While this provides expert opinion, it is not definitive proof and should be considered within the context of the study’s funding.

Modality Shifts: From Fat Reduction to Tissue Support

The aesthetic needs of GLP-1 patients represent a shift in the common modality mix. Traditionally, many aesthetic practices focused on fat reduction technologies. However, with GLP-1 patients, the need moves toward tightening, structural support, and excision of excess skin. Clinics should reduce their reliance on fat-reduction messaging for patients who are already experiencing deflation ²⁰.

External ultrasound and non-needle radiofrequency (RF) devices may see increased use for mild to moderate laxity. A Sofwave study on upper arms found improvement in 93% of treated arms after two sessions ²¹. However, this manufacturer-sponsored evidence should not be automatically applied to older patients, severe laxity, or all body sites ²¹. A SkinCeuticals-associated study combined a topical regimen with one focused-ultrasound treatment, reporting a 44% reduction in graded laxity at 12 weeks ²². These results support the use of ultrasound for mild to moderate cases but do not suggest that energy treatments can replace surgery for severe skin excess ²².

Conversely, RF microneedling faces increased safety and consent pressures. The U.S. Food and Drug Administration (FDA) issued a safety communication on October 15, 2025. It warned of reported burns, scarring, fat loss, disfigurement, and nerve damage with certain aesthetic uses of RF microneedling ²³. This warning applies specifically to RF microneedling, not every form of RF treatment ²³. This could shift demand toward non-needle energy devices or providers with stronger medical oversight ²⁰. Clinical directors must differentiate between needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices in their staff training and patient consent processes. Marketing all of them under a broad “RF tightening” label can hide major differences in depth and risk ²⁴.

For severe hanging skin, surgery remains the primary referral path ²⁰. A Chinese study of post-bariatric patients found that 78.2% reported excess skin, and 37.9% wanted body-contouring surgery ²⁵. While bariatric patients often lose more weight than typical GLP-1 users, this highlights the demand for surgical solutions for significant skin excess ²⁵.

Safety and Timing Considerations

Safety and the appropriate timing of treatments are critical buying criteria for GLP-1 patients. The FDA views RF microneedling as a medical procedure and advises patients to seek licensed providers with device-specific training ²⁴. Providers are also advised to report complications ²⁴. This emphasizes the need for strict protocols and qualified staff.

ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and when gastrointestinal symptoms like nausea, vomiting, abdominal pain, or constipation are active ²⁶. This makes coordination with the prescribing physician an important part of surgical planning ²⁶. A 2026 West Virginia University study on 373 panniculectomy patients found possible differences in wound healing for those taking GLP-1 medicines before surgery, but no clear rise in overall surgical risk ²⁷. This shows that blanket assumptions about risk should be avoided and individualized assessment is necessary ²⁷.

Every service line offered to GLP-1 patients needs clear written rules regarding the medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse-event reporting, and referral pathways ²⁸. Claims should describe likely degrees of improvement, rather than promising prevention or complete removal of loose skin ²⁸.

Building a Post-Weight Loss Service Line

Clinical directors need to establish a service line that is staged, transparent, and built on effective referral networks to serve the GLP-1 patient pool successfully.

Operating Model Principles

The commercial opportunity for post-GLP-1 aesthetic care is large but segmented. ASPS members reported 837,485 patients using prescribed weight-loss medication in 2024 ²⁹. Among these, 41% were considering non-surgical treatment and 39% were considering surgery ²⁹. This means a service line should support both paths, rather than forcing every patient into the clinic’s existing equipment ²⁹.

Pricing transparency is key for conversion. With 60% of GLP-1 patients reducing their overall aesthetic spending, staged plans allow patients to address their highest-priority concerns first, with additional care after weight stabilizes ¹³.

Trust is also a valuable business asset. The 2025 ASDS consumer survey found that 94% of consumers used ratings and review sites when selecting a provider ³⁰. Almost half stated that a provider’s social media presence influenced their appointment decisions ³⁰. Clinics need consistent before-and-after photographs, clear staff credentials, plain language consent forms, and outcomes data separated by age, body site, and severity ³⁰.

Bio2 Laser Studio, an independent laser studio in San Antonio, Texas, provides an example of service packaging for GLP-1 patients ³¹. They explicitly link external RF body and facial contouring to GLP-1 weight loss on their public pages. They also publish clear pricing: $440 for a single body or facial contouring session, $1,980 for a six-session package, and a $175 monthly option ³¹. While their public pages do not provide peer-reviewed post-GLP-1 outcome data, their approach shows how clear pricing and repeat-session structures can reduce buying friction ³¹. For stronger efficacy claims, internal tracking of standardized photography, patient-reported scores, treatment completion rates, and adverse events would be beneficial ³¹.

Data Tracking for Informed Decisions

For clinical directors, building a successful post-weight loss service line requires careful data tracking and a phased expansion approach. There is currently no audited global revenue figure for post-GLP-1 laxity care, and direct studies remain small, observational, or funded by treatment companies ¹⁹. Therefore, clinics should:

• Expand in phases.
• Track their own outcomes diligently.
• Maintain firm surgical referral limits.

Specifically, clinics should track:

• Consultation sources.
• Weight-loss stage (active loss, stabilization, maintenance).
• Type of concern (e.g., facial volume, body laxity).
• Laxity grade (mild, moderate, severe).
• Treatment selected.
• Series completion rates.
• Patient-reported improvement.
• Photography-graded outcomes.
• Adverse events.
• Refunds and repeat care.
• Surgical referrals.

Purchase decisions for new equipment or services should be based on local utilization data and measured results, rather than solely on broad GLP-1 growth headlines ²⁸.

Conclusion to GLP-1 Treatment Adoption and Patient Pool Growth

The rapid adoption of GLP-1 medications for weight loss represents a significant and growing patient pool for aesthetic services. The substantial weight loss achieved by these medications frequently leads to skin laxity, volume loss, and other aesthetic concerns, driving demand for both non-surgical and surgical interventions. While the U.S. market has seen the most immediate growth, global expansion is underway, though access remains uneven. Clinical directors must recognize that these patients often present with multiple, linked concerns and have specific budget considerations. Developing comprehensive, staged, and transparent care models that emphasize tissue support over fat reduction, integrate various modalities, prioritize safety, and leverage strong referral networks will be essential for success. Careful data tracking and a phased approach to expansion will allow clinics to adapt effectively to this evolving patient demographic.

The next section will build on this understanding of patient pool growth by exploring the specific types of skin laxity and tissue changes observed in GLP-1 patients, setting the stage for a detailed analysis of treatment strategies.

Sources

• ¹ Gallup. (2026, July 7). In U.S., GLP-1 Usage Reaches New High. Retrieved from https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
• ² Novo Nordisk. (2026). Novo Nordisk Annual Report 2025: Commercial Execution. Retrieved from https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-annual-report-2025.pdf.html
• ³ World Health Organization. (2025, December 1). WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. Retrieved from https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
• ⁴ Novo Nordisk. (2026). Financial performance – Novo Nordisk Annual Report 2025. Retrieved from https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html
• ⁵ Galderma. (2025). Understanding the Aesthetic Impact of Medication-Driven Weight Loss. Retrieved from https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
• ⁶ New England Journal of Medicine. (2021). Once-Weekly Semaglutide in Adults With Overweight or Obesity. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• ⁷ New England Journal of Medicine. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• ⁸ New England Journal of Medicine. (2021, 2022). STEP 1; SURMOUNT-1.
• ⁹ Olivero and colleagues. (2026). Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss. Journal of Cosmetic Dermatology. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.71145
• ¹⁰ PubMed. (2026, August). Skin Impacts and Tradeoffs of GLP-1 Therapy. Retrieved from https://pubmed.ncbi.nlm.nih.gov/42579223/
• ¹¹ Dermatologic Surgery. (2026). Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Retrieved from https://pubmed.ncbi.nlm.nih.gov/42210883/
• ¹² McKinsey & Company. (2025). GLP-1s Are Boosting Demand for Medical Aesthetics. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
• ¹³ McKinsey & Company. (2025). GLP-1s Are Boosting Demand for Medical Aesthetics. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
• ¹⁴ American Society of Plastic Surgeons. (2025, June 25). 2024 Plastic Surgery Statistics Report. Retrieved from https://www.plasticsurgery.org/news/press-releases/interest-in-aesthetic-health-remained-consistent-despite-economic-uncertainty-in-2024-according-to-new-report-from-american-society-of-plastic-surgeons
• ¹⁵ International Society of Aesthetic Plastic Surgery. (2025, June 19). Global Survey 2024. Retrieved from https://www.isaps.org/discover/about-isaps/global-statistics/global-survey-2024-full-report-and-press-releases/
• ¹⁶ ISAPS Global Survey 2024. (2025, June 19).
• ¹⁷ American Society of Plastic Surgeons. (2025). 2024 Plastic Surgery Statistics Report. Retrieved from https://www.plasticsurgery.org/plastic-surgery-statistics
• ¹⁸ Galderma. (2025, July 17). Final Nine-Month Data on Injectable Treatment After Medication-Driven Weight Loss. Retrieved from https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss
• ¹⁹ GaldermaAesthetics. (2025). Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients. Retrieved from https://www.galdermaaesthetics.com/ca/sites/default/files/2025-11/Consensus-Statements-on-Managing-Aesthetic-Needs-in-Prescription.pdf
• ²⁰ Dermatologic Surgery. (2026). Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Retrieved from https://pubmed.ncbi.nlm.nih.gov/42210883/
• ²¹ Sofwave. (2024). Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy – PubMed. Retrieved from https://api.sofwave.com/app/uploads/2024/12/MK00105_E-Upper-Arm-Lax-Skin-Lifting_Clinical-Study-Summary.pdf
• ²² PubMed. (2026). Clinical Efficacy of a Topical Regimen Before and After Ultrasound in GLP-1 Users. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41781778/
• ²³ U.S. Food and Drug Administration. (2025, October 15). Potential Risks With Certain Uses of Radiofrequency Microneedling. Retrieved from https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
• ²⁴ U.S. Food and Drug Administration. (2025, October 15). Potential Risks With Certain Uses of Radiofrequency Microneedling. Retrieved from https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
• ²⁵ PubMed. (2021). Chinese post-bariatric cohort: evidence of global unmet need. Retrieved from https://pubmed.ncbi.nlm.nih.gov/34365452/
• ²⁶ International Society of Aesthetic Plastic Surgery. (2026, May 22). Emerging Guidance on the Rise of GLP-1 Receptor Agonist Drugs. Retrieved from https://www.isaps.org/media/tw1j4oko/260522_isaps-ps-emerging-guidance_rise-of-glp-1-ra-drugs_final.pdf
• ²⁷ American Society of Plastic Surgeons. (2026). Weight Loss Medications May Affect Some Complications After Panniculectomy. Retrieved from https://www.plasticsurgery.org/news/press-releases/weight-loss-medications-may-affect-some-complications-after-panniculectomy
• ²⁸ GaldermaAesthetics. (2025). Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients. Retrieved from https://www.galdermaaesthetics.com/ca/sites/default/files/2025-11/Consensus-Statements-on-Managing-Aesthetic-Needs-in-Prescription.pdf
• ²⁹ American Society of Plastic Surgeons. (2025, June 25). 2024 Plastic Surgery Statistics Report. Retrieved from https://www.plasticsurgery.org/documents/News/Statistics/2024/plastic-surgery-statistics-report-2024.pdf
• ³⁰ American Society for Dermatologic Surgery. (2025). 2025 Consumer Survey. Retrieved from https://www.asds.net/medical-professionals/practice-resources/consumer-survey-on-cosmetic-dermatologic-procedures
• ³¹ Bio2 Laser Studio. (Accessed 2026, August 29). Radiofrequency Body Contouring and Public Pricing. Retrieved from https://bio2laserstudio.com/radiofrequency-body-contouring-san-antonio

3. Global Access to GLP-1 Drugs and Market Concentration

The emergence of Glucagon-Like Peptide-1 (GLP-1) receptor agonist drugs has reshaped obesity treatment, offering significant weight loss for many patients. However, the availability and adoption of these medications are not uniform across the globe. This uneven expansion directly influences where and when aesthetic demand related to post-weight-loss skin laxity will manifest. Clinical directors must understand these global patterns and market concentrations to make informed decisions about service development, resource allocation, and strategic planning. The rapid uptake of GLP-1 drugs, particularly in the United States, signals a growing patient pool for aesthetic concerns, but this growth is tempered by factors such as manufacturing capacity, pricing, insurance coverage, and local health system policies in other regions. This section examines the current state of GLP-1 access worldwide, highlighting the differences that shape the future aesthetic market.

3.1. Rapid Growth of GLP-1 Adoption, Primarily in the United States

The United States has seen a rapid increase in GLP-1 drug usage for weight loss. In June 2026, 11% of U.S. adults reported currently taking a GLP-1 drug for weight loss. This figure represents a substantial increase from just 3% in 2024, showing nearly a fourfold rise in two years ^[1]. Additionally, 15% of U.S. adults had used a GLP-1 drug at some point, indicating a large and growing pool of patients who may experience weight-loss related aesthetic concerns ^[1].

This growth is driven by the effectiveness of these medications. Clinical trials have demonstrated significant weight loss with GLP-1 drugs. For instance, semaglutide achieved an average weight loss of 14.9% over 68 weeks, while tirzepatide led to up to 20.9% weight loss over 72 weeks ^[4]. Such substantial weight reduction can affect facial fat compartments, neck contours, breasts, arms, abdomen, thighs, and buttocks, leading to various aesthetic changes ^[4]. Clinical directors should expect patients to present with multiple affected areas rather than a single isolated complaint.

The aesthetic industry has already begun to see the effects of this increased GLP-1 adoption. A survey of 406 aesthetic health professionals indicated a mean 137% increase in GLP-1 patients from 2023 to 2024 ^[8]. This rise is a strong signal of demand. The clinicians surveyed treated an average of 1,249 cosmetic patients per year, which reflects active aesthetic practices that are already engaging with this new patient segment ^[8]. While this survey design may overstate growth compared with the full provider market, it confirms a significant and present demand.

The demand for aesthetic care linked to GLP-1 weight loss is not limited to specific issues. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for several linked issues, such as laxity, poor skin quality, and facial deflation ^[10]. This suggests that aesthetic clinics need to offer comprehensive assessments and treatment plans addressing multiple tissue problems rather than focusing on isolated body parts.

However, the patient journey is not always linear. Galderma’s international patient research found that significant facial changes often appear within three to six months after GLP-1 treatment begins ^[9]. This means clinics in markets with recent GLP-1 introduction should expect aesthetic inquiries to follow prescription growth with a delay. Initial consultations may even occur while patients are still actively losing weight. For instance, 48% of over 1,300 surveyed medication-assisted weight-loss patients reported significant facial changes, with 77% experiencing at least one negative change such as sagging, wrinkles, or a tired appearance ^[9]. This indicates that the first major wave of aesthetic consultations can start during the active weight-loss phase.

Despite the rapid growth in GLP-1 use and associated aesthetic concerns, the commercial opportunity has budget limitations. McKinsey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ^[11]. This suggests that while patients are concerned about their appearance changes, they are also managing costs related to medication, nutrition, fitness, and clothing. Clinics need to provide staged plans, transparent pricing, and high-value combinations that align with patient budget realities, rather than assuming unlimited spending.

3.2. Uneven Global Expansion and Market Concentration

While the U.S. market is experiencing rapid GLP-1 adoption, the global expansion of these drugs is uneven. Novo Nordisk, a key manufacturer of GLP-1 drugs like Wegovy, reported that its obesity medicines reached 3.6 million people in 2025 ^[3]. In that same year, Wegovy became available in 52 countries, a notable increase from 17 countries in 2024 ^[3]. This indicates a growing international reach for GLP-1 therapies.

The volume of global branded GLP-1 obesity medicines grew by 104% through November 2025 ^[4]. This sustained growth, even if slightly slower than the prior period’s 119% increase, confirms that the underlying treatment population is doubling at a pace that can support continued aesthetic consultation growth ^[4]. Aesthetic demand is expected to appear in more markets, though typically with a delay after patients start to lose noticeable facial and body volume.

However, despite this expansion, the World Health Organization (WHO) projects that GLP-1 medicines will reach fewer than 10% of the people who could benefit from them by 2030 ^[2]. This significant gap is due to multiple factors, including manufacturing constraints, high prices, limited insurance coverage, and insufficient health system capacity ^[2]. These restrictions mean that post-weight-loss aesthetic demand will remain concentrated in specific countries and cities where GLP-1 access is higher and disposable income allows for both the medication and subsequent aesthetic treatments.

For clinical directors, this uneven access implies that a detailed understanding of local market conditions is vital. Simply extrapolating U.S. trends to other regions without considering these access barriers would be inaccurate. Instead, clinical directors should:

• Monitor country and city-specific prescription data for GLP-1 drugs to identify emerging aesthetic markets.
• Build relationships with local prescribers to understand the patient flow and adoption rates in their specific areas.
• Adjust expectations for demand in new markets, allowing for a delay between drug availability, patient weight loss, and the appearance of aesthetic concerns.

This geographic concentration also means that device manufacturers and aesthetic product companies should avoid treating global obesity prevalence as a direct measure of the aesthetic market size for GLP-1 related concerns. The addressable aesthetic market is limited by actual GLP-1 drug access, which is currently a fraction of the total obesity burden.

3.3. Implications for Aesthetic Practice Planning and Strategy

The global dynamics of GLP-1 access have several direct implications for aesthetic practices.

3.3.1. Identifying Geographic Hotspots for Demand

The primary determinant of where aesthetic demand will emerge is where GLP-1 drugs are accessible and widely used.

Countries with high adoption rates, like the U.S., will likely continue to experience strong demand for post-weight-loss aesthetic care. For example, the U.S. recorded 837,485 patients using prescribed weight-loss medicine under the care of American Society of Plastic Surgeons (ASPS) members in 2024 ^[12]. This concentration of patients translates into a clear need for aesthetic services. In these established markets, clinics can expand services with greater confidence.

As Novo Nordisk expands Wegovy into more countries, aesthetic demand will follow. For instance, the increase from 17 to 52 countries with Wegovy availability in 2025 ^[3] means new regional opportunities. However, clinics in these newer markets must anticipate a time lag between drug launch and the appearance of aesthetic concerns. The Galderma research, showing significant facial changes often appearing within three to six months ^[9], supports this delayed demand model.

For independent clinics, local prescribing patterns and relationships with bariatric and general practice prescribers will be key indicators of future demand. For larger chains, monitoring regional GLP-1 prescription data can inform expansion decisions.

3.3.2. Understanding Patient Expectations and Financial Constraints

The McKinsey data indicating that 60% of GLP-1 patients reduced overall aesthetic spending underscores the importance of clear pricing, staged treatment plans, and value-focused offerings ^[11].

Patients using GLP-1 drugs often have ongoing medical expenses and lifestyle changes (nutrition, fitness, new clothing) that compete for their financial resources. This means clinics must be prepared to offer:

• Staged care: Starting with the highest-priority concern and adding subsequent treatments as budget allows or as weight stabilizes.
• Transparent pricing: Clearly communicating costs for individual treatments and packages.
• Financing options: Offering payment plans or credit solutions to make treatments more accessible.
• High-value combinations: Focusing on treatments that deliver noticeable results for the investment.

An example of this is Bio2 Laser Studio in San Antonio, Texas. This independent studio explicitly targets GLP-1 patients with external radiofrequency body and facial contouring. They publish clear pricing: $440 for one session, $1,155 for three, $1,980 for six, and $2,222 for nine sessions. They also offer monthly options at $175 for one treatment or $350 for two ^[18]. This approach reduces buying friction and caters to patients who may prefer structured, predictable costs. While Bio2 Laser Studio’s public pages do not provide peer-reviewed post-GLP-1 outcome data, its operational model provides a practical example of how smaller clinics are adapting to the market realities.

3.3.3. Developing Comprehensive Service Offerings and Referral Networks

The diverse aesthetic concerns of GLP-1 patients, including laxity, poor skin quality, and facial deflation, require a broad range of solutions ^[10]. Clinics should move beyond single-device or single-injection approaches.

Demand will split between non-surgical care and surgery. Among GLP-1 patients tracked by ASPS members, 20% had already undergone plastic surgery, 39% were considering surgery, and 41% were considering a non-surgical procedure ^[12]. This suggests that clinics need a dual system:

• In-clinic non-surgical treatments: Offering options like hyaluronic acid fillers for volume loss ^[8], biostimulators for collagen formation ^[9], and external radiofrequency or ultrasound for mild to moderate laxity ^[17].
• Strong surgical referral paths: For patients with severe hanging or excess skin that non-surgical methods cannot address. Procedures like abdominoplasty, arm lifts, thigh lifts, and buttock lifts were already seeing increases in 2024, with abdominoplasty at 171,064 procedures ^[13]. These surgical procedures are expected to see continued demand as more GLP-1 patients achieve stable, significant weight loss.

A clinic focusing solely on devices or injections would miss a significant portion of the GLP-1 patient market. Collaboration with plastic surgeons is crucial for providing a full spectrum of care and ensuring patients receive the most appropriate treatments for their degree of skin laxity and excess. This approach aligns with the understanding that standard packages based on one device or one injection type will only fit part of the market ^[10].

3.3.4. Focusing on Tissue Support Over Fat Reduction

The fundamental shift in treatment modality will be from fat reduction to tissue support. Unlike traditional body contouring for localized fat, GLP-1 patients have experienced systemic fat loss. This means:

• Hyaluronic acid fillers will continue to be important for replacing facial volume ^[8].
• Biostimulators that encourage collagen production over time will gain favor ^[15].
• External radiofrequency and ultrasound devices can offer modest tightening for mild to moderate laxity ^[17].

Marketing efforts should reflect this shift. Messaging around fat reduction, which was common in aesthetic practices before GLP-1s, is less relevant for this patient group. Instead, clinics should emphasize skin quality, structural support, and addressing laxity. Severe hanging skin should not be promised surgical-level results with non-invasive devices.

The trend toward combination treatments is also important. A Galderma study combining Sculptra with Restylane reported that 85.7% of patients felt their face looked less gaunt after nine months, and 91.4% would recommend the regimen ^[17]. While this was a company-sponsored study and did not isolate the contribution of each product, it supports the idea that combination approaches addressing multiple issues-volume loss and collagen stimulation-can yield high patient satisfaction.

3.4. The Role of Regulatory Environments and Safety Considerations

Regulatory environments also play a role in shaping market dynamics. The U.S. Food and Drug Administration (FDA) issued a safety communication in October 2025 regarding potential risks with certain uses of radiofrequency (RF) microneedling, citing reported burns, scarring, fat loss, disfigurement, and nerve damage ^[13]. This warning applies specifically to RF microneedling, not all forms of RF treatment, but it highlights the need for heightened safety awareness and clear patient consent.

This regulatory action may lead to a shift in demand toward non-needle energy devices or providers with stronger medical oversight. Clinical directors must distinguish between needle-based RF, external RF, and minimally invasive subdermal RF in training and consent processes. Marketing all under a single “RF tightening” label can mask critical differences in depth and risk.

Furthermore, the WHO treats obesity as a chronic, relapsing disease and conditionally supports long-term GLP-1 therapy ^[2]. This means clinics should plan for care during active weight loss, stabilization, and maintenance phases. Patient intake should record age, percentage and speed of weight loss, medication stage, facial volume loss, body sites, skin quality, weight stability, nutrition, strength, and patient priorities ^[6].

The International Society of Aesthetic Plastic Surgery (ISAPS) recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms are active ^[14]. This necessitates careful coordination with the medication prescriber as part of surgical planning, emphasizing the need for comprehensive patient assessment beyond just aesthetic concerns.

3.5. Data Tracking and Phased Expansion for Clinical Directors

Given the evolving nature of the GLP-1 aesthetic market, clinical directors must adopt a data-driven and phased approach to expansion. As there is no audited global revenue figure for post-GLP-1 laxity care, and most direct studies are small, observational, or company-funded, strong internal data tracking is essential.

Key metrics to track include:

• Consultation source: To understand how GLP-1 patients are finding the clinic.
• Weight-loss stage: Whether the patient is actively losing weight, stable, or in maintenance.
• Concern type and laxity grade: Documenting the specific aesthetic issues and their severity (e.g., mild, moderate, severe).
• Treatment selected and series completion: Which treatments patients choose and their adherence to treatment plans.
• Patient-reported improvement and photography grade: Objective and subjective measures of treatment effectiveness.
• Adverse events: To monitor safety and adjust protocols if needed.
• Referral patterns: Tracking surgical referrals and outcomes.

This data will help clinics make informed purchase decisions for equipment and justify strong efficacy claims. Phased expansion allows clinics to test and refine their offerings based on real-world results in their specific patient population, rather than relying on broad market projections.

For instance, while a Sofwave upper-arm study showed improvement in 93% of treated arms after two sessions ^[18], such manufacturer clinical summaries should not be automatically applied to older patients, severe laxity, or every body site. Local utilization and measured results are more reliable indicators for investment.

3.6. Conclusion and Transition to Next Section

The global access to GLP-1 drugs is expanding, but it remains concentrated in regions with higher disposable income and strong healthcare infrastructure, particularly the United States. This uneven distribution means that aesthetic demand for post-weight-loss skin laxity will emerge in specific markets first, followed by others after a delay. Clinical directors must recognize this geographic and temporal variability. Strategic planning should include monitoring local GLP-1 adoption, offering comprehensive and staged treatment plans that respect patient budgets, building strong referral networks for both non-surgical and surgical care, and prioritizing safety and evidence-based practices. A data-driven approach to tracking patient outcomes and service effectiveness will be critical for sustained success in this evolving market.

The implications of global access patterns are profound, determining also where but also how aesthetic services must adapt. Understanding these demand dynamics sets the stage for a detailed examination of the specific patient profiles emerging from GLP-1 weight loss, which will be the focus of the next section.

4. Definition of ‘Post-GLP-1’ and Treatment Phases

The term ‘Post-GLP-1’ in the context of aesthetic care requires careful definition. It does not consistently mean a period after a patient has stopped using GLP-1 medications entirely. Instead, it more commonly refers to the aesthetic consequences that appear after significant weight loss achieved through ongoing GLP-1 treatment. The World Health Organization (WHO) considers obesity a chronic, relapsing disease and supports long-term GLP-1 therapy under certain conditions ^[4]. This perspective means that clinical directors must plan for patient care that spans multiple phases: active weight loss, stabilization of weight, and long-term maintenance. Understanding these phases is important for timing aesthetic interventions, managing patient expectations, and structuring a comprehensive care strategy.

The rise of GLP-1 medications has dramatically expanded the pool of patients experiencing rapid and substantial weight loss. In June 2026, 11% of U.S. adults were using a GLP-1 drug for weight loss, a significant increase from 3% in 2024. Furthermore, 15% of U.S. adults had used a GLP-1 drug at some point ^[1]. This growing patient base presents new considerations for aesthetic clinics. The weight loss achieved with these medications can be substantial. For example, semaglutide trials showed an average weight loss of 14.9% over 68 weeks, and tirzepatide trials showed up to 20.9% loss over 72 weeks ^[5]. Such changes can alter facial fat compartments, neck contours, and lead to laxity in other body areas like breasts, arms, abdomen, thighs, and buttocks. This section details the concept of ‘Post-GLP-1’ in aesthetic medicine and outlines the distinct treatment phases required for effective patient management.

Understanding the ‘Post-GLP-1’ Concept in Aesthetic Care

The phrase ‘Post-GLP-1’ can be misleading if interpreted as solely referring to patients who have discontinued their GLP-1 medication. The clinical reality for many individuals using these drugs for weight management is one of continuous or long-term therapy. The WHO’s stance on obesity as a chronic condition reinforces the idea that GLP-1 therapy may extend over many years ^[4]. Therefore, ‘Post-GLP-1’ in the context of aesthetic concerns primarily denotes the period after a patient has achieved a noticeable or substantial degree of weight reduction due to GLP-1 use, regardless of whether they are still taking the medication. This distinction is vital because the patient’s physiological state, including ongoing weight changes, nutritional status, and potential medication side effects, will influence the timing and type of aesthetic treatments that are safe and effective.

A significant proportion of patients experiencing weight loss with GLP-1s report skin changes. A 2026 survey of 504 GLP-1 users found that 38.7% reported various skin alterations. Specifically, facial volume loss affected 10.9% of respondents, general sagging was reported by 8.3%, and jowling by 7.7% ^[6]. Another 2026 study reported skin sagging in 44% of individuals who had lost between 10% and 20% of their body weight ^[7]. These figures highlight the widespread nature of aesthetic concerns among this patient group. The onset of these changes can be relatively rapid; 55.1% of those who reported skin changes in the 504-person survey noticed them within the first five months of treatment ^[6]. This rapid onset means aesthetic intervention may be considered while patients are still actively losing weight.

The aesthetic concerns that arise are not always isolated to a single area. Patients frequently present with multiple related issues. A McKinsey survey indicated that 63% of GLP-1 aesthetic patients sought care for several linked problems, such as laxity, poor skin quality, and facial deflation ^[10]. This suggests that a comprehensive assessment by tissue problem, rather than just by body part, is beneficial. Clinical directors must recognize that these patients are not merely seeking cosmetic fixes but rather addressing the visible effects of a significant health improvement. The goal of aesthetic care in this population often aligns with supporting their improved body image and self-confidence, which were reported by 84% and 68.5% of patients, respectively, in the 504-person study ^[6]. Aesthetic care should support these health gains, not imply a cosmetic failure related to weight loss.

Phased Approach to Treatment: Active Weight Loss, Stabilization, and Maintenance

Given that GLP-1 therapy often involves ongoing medication use and continuous physiological changes, a phased approach to aesthetic treatment is essential. This strategy allows clinics to adapt interventions to the patient’s current state of weight loss and stabilization. The three primary phases are: (1) active weight loss, (2) weight stabilization, and (3) weight maintenance.

1. Active Weight Loss Phase

The active weight loss phase occurs when patients are consistently losing weight, often rapidly. This period is marked by ongoing changes in body composition, including reductions in fat volume in the face and body. As fat depots shrink, skin that was previously stretched can become lax. The severity of these changes depends on factors such as age (patients over 55 are at higher risk), total weight lost (over 20 pounds increases risk), and the speed of loss ^[6]. Significant facial changes, such as sagging, wrinkles, or a tired appearance, can appear within three to six months of starting GLP-1 medication ^[9].

During this phase, aesthetic concerns can arise quickly. Patients may experience facial deflation, particularly in the midface and temples. They may also notice skin laxity in the neck, arms, abdomen, and thighs. The primary goal of aesthetic intervention during active weight loss is to provide support and address the most immediate and distressing concerns without performing extensive corrections that may become disproportionate with further weight loss. Early treatment in this phase remains a subject of discussion among experts. A Delphi panel of 10 experts, supported by a Galderma grant, found that 70% would start poly-L-lactic acid (PLLA) at the same time as medication-associated weight loss ^[15]. This suggests an expert consensus for early biostimulation to prompt collagen formation, potentially to prepare the skin for future tightening or to reduce the impact of volume loss.

Treatment Considerations During Active Weight Loss:

• Conservative Volume Replacement: Hyaluronic acid (HA) fillers can be used cautiously for immediate volume restoration in areas like the midface or temples. The goal is to address hollowness that contributes to a gaunt or tired appearance. However, large-volume corrections should be avoided, as further weight loss could lead to an unnatural or overfilled look. Clinicians considered HA filler the best facial treatment for an average of 47% of GLP-1 patients in a survey of 406 providers ^[8].
• Biostimulators: Products like PLLA (e.g., Sculptra) or calcium hydroxylapatite (CaHA) can be used to stimulate collagen production. These treatments work over time to improve skin thickness and elasticity, potentially mitigating laxity as weight loss progresses ^[8]. This aligns with the Delphi panel’s view on initiating PLLA early ^[15].
• Skin Quality Treatments: Treatments that improve skin texture and tone, such as mild chemical peels, microdermabrasion, or certain lasers, can be considered to enhance overall skin health. Topical regimens, as explored in a SkinCeuticals-associated study combining a topical regimen with focused ultrasound, may also play a supporting role ^[17].
• Patient Education and Expectation Management: It is crucial to inform patients that their appearance will continue to change. Treatments during this phase are often temporary or preparatory. Baseline photography and skin assessment should occur early, before significant appearance changes are established ^[6].
• Monitoring and Assessment: Regular assessments of weight loss, skin condition, and patient concerns are necessary. A practical sequence often begins with assessment, followed by conservative structural volume correction, then collagen and skin-quality treatments ^[33].

An example of combination care during this phase is a Galderma phase IV study that used Sculptra with Restylane. Patients received Sculptra plus Restylane at baseline, another Sculptra session with optional filler adjustment at week four, and an optional third Sculptra session at week eight. At month nine, 85.7% reported a less gaunt appearance, and 91.4% would recommend the regimen ^[16]. This suggests that combined approaches addressing both volume and collagen stimulation can be effective even during the active weight loss period.

2. Weight Stabilization Phase

The weight stabilization phase begins when the patient’s weight loss slows significantly or plateaus. This period can last for several months. While the body is no longer undergoing rapid changes, the skin and underlying tissues are still adjusting. This phase is important for assessing the true extent of skin laxity and volume loss, as the rapid changes have subsided.

During weight stabilization, a more definitive treatment plan can be formulated. The focus shifts from merely addressing immediate concerns to preparing for more substantial corrections or improvements. The body has had some time to adapt, and the final contour changes become clearer. This is a critical time for re-evaluating the patient’s aesthetic needs and desires, especially since a McKinsey survey noted that 56% of GLP-1 aesthetic patients desired a natural result close to their earlier appearance, while 44% were open to a different look ^[10].

Treatment Considerations During Weight Stabilization:

• Refined Volume Restoration: Once weight is stable, more precise and potentially larger-volume filler applications can be considered for facial deflation. This can include areas like the cheeks, temples, jawline, and periorbital region. Fat grafting, though debated by the Delphi panel (which split evenly on its use ^[15]), could also be considered for longer-lasting volume.
• Skin Tightening: Energy-based devices become more relevant here for mild to moderate laxity. External radiofrequency (RF) and ultrasound treatments can provide modest tightening. For instance, a Sofwave upper-arm study reported improvement in 93% of treated arms after two sessions ^[34]. A SkinCeuticals-associated study found a 44% reduction in graded facial laxity at 12 weeks with one focused-ultrasound treatment combined with topical care ^[17].
• Further Biostimulation: Continued use of biostimulators can build upon initial treatments, further improving skin elasticity and firmness.
• Body Contouring (Non-surgical): For mild to moderate body laxity, devices like external RF can be applied to areas such as the abdomen, arms, and thighs. Bio2 Laser Studio, for example, offers non-invasive external RF body and facial contouring explicitly linking it to GLP-1 weight loss, with package pricing for multiple sessions ^[37].
• Assessment for Surgical Referral: If severe skin excess or hanging skin is present, this phase is crucial for formal surgical consultation. Non-surgical treatments have limits; surgery remains the main referral path for significant excess skin ^[39]. The American Society of Plastic Surgeons (ASPS) noted that 20% of GLP-1 patients under their members’ care had already undergone plastic surgery, while 39% were considering surgery, and 41% were considering non-surgical procedures ^[12]. This highlights the split in demand and the need for clear referral pathways.

3. Weight Maintenance Phase

The weight maintenance phase is the long-term period where the patient has achieved their goal weight and sustained it. This is typically when the most definitive and lasting aesthetic treatments can be performed, as the body has fully adapted to its new shape. However, because obesity is often considered a chronic, relapsing disease, GLP-1 therapy may continue indefinitely ^[4]. Therefore, continuous monitoring of weight and body changes remains important.

Treatment Considerations During Weight Maintenance:

• Surgical Body Contouring: For patients with severe skin laxity and excess, surgical procedures such as abdominoplasty, arm lifts, thigh lifts, breast lifts, and buttock lifts become the most effective solution. In 2024, U.S. abdominoplasty volume reached 171,064 procedures. Arm lifts rose by 2%, thigh lifts by 3%, and buttock lifts by 3% from 2023 ^[13]. These numbers show a clear demand for surgical solutions for skin excess. It is important to note that ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms are active ^[14].
• Long-term Skin Quality and Tightening: Continued or periodic energy-based treatments and biostimulators can help maintain skin quality and address any minor or recurring laxity.
• Facial Rejuvenation: This phase allows for more comprehensive facial rejuvenation procedures, which may include surgical lifts (e.g., facelift, neck lift) if non-surgical methods are insufficient for significant laxity and jowling. Facial fat grafting, which saw a 19.2% increase in 2024 with about 0.9 million procedures globally, could be used for long-term volume replacement ^[15].
• Integrated Care: Ongoing coordination with the patient’s GLP-1 prescriber and other healthcare providers (e.g., nutritionists, exercise physiologists) is crucial. The aesthetic service line may need links to nutrition, resistance exercise, hair care, and medical management rather than skin treatment alone, as noted by findings that 30% of patients reported hair loss and 19% reduced strength after 10-20% weight loss ^[7].

Key Factors Influencing Treatment Decisions Across Phases

Several factors influence the choice and timing of aesthetic treatments across the different phases of GLP-1 induced weight loss. Clinical directors need to consider these comprehensively to provide safe and effective care.

Patient-Reported Concerns and Expectations

Patient satisfaction with GLP-1 treatment for weight loss is high, with 92% reporting satisfaction, 84% improved body image, and 68.5% greater self-confidence in one study ^[6]. However, appearance concerns exist alongside these positive feelings. A total of 38.7% of GLP-1 users reported skin changes ^[6]. The patient’s specific concerns (e.g., facial deflation, neck laxity, loose body skin) should guide treatment ^[8]. It is important to ascertain whether the patient seeks to restore a prior appearance or is open to a new look. McKinsey found that 56% wanted a natural result close to their earlier appearance, while 44% were open to a different look ^[10]. This requires careful consultation and clear communication of realistic outcomes.

Age, Weight Loss Amount, and Speed of Loss

These are critical biological factors. Skin changes are more commonly associated with age over 55 and weight loss exceeding 20 pounds ^[6]. The speed of weight loss also plays a role; rapid loss can leave less time for the skin to contract, potentially leading to greater laxity. Intake protocols should carefully record age, the percentage and speed of weight loss, medication stage, specific body sites affected, skin quality, and weight stability ^[23].

Severity of Laxity

The degree of skin laxity is a primary determinant of treatment modality. A three-level grading system (mild, moderate, or severe) can help classify laxity and guide treatment pathways ^[23]. For mild laxity, non-invasive energy-based devices (e.g., external ultrasound, non-needle RF) may be sufficient ^[34]. Moderate laxity may benefit from a combination of non-invasive treatments or minimally invasive procedures. Severe laxity, often presenting as hanging or excess skin, almost always requires surgical excision ^[39]. Clinics should maintain firm surgical referral limits and avoid promising surgical-level results from device-based treatments for severe cases ^[39].

Table 1: Treatment Modality by Laxity Grade

Laxity Grade	Characteristics	Primary Treatment Modalities	Examples
Mild	Subtle looseness, slight loss of elasticity, mostly aesthetic concern.	Non-invasive energy devices, topical treatments, biostimulators.	External RF, focused ultrasound, PLLA, CaHA, quality skincare.
Moderate	Noticeable skin folds when compressed, some sagging, early jowling.	Combination of injectables and energy devices, minimally invasive options.	HA fillers (volume), PLLA/CaHA (collagen), focused ultrasound, external RF, potentially thread lifts.
Severe	Significant folds, hanging skin, functional issues (e.g., intertrigo).	Surgical excision is the most effective approach.	Abdominoplasty, arm lift, thigh lift, breast lift, facelift.

Patient Budget and Expectations

McKinsey’s research indicated that approximately 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ^[11]. This suggests that aesthetic care for this group must be budget-conscious and provide clear value. Staged treatment plans, starting with the highest-priority concerns and allowing for subsequent care after weight stability, can accommodate budget limitations ^[11]. Clinics should offer clear pricing and high-value combinations rather than presuming unlimited spending capacity ^[11]. Transparency in pricing and realistic expectations for outcomes are important for building trust, especially given that 94% of consumers use ratings and review sites when choosing a provider ^[16].

Safety and Timing Considerations for Specific Modalities

The safety profile and appropriate timing of specific aesthetic treatments are paramount. The U.S. Food and Drug Administration (FDA) issued a safety communication on October 15, 2025, regarding potential risks with certain uses of radiofrequency (RF) microneedling, citing reported burns, scarring, fat loss, disfigurement, and nerve damage ^[13]. This warning specifically applies to RF microneedling and not every form of RF treatment. Clinical directors must differentiate between needle-based RF, external RF, and minimally invasive subdermal RF in staff training and patient consent processes ^[44]. This FDA warning may shift demand toward non-needle energy devices or providers with stronger medical oversight ^[44].

Furthermore, surgical procedures require careful timing. ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and when patients experience active gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, constipation) ^[14]. This necessitates coordination with the patient’s medication prescriber to ensure patient safety and optimal surgical outcomes. A 2026 study from West Virginia University found possible differences in wound healing but no clear rise in overall surgical risk for panniculectomy patients on GLP-1s, highlighting the need for specific, rather than blanket, assumptions regarding surgical risk ^[46].

The Interconnectedness of Care and the Role of Clinical Directors

The phenomenon of GLP-1 induced weight loss requires an integrated and flexible approach to aesthetic care. Clinical directors play a pivotal role in shaping this service line within their practices. This includes:

• Comprehensive Intake and Assessment: Beyond aesthetic concerns, intake should include medical history, GLP-1 medication details (type, dosage, duration), weight loss trajectory, nutritional status, physical activity levels, and psychological well-being. A thorough initial assessment helps establish realistic goals and appropriate treatment pathways.
• Staged Treatment Plans: Offering staged plans that align with the patient’s weight loss phase and budget is crucial. This means starting with less permanent, more conservative treatments during active weight loss and reserving more definitive or surgical options for the stabilization and maintenance phases ^[11].
• Clear Communication and Consent: Patients need to understand the potential for ongoing changes, the limitations of various treatments, expected outcomes, and associated costs. Consent forms should clearly distinguish between different RF technologies and their respective risks ^[44].
• Referral Networks: Establishing strong referral relationships with plastic surgeons for severe laxity, as well as with nutritionists and exercise specialists, is important. A clinic offering only devices should build a formal plastic-surgery referral path ^[12]. The aesthetic service line may also need to connect with hair care and medical management for other reported issues like hair loss ^[7].
• Outcome Tracking: To validate treatment efficacy and improve patient care, clinics should track specific outcomes. This includes consultation source, weight-loss stage, concern type, laxity grade, selected treatment, series completion rates, patient-reported improvement scores, photography grades, adverse events, refunds, repeat care, and surgical referrals ^[38]. This data can inform future purchase decisions and strengthen efficacy claims. For example, Bio2 Laser Studio’s public pages do not provide peer-reviewed post-GLP-1 outcome data, highlighting the need for internal tracking to support stronger efficacy claims ^[37].

The global aesthetic market is already substantial, with nearly 38 million procedures performed in 2024, including over 17.4 million surgical and 20.5 million non-surgical procedures ^[14]. The influx of GLP-1 patients is adding to this existing demand base. Clinical directors must expand their services thoughtfully, track their own outcomes, and maintain clear surgical referral limits ^[15].

Conclusion for this section

The definition of ‘Post-GLP-1’ in aesthetic care is nuanced, extending beyond merely stopping medication. It recognizes the continuous nature of obesity management and the aesthetic consequences of significant weight loss during ongoing treatment. A phased approach that considers the active weight loss, stabilization, and maintenance periods is important for effective patient care. Clinical directors must adapt their services to address multiple patient concerns, manage expectations, and integrate diverse treatment modalities, including surgical referrals for severe cases. By focusing on comprehensive assessment, staged treatment plans, and transparent communication, clinics can meet the growing demand from GLP-1 patients while maintaining high standards of safety and efficacy. This framework ensures that aesthetic interventions support the overall health and well-being goals of these patients.

The subsequent section will explore into the specific patient-reported concerns and risk factors for skin laxity, providing a more detailed understanding of who is affected and what challenges they face.

---

Sources

1. In U.S., GLP-1 Usage Reaches New High – Gallup – July 7, 2026 – https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
2. Novo Nordisk Annual Report 2025: Commercial Execution – Novo Nordisk – 2026 – https://annualreport.novonordisk.com/2025/strategic-aspirations/commercial-execution.html
3. Global Survey 2024 – International Society of Aesthetic Plastic Surgery – June 19, 2025 – https://www.isaps.org/media/lcvdjt1f/isaps-global-survey_2024.pdf
4. WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity – World Health Organization – December 1, 2025 – https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
5. Once-Weekly Semaglutide in Adults With Overweight or Obesity – New England Journal of Medicine – 2021 – https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
6. Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss – Journal of Cosmetic Dermatology – 2026 – https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.71145
7. Skin Impacts and Tradeoffs of GLP-1 Therapy – PubMed – August 2026 – https://pubmed.ncbi.nlm.nih.gov/42579223/
8. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss – Dermatologic Surgery – 2026 – https://pubmed.ncbi.nlm.nih.gov/42210883/
9. Understanding the Aesthetic Impact of Medication-Driven Weight Loss – Galderma – 2025 – https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
10. GLP-1s Are Boosting Demand for Medical Aesthetics – McKinsey & Company – 2025 – https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
11. GLP-1s Are Boosting Demand for Medical Aesthetics – McKinsey & Company – 2025 – https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
12. 2024 Plastic Surgery Statistics Report – American Society of Plastic Surgeons – June 25, 2025 – https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
13. Plastic Surgery Statistics | American Society of Plastic Surgeons – https://www.plasticsurgery.org/plastic-surgery-statistics?utm_source=openai
14. Emerging Guidance on the Rise of GLP-1 Receptor Agonist Drugs – International Society of Aesthetic Plastic Surgery – May 22, 2026 – https://www.isaps.org/media/tw1j4oko/260522_isaps-ps-emerging-guidance_rise-of-glp-1-ra-drugs_final.pdf
15. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients – Journal of Cosmetic Dermatology – 2025 – https://www.galdermaaesthetics.com/ca/sites/default/files/2025-11/Consensus-Statements-on-Managing-Aesthetic-Needs-in-Prescription.pdf
16. Final Nine-Month Data on Injectable Treatment After Medication-Driven Weight Loss – Galderma – July 17, 2025 – https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss
17. Clinical Efficacy of a Topical Regimen Before and After Ultrasound in GLP-1 Users – PubMed – 2026 – https://pubmed.ncbi.nlm.nih.gov/41781778/
18. Risk varies by age, weight loss, and treatment phase – Section 2 in Main Insights.
19. Implication: A practical sequence is assessment first, conservative structural volume correction second, collagen and skin-quality treatment third, and surface treatment last. Reassess during active loss. Avoid large early corrections that may look excessive after further weight change. – Section 3 in Main Insights.
20. External ultrasound and non-needle RF may gain share for mild or moderate laxity. A Sofwave upper-arm study found improvement in 93% of treated arms after two sessions. The evidence came from a manufacturer clinical summary and should not be applied automatically to older patients, severe laxity, or every body site. – Section 4 in Main Insights. https://api.sofwave.com/app/uploads/2024/12/MK00105_E-Upper-Arm-Lax-Skin-Lifting_Clinical-Study-Summary.pdf
21. Bio2 Laser Studio: small-clinic packaging for GLP-1 patients – Section 6 in Notable Examples. https://bio2laserstudio.com/radiofrequency-body-contouring-san-antonio
22. Implication: Track consultation source, weight-loss stage, concern type, laxity grade, treatment selected, series completion, patient-reported improvement, photography grade, adverse events, refunds, repeat care, and surgical referrals. Purchase decisions should be based on local utilization and measured results, not a broad GLP-1 growth headline. – Section 6 in Main Insights.
23. The modality mix will move from fat removal to tightening, structure, and excision – Section 4 in Main Insights.
24. The FDA warning does not apply equally to every RF platform. Clinical directors should separate needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices in staff training and consent. Marketing all of them under one broad “RF tightening” label can hide major differences in depth and risk. – Section 5 in Main Insights.
25. A 2026 West Virginia University study examined 373 panniculectomy patients treated from 2013 to 2023. Of them, 21.7% were taking GLP-1 medicines before surgery. The study found possible differences in wound healing but no clear rise in overall surgical risk, showing why blanket assumptions are unsafe. – Section 5 in Main Insights. https://www.plasticsurgery.org/news/press-releases/weight-loss-medications-may-affect-some-complications-after-panniculectomy

5. Incidence and Types of Skin Changes

Weight loss achieved through Glucagon-Like Peptide-1 (GLP-1) receptor agonists provides significant health benefits for many individuals. However, rapid and substantial reductions in body mass can lead to noticeable changes in skin appearance. These changes often present as cosmetic concerns for patients. Clinical directors must understand the frequency and specific kinds of skin alterations that occur with GLP-1 use. This understanding helps in planning appropriate aesthetic interventions. The goal is to support patients’ overall well-being and confidence following their weight loss success.

The patient population using GLP-1 medicines for weight loss has grown quickly. In June 2026, 11% of U.S. adults were current GLP-1 users for weight loss, up from 3% in 2024. An additional 4% had used a GLP-1 medicine at some point in the past, bringing the total to 15% of U.S. adults who had used one ^[1]. This expansion means that the number of people experiencing potential skin changes is also rising. Novo Nordisk reported that its obesity medicines reached 3.6 million people in 2025. Wegovy, one such medicine, was available in 52 countries that year, a rise from 17 countries in 2024 ^[2]. This global reach, though uneven, ensures a growing pool of individuals who may seek aesthetic care for skin changes related to weight loss.

It is important to note that “Post-GLP-1” generally refers to the state after significant weight loss has occurred, rather than after stopping treatment. The World Health Organization (WHO) considers obesity a chronic condition that can return. It supports long-term GLP-1 therapy under certain conditions ^[3]. Therefore, clinics must plan for patient care during active weight loss, during the stabilization phase, and for long-term maintenance. Skin changes can appear at different stages of this process. The types of changes and their severity depend on various factors, including age, the amount of weight lost, and the speed of weight loss. Clinics are already observing increased demand for aesthetic services from GLP-1 patients ^[4]. This section reviews the reported rates and specific types of skin changes, offering a detailed analysis of their incidence and characteristics.

5.1 Overall Incidence Rates of Skin Changes

Skin changes are a common result of significant weight loss, regardless of how the weight loss is achieved. However, the specific rates reported in studies vary. These differences often stem from varying study designs, patient populations, and definitions of “skin changes.” One 2026 survey, which included 504 GLP-1 users, reported that 38.7% noticed skin changes ^[5]. This figure suggests that a substantial portion of individuals using GLP-1 medicines will experience some form of skin alteration.

A separate 2026 study focused on individuals who had lost 10% to 20% of their body weight. In this group, 44% reported skin sagging ^[6]. This rate is higher than the 8.3% sagging rate reported in the 504-person survey. The difference highlights the importance of considering the specific weight loss range and the focus of the questions asked in each study. The initial study measured a broad category of “skin changes,” while the second study specifically inquired about “skin sagging.”

Another research project, an international four-month study reported by Galderma in 2025, involved over 1,300 patients undergoing medication-assisted weight loss. This study found that 48% of these patients experienced significant facial changes ^[7]. Furthermore, 77% reported at least one negative change, such as sagging, wrinkles, or a tired appearance ^[7]. These findings suggest that facial appearance is particularly sensitive to weight loss. The changes typically appear within three to six months of starting treatment ^[7]. This timing means that patients may seek aesthetic consultations while still actively losing weight.

The variance in reported rates underscores the need for clear definitions and standardized assessment methods in future research. Factors like patient demographics, initial body mass index (BMI), total weight lost, and the duration of GLP-1 treatment can all influence the incidence of skin changes. Despite the variability, the data consistently indicate that skin changes are a frequent side effect of GLP-1 induced weight loss, affecting a significant minority, and in some cases, nearly half, of users. This high incidence creates a substantial demand for aesthetic services. Clinical directors must be ready to address these concerns.

Table 5.1: Reported Incidence Rates of Skin Changes Among GLP-1 Users

Study Source	Year	Patient Population	Reported Incidence	Specific Type
Olivero and colleagues [5]	2026	504 GLP-1 users	38.7%	General skin changes
“Skin Impacts and Tradeoffs of GLP-1 Therapy” [6]	2026	Subgroup of 395 respondents with 10-20% weight loss	44%	Skin sagging
Galderma Medication-Driven Weight Loss Report [7]	2025	>1,300 medication-assisted weight-loss patients	48%	Significant facial changes
Galderma Medication-Driven Weight Loss Report [7]	2025	>1,300 medication-assisted weight-loss patients	77%	At least one negative change (sagging, wrinkles, tired appearance)

5.2 Specific Types of Skin Changes

GLP-1 induced weight loss can result in several distinct types of skin changes. These changes affect both the face and body. The most commonly reported issues include facial volume loss, skin sagging, and jowling. These are often accompanied by other concerns like changes in skin quality or texture.

5.2.1 Facial Volume Loss

Facial volume loss is a prominent concern among GLP-1 users. The 2026 survey of 504 GLP-1 users found that 10.9% specifically reported facial volume loss ^[5]. This condition, sometimes called “GLP-1 face” or “Ozempic face,” results from the reduction of subcutaneous fat in the face. This fat contributes to a youthful, full appearance. When it decreases, the face can appear gaunt, hollow, or older than the patient’s actual age. Areas commonly affected include the cheeks, temples, and under-eye regions. The decrease in volume can make wrinkles and fine lines more noticeable.

In the “Skin Impacts and Tradeoffs of GLP-1 Therapy” study, 37% of respondents with 10% to 20% weight loss reported decreased facial volume ^[6]. This higher percentage indicates that even moderate weight loss can significantly impact facial fullness. The rapid nature of GLP-1 induced weight loss can exacerbate this effect, as the skin may not have enough time to adapt to the reduced underlying support. The Galderma report also noted that significant facial changes were common, with 48% of patients reporting them ^[7]. These changes often included aspects related to volume loss, contributing to a tired or aged appearance.

5.2.2 Skin Sagging and Laxity

Skin sagging, also referred to as skin laxity, is another frequent outcome of weight loss. As fat stores decrease, the skin, which has been stretched to accommodate the larger body volume, may not fully retract. This leads to loose or redundant skin. In the 2026 survey of GLP-1 users, 8.3% reported skin sagging ^[5]. The other 2026 study, specifically asking about sagging in patients with 10-20% weight loss, found a much higher incidence of 44% ^[6]. This difference suggests that general “skin changes” in one survey are not the same as specific “skin sagging” in another. Sagging can occur on both the face and various body areas.

Common body sites for skin sagging include:

• The abdomen (leading to an “apron” or pannus)
• Upper arms (often called “bat wings”)
• Thighs
• Breasts
• Buttocks

The severity of sagging is often related to the total amount of weight lost, the speed of loss, and individual factors like age and skin elasticity. Patients undergoing significant weight loss, such as those achieving the 14.9% with semaglutide or up to 20.9% with tirzepatide in clinical trials, are at a higher risk for widespread skin laxity ^[8][9]. This means clinical directors should expect patients to present with concerns across multiple body parts, not just isolated areas.

5.2.3 Jowling

Jowling is a specific type of facial sagging that occurs along the jawline. It results from a combination of skin laxity and gravity, where facial tissues descend and collect around the lower jaw. The 2026 survey found that 7.7% of GLP-1 users reported jowling ^[5]. This condition can alter the facial contour, making the jawline less defined and contributing to an older appearance. Jowling is a direct consequence of the loss of structural support from underlying fat and the diminished elasticity of the skin. It is often a key concern for patients seeking facial rejuvenation after weight loss.

5.2.4 Other Skin Quality and Related Concerns

Beyond volume loss and sagging, patients may experience other changes in skin quality. The Galderma report indicated that 77% of patients reported at least one negative change, including wrinkles or a tired appearance ^[7]. These can involve changes in skin texture, elasticity, and overall tone. While not explicitly detailed as “types” of changes in all studies, these are linked to the overarching effect of rapid weight reduction on skin health. Poor skin quality can exacerbate the visual impact of laxity and volume loss.

The problems faced by GLP-1 aesthetic patients are often interconnected. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for several linked issues ^[10]. These included laxity, poor skin quality, and facial deflation ^[10]. This confirms that skin changes are not isolated events but rather part of a complex presentation requiring a comprehensive approach.

5.3 Factors Influencing Skin Changes

Several factors influence the likelihood and severity of skin changes following GLP-1 induced weight loss. Understanding these factors helps clinicians identify patients at higher risk and tailor their consultation and treatment plans. The main influencing factors include age, total weight lost, and the speed of weight loss.

5.3.1 Age

Age is a significant predictor of skin changes. The 2026 survey found that skin changes were more common in individuals over 55 years old ^[5]. Older skin naturally has reduced elasticity and collagen content compared to younger skin. This means it is less capable of retracting and adapting to changes in body volume. As a result, older GLP-1 users are more likely to experience pronounced sagging and laxity after weight loss. This factor must be considered during initial assessment and treatment planning. Patients over 55 may require more aggressive or combination treatments to achieve satisfactory results.

5.3.2 Total Weight Lost

The amount of weight lost directly correlates with the extent of skin changes. The 2026 survey reported that skin changes were associated with a weight loss above 20 pounds ^[5]. Larger weight reductions mean more significant stretching of the skin. This leads to a greater likelihood of redundant skin that cannot fully contract. Clinical trials for GLP-1 medicines show substantial weight loss: 14.9% with semaglutide and up to 20.9% with tirzepatide ^[8][9]. These levels of weight loss are sufficient to cause considerable changes in facial fat compartments, neck contours, and body areas such as breasts, arms, abdomen, thighs, and buttocks ^[8][9]. Therefore, clinical directors should expect patients with significant weight loss to present with concerns affecting several areas of the body.

5.3.3 Speed of Weight Loss

The speed at which weight is lost also plays a role. Rapid weight loss can give the skin less time to gradually adapt and retract. The 2026 survey highlighted that among those who reported skin changes, 55.1% noticed them within the first five months of GLP-1 treatment ^[5]. This suggests that the early, rapid phase of weight loss is when skin changes become apparent. This timing underscores the importance of early intervention and assessment. Baseline photography and skin evaluation should be performed before significant appearance changes are fully established. This helps in tracking progression and planning timely treatments. Early, conservative treatments might help support skin health as weight loss progresses.

5.3.4 Other Contributing Factors

While not as explicitly detailed in the provided research text, other factors likely contribute to skin changes. These include genetics, sun exposure history, smoking status, nutritional status, and skin care practices. For instance, individuals with a history of extensive sun exposure may have poorer skin elasticity, making them more prone to sagging. Good nutrition, especially adequate protein intake, is vital for skin health and repair. Clinical directors should consider these broader factors during patient consultations to provide holistic advice and treatment plans.

5.4 Patient Experience and Demand for Aesthetic Care

The incidence of skin changes directly drives the demand for aesthetic treatments among GLP-1 users. Clinical directors are already experiencing this increased demand. A survey of 406 aesthetic health professionals reported a mean increase of 137% in GLP-1 patients from 2023 to 2024 ^[4]. This sharp rise indicates a clear need for aesthetic services custom to this population.

The leading concerns reported by these professionals included midface volume loss, face and neck laxity, and loose body skin ^[4]. This aligns with the specific types of skin changes observed in patient surveys. The American Society of Plastic Surgeons (ASPS) also tracked GLP-1 patients. Among these patients, 20% had already undergone plastic surgery related to weight loss, 39% were considering surgery, and 41% were considering a non-surgical procedure ^[11]. This data shows a clear split in demand between surgical and non-surgical interventions, with a substantial patient base for both.

Despite the cosmetic concerns, it is important to recognize that GLP-1 users generally experience high satisfaction with their medication and overall health improvements. The 504-person study found that 92% were satisfied with the medication, 84% reported improved body image, and 68.5% reported greater self-confidence ^[5]. This means aesthetic care should support these health gains rather than frame weight loss as a cosmetic failure. The focus should be on enhancing positive outcomes and addressing specific concerns to improve overall quality of life.

The high incidence of multiple concerns means that patients often seek comprehensive solutions. The McKinsey survey revealing that 63% of GLP-1 aesthetic patients requested care for several linked issues confirms this ^[10]. These issues include laxity, poor skin quality, and facial deflation. This indicates that standard treatment packages based on a single device or injection type will likely only fit a portion of the market. Instead, combination plans that address various tissue problems will likely gain market share.

5.5 Clinical Implications and Assessment Strategies

The frequent incidence and specific types of skin changes among GLP-1 users have direct clinical implications for aesthetic practices. Clinical directors need to adopt specific assessment strategies and treatment approaches to effectively manage these patients.

5.5.1 Comprehensive Patient Intake and Assessment

A thorough intake process is crucial. It should gather information beyond standard aesthetic concerns. Key data points for GLP-1 patients include:

• Age: To assess baseline skin elasticity and potential for significant changes.
• Percentage and Speed of Weight Loss: To gauge the severity and timing of expected skin alterations.
• Medication Stage: Whether the patient is actively losing weight, stable, or in maintenance.
• Specific Concerns: Detailed reporting of facial volume loss, body sagging sites, and skin quality changes.
• Weight Stability: To determine the optimal timing for certain interventions.
• Nutritional Status: To understand factors influencing skin health and healing.
• Strength and Exercise Regimen: Muscle mass can influence overall body contour and skin support.
• Patient Priorities: What bothers the patient most, and what their aesthetic goals are.

Baseline photography is essential to document the initial state and track changes over time. Skin assessment should occur early in the weight loss journey, even before large appearance changes are fully established. This proactive approach allows for early intervention and education.

5.5.2 Grading Skin Laxity

To guide treatment decisions, a system for grading laxity is useful. A simple three-level grade – mild, moderate, or severe – can help. This classification guides appropriate interventions:

• Mild Laxity: May respond well to non-invasive devices like external radiofrequency (RF) or ultrasound, or topical treatments.
• Moderate Laxity: May benefit from combination non-surgical approaches, possibly including injectables for volume and biostimulators for collagen.
• Severe Laxity (e.g., hanging skin, significant excess): Often requires surgical referral for excision.

It is critical that clinicians manage patient expectations. Energy-based treatments, even advanced ones, cannot replace surgery for severe skin excess. Bio2 Laser Studio, for example, offers external RF body and facial contouring services and links them to GLP-1 weight loss ^[12]. While such treatments can address mild to moderate laxity, it is important to set realistic expectations for patients with severe cases. Clinical directors should avoid promising surgical-level results from non-surgical interventions in cases of severe laxity.

5.5.3 Timing of Interventions

The timing of aesthetic interventions needs careful consideration. Early treatment, possibly while patients are still losing weight, remains a subject of discussion among experts. A Delphi panel of 10 experts, supported by a Galderma grant, found that 70% would start poly-L-lactic acid (a biostimulator) at the same time as medication-associated weight loss ^[13]. However, the panel was evenly split on the timing of fat transfer procedures ^[13].

A practical sequence for interventions is:

1. Assessment: First and ongoing throughout the weight loss journey.
2. Conservative Structural Volume Correction: Addressing facial deflation with fillers, being mindful not to overcorrect if further weight loss is expected.
3. Collagen and Skin Quality Treatment: Using biostimulators or skin-quality enhancing treatments.
4. Surface Treatments: Addressing texture and superficial concerns.

During active weight loss, reassessment is important. Large early corrections should be avoided, as they might appear excessive after further weight changes. Waiting for weight stabilization often allows for more precise and lasting aesthetic results, especially for volume replacement and surgical body contouring. However, early interventions for skin quality and mild laxity can help support the skin as weight loss progresses.

5.5.4 Referral Pathways

Given the range of severity and types of skin changes, establishing clear referral pathways is critical. Clinics that primarily offer non-surgical treatments should have formal relationships with plastic surgeons for patients requiring surgical intervention. ASPS data show that a significant portion of GLP-1 patients will either need or consider surgery ^[11]. Therefore, a dual system of care is necessary. Mild and moderate cases can often be managed in the aesthetic clinic, while severe cases of hanging or excess skin require surgical expertise. This collaborative approach ensures that patients receive the most appropriate and effective care for their specific needs.

5.6 Future Outlook for Incidence and Types of Skin Changes

The incidence and types of skin changes among GLP-1 users will continue to influence aesthetic practices as GLP-1 adoption expands globally. The World Health Organization estimates that fewer than 10% of those who could benefit will receive these medicines by 2030, meaning there is still vast room for growth ^[3]. This indicates that the number of patients experiencing skin changes will rise significantly over the coming years.

The ongoing research will likely refine our understanding of the specific biological mechanisms underlying these skin changes. This could lead to more targeted interventions. As more individuals achieve significant weight loss through GLP-1 medicines, the demand for comprehensive aesthetic solutions will grow. This will push for more combination treatments that address volume loss, laxity, and skin quality simultaneously. Clinical directors should prepare for a sustained increase in patient consultations related to GLP-1 induced skin changes. They should remain flexible in their offerings and referral networks.

The understanding of incidence and types of skin changes forms the foundation for developing effective treatment strategies. This leads directly to the discussion of specific treatment approaches. The next section will explore the various modalities available for addressing these changes, from injectables to energy-based devices and surgical options.

5.7 Detailed Analysis of Specific Types of Skin Changes and Their Impact

The various types of skin changes associated with GLP-1 induced weight loss are not merely cosmetic issues. They can have a significant impact on a patient’s self-perception, social interactions, and overall quality of life. Understanding these impacts helps clinical directors approach patient care with greater empathy and effectiveness.

5.7.1 Facial Volume Loss: The “GLP-1 Face” Phenomenon

The term “GLP-1 face” has emerged to describe the specific facial aesthetic changes that occur with rapid and significant weight loss using these medications. As previously noted, facial volume loss affected 10.9% of GLP-1 users in one survey ^[5] and 37% of a subgroup with 10-20% weight loss in another ^[6]. This loss of facial fat can lead to:

• Hollowed Cheeks: The natural fullness of the midface diminishes, creating a sunken appearance.
• Temple Hollowing: Loss of fat in the temporal region can make the face appear more angular and aged.
• Prominent Nasolabial Folds and Marionette Lines: With reduced skin support, these lines can deepen and become more noticeable.
• Under-Eye Hollowness: The tear trough area can become more pronounced, giving a fatigued look.
• Loss of Jawline Definition: While jowling contributes, the overall reduction in facial volume can make the lower face appear less structured.

These changes can contradict the positive feelings associated with weight loss. Patients often feel healthier but may struggle with a facial appearance that seems older or gaunt. This discrepancy drives a strong desire for facial rejuvenation. The Galderma report highlighted that 77% of patients reported at least one negative facial change, such as a tired appearance ^[7]. Addressing facial volume loss is therefore a primary concern for many GLP-1 patients seeking aesthetic treatment.

5.7.2 Skin Sagging and Laxity: Body-Wide Concerns

Skin sagging is a widespread issue, affecting various parts of the body. The 44% incidence of skin sagging in patients with 10-20% weight loss ^[6] points to its commonality. The extent of sagging is often proportional to the amount of weight lost.

• Abdominal Laxity: This is one of the most common and distressing forms of body laxity. It can range from mild skin folds to a full pannus (excess apron of skin). This can cause discomfort, hygiene issues, and challenges with clothing. Abdominoplasty volume in the U.S. was 171,064 procedures in 2024, indicating a high existing demand for this surgical correction ^[14]. While not all are GLP-1 related, it shows the scale of need for body contouring.
• Upper Arm Laxity: “Bat wings” are a frequent complaint, where excess skin hangs from the upper arms. This can limit clothing choices and impact self-confidence.
• Thigh Laxity: Loose skin on the inner and outer thighs can cause chafing and discomfort, especially during physical activity. Thigh lifts saw a 3% increase from 2023 ^[14].
• Breast Ptosis: Weight loss can cause breasts to lose volume and sag, requiring lifts or augmentation.
• Buttock Sagging: Loss of volume and laxity can lead to a flattened or sagging appearance of the buttocks, impacting body shape. Buttock lifts increased by 3% from 2023 ^[14].
• Neck Laxity: Often referred to as “turkey neck,” this involves loose skin and bands around the neck, contributing to an aged appearance. Face and neck laxity were among the leading concerns reported by aesthetic professionals seeing GLP-1 patients ^[4].

The presence of skin sagging across multiple body areas means that patients often require comprehensive body contouring plans. This can involve a combination of non-surgical tightening procedures for mild cases and surgical excisions for moderate to severe laxity. The fact that 63% of GLP-1 aesthetic patients in a McKinsey survey requested care for several linked issues underscores the body-wide nature of these concerns ^[10].

5.7.3 Jowling: Impact on Jawline Definition

Jowling, reported by 7.7% of GLP-1 users ^[5], specifically affects the definition of the jawline. A clear, well-defined jawline is often associated with youth and attractiveness. When jowls form, the contour of the jawline becomes blurred, creating a heavier, less defined lower face. This can contribute to a disproportionate appearance in contrast to the overall thinner body. Patients seeking aesthetic improvements often prioritize restoring jawline definition as it significantly impacts facial harmony.

5.7.4 Hair Loss and Muscle Loss: Broader Considerations

While the primary focus of this section is skin changes, it is important to acknowledge other related issues. The “Skin Impacts and Tradeoffs of GLP-1 Therapy” study reported hair loss in 30% of the subgroup with 10-20% weight loss ^[6]. Reduced strength was reported in 19% ^[6]. Hair loss, often telogen effluvium, is a common temporary side effect of rapid weight loss due to physiological stress. Muscle loss can also occur with rapid weight reduction, impacting overall body shape and contributing to the appearance of skin laxity.

These broader concerns suggest that an aesthetic service line for GLP-1 patients may need to connect with other health services. This could include nutrition counseling, resistance exercise guidance, hair care specialists, and general medical management. A holistic approach can better support patients’ overall health and aesthetic goals.

5.8 Preparing for Future Demand

The data indicates that the problem of skin changes due to GLP-1 induced weight loss is substantial and growing. Aesthetic clinics must prepare for a steady influx of patients presenting with these concerns.

• Educate Staff: Ensure all staff, from front desk to providers, understand the nature of GLP-1 induced skin changes and how to compassionately address patient concerns.
• Review Modality Mix: Clinics should assess their current equipment and services. There will be a shift from fat reduction procedures to those focused on tissue support, volume replacement, and skin excision ^[15].
• Develop Combination Treatment Plans: Given that 63% of patients seek care for multiple issues ^[10], combination therapies will be key. This means combining injectables, energy-based devices, and potentially linking to surgical referrals.
• Emphasize Transparency and Staged Care: McKinsey found that 60% of GLP-1 patients reduced aesthetic spending, while 40% increased it ^[10]. This calls for clear pricing, staged treatment plans, and realistic outcome expectations.

Bio2 Laser Studio’s approach of transparently listing pricing for multi-session body and facial contouring packages, even without published GLP-1 specific outcome data, is an example of preparing for this demand ^[12]. Such clarity can reduce patient buying friction. However, clinical directors should also prioritize internal tracking of patient outcomes, completion rates, and satisfaction to refine their offerings and support efficacy claims.

The comprehensive understanding of the incidence and specific types of skin changes provides the necessary foundation for clinical directors to adapt their practices. The transition from general aesthetic services to specialized post-GLP-1 care requires careful planning and a patient-centered approach.

5.9 Conclusion of Incidence and Types of Skin Changes

The evidence consistently shows that a significant proportion of GLP-1 users experience skin changes as a result of their weight loss. These changes include facial volume loss, various forms of skin sagging, and jowling. The incidence rates vary across studies, but all point to a substantial aesthetic need. Factors such as age, total weight lost, and the speed of weight loss play a crucial role in determining the likelihood and severity of these changes.

The rise in GLP-1 adoption means clinical directors must be prepared to address these concerns effectively. This involves comprehensive patient assessment, careful grading of laxity, strategic timing of interventions, and established referral pathways for surgical cases. The demand for aesthetic services from GLP-1 patients is already high and is expected to continue growing. Therefore, adapting clinical practices to offer combination treatments and transparent, staged care plans is essential for meeting this evolving market need. The types of skin changes observed directly influence the selection of appropriate treatment modalities, which will be explored in detail in the following sections.

The profound impact of GLP-1 induced weight loss on skin appearance highlights a significant area for aesthetic intervention. As patients continue their health journey, addressing these physical changes can further enhance their quality of life. The upcoming sections will discuss the various treatment modalities and shifts in demand that clinical directors need to consider.

6. Factors Influencing Skin Changes

The rise in GLP-1 medication use for weight loss has brought increased attention to associated aesthetic changes, particularly skin laxity. Understanding the specific factors that influence the development and severity of these skin changes is vital for clinical directors, aesthetic professionals, and patients. Not every individual undergoing GLP-1 mediated weight loss will experience the same degree of skin alteration. A range of variables, including individual biological characteristics and the dynamics of weight loss itself, play a significant part. This section will examine the key factors that correlate with the development of skin changes after GLP-1 medication use, providing a detailed analysis of how age, total weight lost, and speed of weight loss contribute to these outcomes. By dissecting these elements, clinics can better predict patient needs, tailor treatment plans, and set realistic expectations for aesthetic interventions.

The patient population using GLP-1 medications for weight loss is expanding rapidly. In June 2026, 11% of U.S. adults reported current GLP-1 use for weight loss, a substantial rise from 3% in 2024. Furthermore, 15% of U.S. adults had used a GLP-1 medication at some point¹. This growing cohort presents a substantial demand for aesthetic care addressing concerns linked to weight loss. Novo Nordisk reported that its obesity medicines reached 3.6 million people in 2025, with Wegovy available in 52 countries, up from 17 in 2024³. The volume of global branded GLP-1 obesity medicine increased by 104% through November 2025⁴. This expanding user base suggests a continued increase in patients seeking solutions for post-weight loss skin changes.

Skin changes are a common consequence of significant weight reduction, with reported rates varying across studies due to differences in definitions and patient groups. A 2026 survey of 504 GLP-1 users found that 38.7% reported experiencing skin changes⁶. Specific facial concerns included volume loss (10.9%), sagging (8.3%), and jowling (7.7%)⁶. Another 2026 study reported that 44% of individuals who lost 10% to 20% of their body weight experienced skin sagging⁷. These figures underline the frequency of aesthetic issues. The presence and severity of these changes are not uniform and are influenced by several identifiable factors.

6.1. Age as a Determining Factor for Skin Changes

Age is a significant and independently recognized factor influencing skin elasticity and its ability to retract after weight loss. As individuals age, the structural components of the skin, such as collagen and elastin fibers, naturally degrade and decrease in production. This leads to a reduction in skin firmness and resilience. When significant fat volume is lost, older skin, with its diminished elastic recoil, is less able to conform to the new body contours, resulting in laxity and sagging.

The provided research highlights the direct correlation between older age and a higher incidence of skin changes following GLP-1 mediated weight loss. A 2026 survey of 504 GLP-1 users specifically identified an increased risk for individuals over the age of 55⁶. This finding is critical for clinical directors. Patients in this age group may require more proactive and potentially more intensive aesthetic interventions compared to younger patients who lose a similar amount of weight. The biological mechanisms at play include:

• Reduced Collagen and Elastin Production: With age, fibroblasts, the cells responsible for producing collagen and elastin, become less active. Collagen provides skin with its strength, while elastin provides its stretch and recoil properties. A reduction in these proteins means the skin has less structural support and is less able to spring back into place after being stretched.
• Decreased Hyaluronic Acid: Hyaluronic acid, a natural component of the skin, helps maintain hydration and plumpness. As its levels decline with age, skin can appear drier, thinner, and less able to maintain volume, exacerbating the appearance of laxity after fat loss.
• Fat Compartment Changes: The distribution and integrity of facial and body fat compartments also change with age. Facial fat pads, for instance, can diminish and shift, contributing to a deflated or hollowed appearance. When combined with GLP-1 induced fat loss, these pre-existing changes can be amplified.
• Cumulative Environmental Damage: Years of exposure to environmental factors like ultraviolet (UV) radiation, pollution, and lifestyle choices (e.g., smoking) contribute to photoaging and oxidative stress. This damage further impairs the skin’s structural integrity and its capacity to recover from significant changes like weight loss.

For instance, a patient aged 60 losing 30 pounds may experience more pronounced facial sagging and body laxity than a 30-year-old patient losing the same amount of weight, even if other factors are equal. This distinction is vital for patient consultation and treatment planning. Clinics should prioritize a thorough skin assessment for older GLP-1 patients, focusing on skin quality, elasticity, and existing signs of photoaging or chronological aging. Early intervention or a more comprehensive treatment strategy might be considered for this demographic.

In clinical practice, this means age should be a primary consideration during the initial patient intake. For patients aged 55 and older who are beginning GLP-1 therapy or who have already achieved substantial weight loss, a detailed discussion about the heightened potential for skin laxity is appropriate. This allows for informed decision-making and the establishment of realistic expectations. It also permits the early integration of treatments designed to stimulate collagen production or provide structural support, potentially mitigating the severity of future changes. Bio2 Laser Studio, like other clinics, would consider these age-related factors when recommending treatments such as external radiofrequency (RF) body and facial contouring for GLP-1 patients, knowing that older skin may respond differently or require a greater number of sessions to achieve desired firmness¹⁸.

The emphasis on age does not mean younger patients are immune to skin changes, but rather that the biological capacity for skin recovery tends to be higher in younger individuals. Younger patients may still experience skin laxity, especially with high amounts of weight loss, but the likelihood and severity of these changes are generally lower than in older counterparts. Therefore, while age is a critical predictor, it must be considered in conjunction with other factors.

Table 1: Age-Related Skin Changes and Their Impact on Weight Loss Outcomes

Age Group	Key Skin Characteristics	Predicted Impact on Post-GLP-1 Skin Laxity	Clinical Implications
Under 40	Higher collagen/elastin production, good skin elasticity, ample hyaluronic acid.	Generally better skin retraction; less severe laxity, though still possible with large weight loss.	Focus on prevention, early volume restoration (if needed), skin quality maintenance.
40-55	Moderate decline in collagen/elastin, reduced elasticity, early signs of aging.	Increased risk of mild to moderate laxity, especially in areas with significant fat loss.	Combined strategies for volume and firmness, proactive collagen stimulation.
Over 55	Significant decline in collagen/elastin, poor elasticity, reduced hydration, advanced aging.	Higher likelihood of moderate to severe laxity and sagging; skin less able to retract.	Comprehensive approach, considering surgery for severe cases; more intensive non-surgical options.

This table demonstrates how age directly influences the severity and presentation of skin changes, guiding clinicians in their assessment and treatment strategy. For example, while a younger patient might primarily need volume restoration, an older patient might require a combination of volume replacement, skin tightening, and potentially surgical referral for hanging skin.

6.2. Total Weight Lost and its Effect on Skin Integrity

The absolute amount of weight an individual loses is arguably the most straightforward and impactful factor influencing skin changes. The human skin, particularly when significant weight gain has occurred, stretches to accommodate the increased volume. When this volume is rapidly or substantially reduced, the stretched skin may not be able to fully contract to its previous state. The greater the initial distension and the more volume lost, the more excess skin is likely to remain.

GLP-1 medications are known to induce substantial weight loss. For example, semaglutide trials showed an average weight loss of 14.9% over 68 weeks, while tirzepatide trials demonstrated up to 20.9% weight loss over 72 weeks⁵. Such levels of weight loss are sufficient to change facial fat compartments, neck contours, breasts, arms, abdomen, thighs, and buttocks⁵. This magnitude of change inevitably places stress on the skin’s structure.

The 2026 survey of GLP-1 users affirmed that skin changes were associated with weight loss exceeding 20 pounds⁶. This threshold provides a practical benchmark for clinicians. Once a patient approaches or surpasses this amount of weight loss, the probability of experiencing noticeable skin laxity increases. A separate 2026 study found that 44% of individuals who lost 10% to 20% of their body weight reported skin sagging⁷. This indicates that even moderate weight loss percentages can lead to reported sagging.

The impact of total weight lost can be analyzed through several lenses:

• Skin Overstretching: Prolonged and significant distension of the skin due to obesity can damage the elastin and collagen fibers, weakening their ability to recoil. The higher the peak body weight and the more pounds lost, the more likely these fibers are permanently damaged.
• Fat Pad Depletion: Facial fat pads provide natural volume and support. When weight loss leads to their significant reduction, it can cause a “deflated” appearance, emphasizing wrinkles, folds, and jowling. This is particularly noticeable in the midface, temples, and periorbital areas.
• Body Contouring Issues: In areas like the abdomen, arms, thighs, and breasts, large amounts of lost fat can leave behind significant folds of excess skin. This is often the primary driver for body contouring surgical procedures in post-bariatric patients, and increasingly, in post-GLP-1 patients.
• Severity of Laxity: The extent of weight loss directly correlates with the severity of skin laxity. Minor weight loss (e.g., 5-10 pounds) might cause subtle changes, while major weight loss (e.g., 50+ pounds) almost invariably results in moderate to severe laxity requiring intervention.

Clinical directors should conduct a thorough assessment of the patient’s weight loss history, including initial weight, current weight, and target weight. Understanding the percentage of total body weight lost is more informative than just the absolute number of pounds, as it normalizes the impact across different body sizes. For instance, a 20-pound loss for someone who weighed 150 pounds is a 13.3% reduction, whereas for someone who weighed 300 pounds, it is only a 6.7% reduction, with potentially different aesthetic outcomes. The Galderma medication-driven weight loss report in 2025 indicated that 48% of more than 1,300 surveyed medication-assisted weight-loss patients experienced significant facial changes⁹. These changes usually appeared within three to six months. Seventy-seven percent reported at least one negative change, such as sagging, wrinkles, or a tired appearance⁹. This highlights that these changes can be substantial and widespread.

When considering treatment options, the total weight lost guides the selection between non-surgical and surgical approaches. For patients with mild laxity after moderate weight loss, non-surgical options like external radiofrequency, ultrasound, or biostimulators might be effective. However, for those with severe excess skin after significant weight loss, surgical removal remains the most effective solution. The American Society of Plastic Surgeons (ASPS) reported 837,485 patients using prescribed weight-loss medication under their members’ care in 2024. Among these, 20% had undergone plastic surgery, 39% were considering surgery, and 41% were considering non-surgical care¹². This data underscores that a significant portion of patients with medication-induced weight loss require or consider surgical intervention, indicating the severity of skin changes experienced by a large number of individuals. U.S. abdominoplasty volume reached 171,064 procedures in 2024, with arm, thigh, and buttock lifts also showing increases, suggesting a pre-existing demand for excess skin removal procedures even before the full impact of GLP-1 cohorts¹³.

Clinics should document the patient’s maximum historical weight and the current weight to calculate the total weight lost and the percentage of body weight lost. This information is crucial for anticipating the degree of skin laxity and guiding discussions about realistic outcomes from various aesthetic procedures. Bio2 Laser Studio’s approach to offering both single sessions and multi-session packages for radiofrequency contouring allows for flexibility based on the individual’s needs, which are often dictated by the total weight lost. Patients with higher amounts of weight loss may find themselves opting for the six or nine-session packages to achieve more substantial improvements over time¹⁸.

6.3. Speed of Weight Loss and its Contribution to Skin Laxity

The rate at which weight is lost is another critical factor influencing the skin’s ability to adapt. While the skin possesses some elastic properties, it requires time to contract and remodel. Rapid weight loss, irrespective of the total amount, often does not allow sufficient time for the skin to gradually retract, leading to more pronounced laxity and sagging compared to a slower, more gradual weight reduction.

GLP-1 medications are designed to facilitate effective and sometimes rapid weight reduction. The research indicates that these changes can occur relatively quickly. Among GLP-1 users who reported skin changes, 55.1% noticed these changes within the first five months of treatment⁶. This suggests that the speed of weight loss, particularly in the initial phases of GLP-1 therapy, plays a significant role in the early onset of aesthetic concerns.

The biological rationale behind this correlation includes:

• Insufficient Time for Remodeling: Skin remodeling is a biological process involving the breakdown of old collagen and elastin and the synthesis of new, tighter fibers. This process is not instantaneous. When fat volume is lost too quickly, the skin’s matrix does not have adequate time to reorganize and contract.
• Collagen and Elastin Integrity: Sudden changes in skin tension, as seen in rapid weight loss, can place immediate and excessive strain on collagen and elastin fibers. This can lead to tears or damage, further impairing the skin’s elastic recoil capabilities.
• Nutritional Deficiencies: Rapid weight loss, especially if not managed with proper nutritional support, can sometimes lead to deficiencies in vitamins, minerals, and proteins vital for skin health and collagen synthesis. This can further compromise the skin’s ability to maintain its structure and elasticity.

For clinical directors, understanding the speed of weight loss is crucial for several reasons. It helps in:

• Timing of Interventions: Knowing that skin changes can appear within five months suggests that early aesthetic consultations and potential interventions could be beneficial. However, the timing of treatment is debated. A 10-expert Delphi panel found that 70% would start poly-L-lactic acid (a biostimulator) at the same time as medication-associated weight loss¹⁵. This indicates a proactive approach to collagen stimulation might be considered even during active weight loss to support skin retraction. Conversely, other experts may suggest waiting until weight stabilization for more definitive interventions, especially volume replacement.
• Patient Education: Patients should be informed that rapid weight loss, while desirable for health, can contribute to skin laxity. Managing expectations about potential aesthetic outcomes from the outset is important.
• Monitoring and Assessment: Regular skin assessments, perhaps with baseline photography, should be implemented early in the weight loss journey, particularly for those experiencing rapid weight reduction. This allows clinicians to track changes and intervene appropriately.

The concept of “post-GLP-1” often refers to the period after major weight loss has been achieved, rather than after stopping treatment, as the World Health Organization (WHO) supports long-term GLP-1 therapy for obesity as a chronic, relapsing disease². This means clinics should plan for care during active weight loss, stabilization, and maintenance phases. The speed of weight loss will be a factor during the active weight loss phase.

While patients are still actively losing weight, conservative structural volume correction and collagen and skin quality treatments might be considered. Large early corrections should be avoided, as they might appear excessive after further weight changes¹⁵. This phased approach accounts for the dynamic nature of rapid weight loss and its impact on skin. The 2025 Galderma report noted that significant facial changes typically appeared within three to six months⁹. This timeline further supports the idea that the speed of weight reduction plays a substantial role in the manifestation of these concerns.

Consider a patient losing 30 pounds in three months versus a patient losing 30 pounds over a year. The patient with rapid weight loss is more likely to exhibit noticeable skin laxity because the skin has had less time to adapt. This informs the discussion around treatment selection, such as prioritizing skin tightening devices or biostimulators earlier for the rapid weight loss group, while the slower weight loss group might see more natural skin retraction.

6.4. Other Contributing Factors to Skin Changes

Beyond age, total weight lost, and speed of weight loss, several other factors can influence the degree and presentation of skin changes following GLP-1 medication use. While these were not as prominently highlighted with specific data points in the provided research, they are generally recognized in dermatological and aesthetic medicine.

6.4.1. Genetics and Skin Quality

An individual’s genetic makeup plays a role in their skin’s inherent elasticity, collagen quality, and propensity for laxity. Some people naturally have more resilient skin with better elastic recoil, while others may be genetically predisposed to thinner, less elastic skin. This inherent quality will affect how the skin responds to volume loss. For example, individuals with a genetic predisposition to good skin turgor may experience less severe sagging even with substantial weight loss. Conversely, those with inherently poorer skin quality may find that even moderate weight loss leads to noticeable laxity.

6.4.2. Nutritional Status and Hydration

Adequate nutrition and hydration are fundamental for maintaining skin health. Deficiencies in essential vitamins (like Vitamin C, critical for collagen synthesis), minerals (like zinc and copper), and proteins (amino acids are building blocks for collagen and elastin) can impair the skin’s ability to repair and remodel itself. Patients undergoing weight loss, especially if they are not maintaining a balanced diet, might experience compromised skin health, exacerbating laxity. Proper hydration is also key for skin plumpness and elasticity. Dehydrated skin can appear duller and emphasize fine lines and wrinkles.

The research mentions that the aesthetic service line may need links to nutrition, resistance exercise, hair care, and medical management rather than skin treatment alone, following a study finding decreased facial volume, hair loss, and reduced strength in a subgroup of GLP-1 users⁷. This supports the idea that holistic patient support, including nutritional guidance, can indirectly support skin health during weight loss.

6.4.3. Lifestyle Factors

Long-term lifestyle habits can impact skin quality and its resilience to weight changes.

• Smoking: Smoking significantly degrades collagen and elastin fibers, leading to premature skin aging and reduced elasticity. Smokers who lose weight are more likely to experience pronounced skin laxity compared to non-smokers.
• Sun Exposure: Chronic exposure to ultraviolet (UV) radiation damages collagen and elastin, contributing to photoaging. Sun-damaged skin has reduced ability to retract after weight loss.
• Previous Weight Fluctuations: Individuals who have a history of significant weight cycling (gaining and losing large amounts of weight multiple times) may have already stretched their skin beyond its elastic limits. Each cycle can progressively damage collagen and elastin, making the skin less able to rebound after subsequent weight loss, including that induced by GLP-1 medications.

6.4.4. Body Area and Skin Thickness

Different areas of the body have varying skin thickness and structural support, affecting how they respond to weight loss. For instance, facial skin, while generally thinner, has underlying muscle and bone structures that can influence how laxity appears. The abdomen, inner thighs, and arms often experience the most significant skin excess dueance to larger fat deposits and greater skin stretching, combined with less inherent structural support. The skin on the back of the hands, for example, is very thin and can show volume loss quickly, while the skin on the back of the torso might be thicker but still prone to sagging.

6.5. Clinical Assessment and Implications for Treatment Planning

Given the multitude of factors influencing skin changes, a comprehensive and individualized assessment is critical for all patients undergoing GLP-1 mediated weight loss. This assessment should go beyond simply noting the presence of loose skin.

6.5.1. Comprehensive Patient Intake

Clinical directors should ensure patient intake protocols collect detailed information on:

• Demographics: Age, gender (hormonal differences can affect skin quality).
• Weight History: Highest historical weight, current weight, target weight, total weight lost, rate of weight loss (e.g., pounds per month).
• GLP-1 Treatment Details: Start date, current dosage, duration, and whether the patient is in active weight loss, stabilization, or maintenance phase.
• Medical History: Any underlying skin conditions, collagen vascular diseases, nutritional deficiencies, or medications affecting skin health.
• Lifestyle Factors: Smoking status, sun exposure habits, history of weight cycling.
• Patient Concerns and Expectations: What specific areas concern them, their goals for aesthetic treatment, and their understanding of realistic outcomes.

The research states that intake should record age, percentage and speed of weight loss, medication stage, facial volume loss, body sites, skin quality, weight stability, nutrition, strength, and patient priorities¹⁵. This comprehensive approach ensures that all relevant factors are considered.

6.5.2. Objective Skin Assessment

Objective assessment tools should be used alongside patient-reported concerns:

• Visual Inspection: Evaluation of skin texture, turgor, presence of fine lines, wrinkles, folds, and significant sagging.
• Palpation: Assessing skin thickness, elasticity, and the presence of underlying fat pads.
• Photography: Standardized baseline photography from multiple angles is invaluable for tracking changes over time and demonstrating treatment efficacy. This helps manage expectations and provides objective evidence of progress.
• Laxity Grading: Implementing a consistent grading system (e.g., mild, moderate, severe) for skin laxity across different body areas. This can guide treatment decisions, determining if non-surgical devices, combination therapies, or surgical referral is most appropriate¹⁵.

6.5.3. custom Treatment Strategies

The understanding of these factors directly translates into custom treatment strategies.

• Prevention and Early Intervention: For older patients, or those expecting significant or rapid weight loss, proactive measures may be considered. This could involve early discussions about collagen-stimulating treatments or nutritional support. A 10-expert Delphi panel suggested starting poly-L-lactic acid simultaneously with medication-associated weight loss¹⁵.
• Combination Approaches: Many patients present with multiple concerns, such as laxity, poor skin quality, and facial deflation¹⁰. Standard packages based on a single device or injection type will not fit every patient¹⁰. A sequential approach, such as conservative structural volume correction, followed by collagen and skin quality treatments, and then surface treatments, may be beneficial, reassessing during active weight loss¹⁵.
• Realistic Expectations: Clinical directors must set realistic expectations, especially for patients with advanced age or very significant weight loss. Non-surgical treatments can provide improvements for mild to moderate laxity, but they cannot replace surgery for severe excess or hanging skin¹⁸. The FDA’s October 2025 communication about RF microneedling safety also highlights the need for clear consent and appropriate device use, ensuring patients understand risks and realistic outcomes¹³.
• Referral Pathways: For patients with severe skin laxity or hanging skin, surgical consultation is often the most appropriate pathway. Clinics should establish clear referral processes with plastic surgeons. The ASPS data shows that a significant portion of GLP-1 patients are considering surgery (39%) or non-surgical care (41%)¹², indicating a need for both options. Bio2 Laser Studio, focusing on non-invasive external RF, would need a clear surgical referral path for cases beyond the scope of their services¹⁸.

6.6. Conclusion on Factors Influencing Skin Changes

The emergence of GLP-1 medications has dramatically increased the number of individuals experiencing significant weight loss, bringing with it a corresponding rise in demand for aesthetic interventions addressing skin changes. The factors influencing the development and severity of skin laxity are well-defined: age, total weight lost, and the speed of weight loss are particularly impactful. Older individuals, those who lose a substantial amount of weight (especially over 20 pounds or 10-20% of body weight), and those who lose weight rapidly, are more prone to experiencing noticeable skin laxity.

Clinical directors must integrate these insights into their assessment and treatment planning protocols. A thorough patient intake that documents age, comprehensive weight loss history, and GLP-1 treatment phase is essential. Objective skin assessments, including baseline photography and laxity grading, further refine the understanding of each patient’s unique needs. This enables the development of custom treatment plans, ranging from proactive collagen stimulation during active weight loss to staged combination therapies or timely surgical referrals for severe cases.

By acknowledging and systematically addressing these influencing factors, aesthetic clinics, including Bio2 Laser Studio, can optimize patient care, manage expectations effectively, and achieve more predictable and satisfying outcomes in the evolving field of post-GLP-1 aesthetic demands. This systematic approach ensures that clinical practices remain ethical, effective, and patient-centered in response to the growing needs of this population.

The next section will build upon this foundation by exploring the anticipated demand shifts across different aesthetic modalities, examining how these influencing factors translate into specific treatment needs and preferences.

7. Current Demand for Aesthetic Care from GLP-1 Patients

The rapid rise in the use of Glucagon-Like Peptide-1 (GLP-1) receptor agonists for weight loss has created a new and expanding patient population seeking aesthetic treatments. These medicines, initially developed for diabetes, have shown significant efficacy in weight reduction, leading to widespread adoption for obesity management ^{[4] [5]}. While the health benefits of substantial weight loss are clear, a common side effect for many patients is the development of skin changes, including facial volume loss and laxity. Clinical directors and aesthetic professionals are now observing a clear increase in demand from this group. Understanding the scope, nature, and specific concerns of these patients is important for developing suitable treatment strategies.

The patient pool for GLP-1 medications has grown quickly. In June 2026, 11% of adults in the United States reported taking a GLP-1 drug for weight loss. This marks a significant increase from just 3% in 2024. An even larger proportion, 15% of U.S. adults, had used a GLP-1 drug at some point ^[1]. This expansion is not limited to the U.S. Novo Nordisk, a major manufacturer, reported that its obesity medicines reached 3.6 million people in 2025. The availability of Wegovy, one such medicine, expanded from 17 countries in 2024 to 52 countries in 2025 ^[3]. The global market for branded GLP-1 obesity medicine volume grew by 104% through November 2025 ^[4]. While access remains uneven globally, with the World Health Organization (WHO) expecting fewer than 10% of those who could benefit to receive these medicines by 2030, the underlying treatment population is doubling at a pace that supports continued growth in aesthetic consultations ^{[2] [19] [23]}.

It is important to note that “Post-GLP-1” often refers to the period after significant weight loss has occurred, rather than after stopping treatment ^[2]. The WHO considers obesity a chronic, relapsing disease and supports long-term GLP-1 therapy ^[2]. This means clinics should plan for care that spans active weight loss, stabilization, and maintenance phases. The substantial weight loss achieved with GLP-1s, averaging 14.9% with semaglutide and up to 20.9% with tirzepatide in trials, can lead to noticeable changes in facial fat compartments, neck contours, breasts, arms, abdomen, thighs, and buttocks ^{[5] [24] [25]}. Clinical directors should therefore expect patients to present with concerns across several body areas rather than just one isolated problem ^[25].

Observable Increase in Aesthetic Consultations

Aesthetic clinics are already experiencing a clear demand effect from GLP-1 patients. A survey of 406 aesthetic health professionals found that respondents reported a mean 137% increase in GLP-1 patients seeking aesthetic treatments from 2023 to 2024 ^[8]. These surveyed clinicians typically treated a mean of 1,249 cosmetic patients per year, suggesting that the reported growth reflects active aesthetic practices ^[8]. This rise serves as a strong signal of increased demand, although the voluntary nature of the survey might lead to an overestimation compared to the overall provider market ^[8].

The first major wave of aesthetic consultations can begin while patients are still losing weight. Galderma’s international patient research, which involved over 1,300 medication-assisted weight-loss patients, reported that 48% experienced significant facial changes. These changes typically appeared within three to six months of starting treatment ^[9]. Overall, 77% of these patients reported at least one negative change, such as sagging, wrinkles, or a tired appearance ^{[9] [30]}.

Demand for aesthetic care is also reflected in the data from plastic surgery societies. Members of the American Society of Plastic Surgeons (ASPS) reported caring for 837,485 patients using prescribed weight-loss medicine in 2024 ^{[12] [42]}. Among these patients, 20% had already undergone plastic surgery related to medication-induced weight loss. Another 39% were considering surgery, and 41% were considering non-surgical procedures ^{[12] [42]}. This indicates a broad spectrum of demand, requiring capacity for both surgical and non-surgical options ^[12].

The global aesthetic procedure volume in 2024 was nearly 38 million procedures, comprising over 17.4 million surgical procedures and 20.5 million non-surgical procedures. This total volume was 42.5% higher than in 2020 ^[14]. This context suggests that post-weight-loss care is entering an already large and accepting market with established provider capacity ^[14].

One specific area showing early commercial impact is facial volume and skin services. Global facial fat grafting procedures increased by 19.2% in 2024 compared to 2023, reaching about 0.9 million procedures ^[15]. During the same period, face and head procedures generally rose by 4.3%, while body and extremity procedures decreased by 14.8% ^[15]. This suggests that the aesthetic consequences of GLP-1 weight loss are initially most evident and addressed in the facial region ^[15].

Primary Patient Concerns and Skin Changes

Skin changes are a common outcome of significant weight loss, though reported rates can vary due to different definitions and patient groups ^[6]. A 2026 survey of 504 GLP-1 users found that 38.7% reported skin changes ^{[6] [26]}. Specific concerns included facial volume loss, reported by 10.9% of users, sagging, reported by 8.3%, and jowling, reported by 7.7% ^{[6] [26]}. Among those who reported skin changes, 55.1% noticed them within the first five months of treatment ^{[6] [26]}.

Another 2026 study focused on individuals who had lost 10% to 20% of their body weight, reporting skin sagging in 44% of respondents ^[7]. This subgroup also reported decreased facial volume in 37% of cases, hair loss in 30%, and reduced strength in 19% ^{[7] [27]}. The discrepancy in sagging rates between the two studies (8.3% vs. 44%) can be explained by different methodologies and patient populations ^[28]. However, both studies highlight skin changes as a significant concern.

The extent and type of skin changes are influenced by several factors. Age, total weight lost, and the speed of weight loss all play a role ^[6]. The 2026 survey of 504 GLP-1 users showed that the risk of skin changes was higher for individuals over age 55 and those who lost more than 20 pounds ^{[6] [28]}. Clinical intake should therefore record the patient’s age, the percentage and speed of weight loss, the stage of medication, the presence of facial volume loss, affected body sites, skin quality, weight stability, nutrition, strength, and the patient’s priorities ^[29].

The addressable problem is often larger than just loose skin. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for multiple linked issues, such as laxity, poor skin quality, and facial deflation ^[10]. This suggests that aesthetic assessments should focus on tissue problems rather than only by specific body parts ^{[10] [31]}. Patients often seek a natural result, with 56% desiring to return to an appearance close to their previous one. However, 44% were open to a different look ^{[10] [31]}. This indicates that standard packages based on a single device or injection type will only meet the needs of a portion of the market ^[31].

Specific concerns commonly reported by GLP-1 patients to aesthetic professionals include:

• Midface volume loss: This is a leading concern, contributing to a gaunt or tired appearance ^[8].
• Face and neck laxity: Skin sagging in these areas is frequently reported ^[8].
• Loose body skin: This includes areas like the arms, abdomen, and thighs ^[8].
• Jowling: Sagging of the skin along the jawline ^[6].
• Wrinkles: Increased prominence of wrinkles due to reduced underlying volume ^[9].

Despite these appearance concerns, satisfaction with GLP-1 medication can remain high. In the 504-person study, 92% were satisfied with the medication, 84% reported improved body image, and 68.5% reported greater self-confidence ^{[6] [28]}. This underscores the importance of aesthetic care supporting overall health gains rather than framing weight loss as an aesthetic failure ^[28].

Modality Shifts and Treatment Approaches

The demand from GLP-1 patients is causing a shift in preferred aesthetic modalities. The shift is moving away from fat reduction treatments toward tissue support procedures ^[8]. Clinics should reconsider relying on fat-reduction messaging for patients who are already experiencing deflation ^[40].

The expected shifts include:

• Volume replacement: Hyaluronic acid (HA) fillers are key for replacing lost facial volume, particularly in the midface and temples ^{[8] [32]}. Clinicians in the 406-provider survey considered HA fillers the best facial treatment for an average of 47% of GLP-1 patients ^{[8] [32]}.
• Collagen stimulation: Biostimulators, which promote collagen formation over time, are gaining interest ^[8]. Galderma’s patient research showed 48% interest in biostimulators, and 41% interest in HA injections. Among surveyed clinics, 54% offered or were considering biostimulators, and 89% offered or were considering fillers ^[33].
• Skin tightening: External radiofrequency (RF) and ultrasound treatments offer modest tightening for mild to moderate laxity ^{[8] [38]}. Non-invasive ultrasound and non-needle RF devices may gain market share due to demand for low-downtime care ^{[11] [38]}. For example, a focused-ultrasound and topical study reported a 44% reduction in graded laxity at 12 weeks, and a separate manufacturer study found improvement in 93% of treated upper arms after two ultrasound sessions ^{[18] [39]}. However, these results do not suggest that energy treatments can replace surgery for severe skin excess ^[39].
• Surgical excision: Surgery remains the primary referral path for significant hanging or severe excess skin ^{[8] [40]}. U.S. abdominoplasty volume reached 171,064 procedures in 2024. Arm lifts, thigh lifts, and buttock lifts also saw increases of 2%, 3%, and 3% respectively from 2023 ^{[13] [40] [44]}. These increases occurred before the full GLP-1 cohorts of 2025 and 2026 reached stable weight ^[13]. A Chinese study of post-bariatric patients found that 78.2% reported excess skin and 37.9% desired body-contouring surgery ^[45].

Combination treatment plans are expected to gain share over single treatments ^[11]. A Galderma trial combining Sculptra with Restylane reported that 85.7% of patients felt their face looked less gaunt after nine months, and 91.4% would recommend the regimen ^{[17] [34] [43]}. This study supports combination care, though its company sponsorship and lack of isolated product contribution limit broad claims ^{[17] [34]}.

Early treatment during active weight loss remains a subject of discussion among experts. A Delphi panel of 10 experts found that 70% would start poly-L-lactic acid (PLLA) concurrently with medication-associated weight loss. However, the panel was evenly split on the timing of fat transfer ^{[15] [35]}. A practical sequence for treatment involves initial assessment, followed by conservative structural volume correction, then collagen and skin-quality treatments, and finally surface treatments. Reassessment should occur during active weight loss to avoid overly aggressive corrections that might appear excessive after further weight reduction ^[36].

Safety and Timing Considerations

Safety and appropriate timing are increasingly important criteria for GLP-1 patients seeking aesthetic care. The U.S. Food and Drug Administration (FDA) issued a safety communication in October 2025 regarding radiofrequency (RF) microneedling. The warning highlighted reported burns, scarring, unwanted fat loss, disfigurement, and nerve damage with certain uses ^{[13] [38]}. The FDA stated that RF microneedling is a medical procedure and advised patients to seek licensed providers with device-specific training. Providers were also advised to report complications ^{[40] [41]}. This warning applies specifically to RF microneedling, not all forms of RF treatment ^[13]. This may lead to a shift in demand toward non-needle energy devices or providers with stronger medical oversight ^[38].

The International Society of Aesthetic Plastic Surgery (ISAPS) recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms like nausea, vomiting, abdominal pain, or constipation are active ^{[14] [40]}. This necessitates coordination with the prescribing physician for surgical planning ^[40]. A 2026 West Virginia University study of 373 panniculectomy patients (2013-2023) found that 21.7% were taking GLP-1 medicines before surgery. While the study found possible differences in wound healing, it did not identify a clear increase in overall surgical risk, demonstrating that blanket assumptions are inappropriate ^[40].

Every aesthetic service line needs clear, written rules regarding medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse-event reporting, and referral protocols ^[41]. Claims about treatments should describe likely degrees of improvement rather than promising to prevent or eliminate loose skin ^[41].

Commercial Considerations and Patient Budget

The commercial opportunity presented by GLP-1 patients has budgetary limits. A McKinsey survey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ^{[11] [37]}. This is because patients are also incurring costs for medication, nutrition, fitness programs, and clothing changes ^{[11] [37]}. Clinics should therefore anticipate demand for staged treatment plans, clear pricing, and combinations that offer high value, rather than expecting unlimited spending ^{[11] [37]}.

The market for GLP-1 aesthetic patients is large but segmented. Of the 837,485 patients using prescribed weight-loss medicine under ASPS members’ care in 2024, 41% were considering non-surgical treatment and 39% were considering surgery ^[42]. An effective service line should accommodate both paths rather than attempting to fit every patient into the clinic’s existing equipment ^[42].

Transparency in pricing directly impacts conversion rates. Staged plans can address the most pressing concerns first, with additional care offered once weight stabilizes ^[37]. Building trust is a business imperative. The 2025 American Society for Dermatologic Surgery (ASDS) consumer survey revealed that 94% of consumers used ratings and review sites to select a provider. Nearly half reported that a provider’s social media presence influenced their appointment decisions ^{[16] [46]}. Therefore, clinics need consistent photographs, clear credentials, easily understandable consent forms, and outcomes data separated by age, body site, and severity ^[46].

For example, Bio2 Laser Studio, a small clinic, explicitly links external RF body and facial contouring to GLP-1 weight loss on its public pages ^{[18] [47]}. They publish pricing such as $440 for a single body or facial contouring session, $1,980 for a six-session package, and a $175 monthly option ^{[18] [47]}. This approach of transparent pricing and package options can reduce purchasing barriers. However, Bio2 Laser Studio’s public pages do not provide peer-reviewed post-GLP-1 outcome data ^[47]. To support stronger efficacy claims, internal tracking of standardized photography, patient-reported scores, treatment completion, and adverse events would be beneficial ^[47]. This illustrates how even smaller clinics can adapt to this new patient demand while highlighting the need for rigorous outcome tracking.

In summary, the current demand for aesthetic care from GLP-1 patients is substantial and growing, driven by the increasing adoption of these weight-loss medications and the resulting skin changes. Clinical directors must understand the specific concerns of these patients, which often involve midface volume loss and laxity across multiple body areas. The treatment field is shifting toward combination therapies focusing on volume replacement, collagen stimulation, and skin tightening, with surgical referral for severe cases. Navigating this demand successfully requires a strategic approach that prioritizes patient safety, transparent communication, and flexible treatment plans, while acknowledging the financial realities of this patient group.

8. Patient Concerns Beyond Loose Skin

Weight loss achieved through GLP-1 medications offers important health benefits for many patients. However, significant body changes can result in new aesthetic concerns beyond skin laxity. Clinical directors must understand that patients using GLP-1 drugs often present with a range of connected issues. These can include poor skin quality, loss of facial volume, and general physical changes. A comprehensive assessment approach is needed to address these varied patient needs. Focusing only on loose skin misses a wider picture of concerns that impact a patient’s self-perception and overall satisfaction after weight loss ^[10].

The shift in patient demographics and their aesthetic needs demands a broader understanding from clinics. Before GLP-1 medicines, weight loss patients primarily sought help for sagging skin after bariatric surgery. These patients often experienced severe excess skin. The current GLP-1 patient group can experience a range of weight loss levels and rates. This leads to a different set of aesthetic concerns. Clinical directors need to move beyond a narrow view of “loose skin” to consider all patient concerns that arise from GLP-1 induced weight loss ^[10].

The total patient population using GLP-1 medicines for weight loss is growing quickly. In June 2026, 11% of U.S. adults were taking a GLP-1 drug for weight loss. This is up from 3% in 2024. A total of 15% of U.S. adults had used a GLP-1 drug at some point ^[1]. This expansion suggests a continued rise in patients who may seek aesthetic care for weight loss related concerns. Novo Nordisk, a key manufacturer, reported its obesity medicines reached 3.6 million people in 2025. Wegovy was available in 52 countries in 2025, up from 17 in 2024 ^[3]. This global reach means clinics in more markets will face these patient concerns. The World Health Organization (WHO) expects GLP-1 medicines to reach fewer than 10% of people who could benefit by 2030, showing that access issues will concentrate demand in certain regions ^[2].

The average weight loss with these medicines is significant. Semaglutide trials show an average loss of 14.9% of body weight over 68 weeks. Tirzepatide trials show up to 20.9% loss over 72 weeks ^[4], ^[5]. This level of weight change can affect facial fat, neck contours, breasts, arms, abdomen, thighs, and buttocks. This indicates that patients will likely present with multiple affected areas rather than a single problem ^[5].

8.1 The Broad Spectrum of Patient-Reported Aesthetic Changes

While loose skin is a common result of weight loss, GLP-1 patients report a variety of aesthetic changes. These go beyond simple sagging. A 2026 survey of 504 GLP-1 users found that 38.7% reported skin changes ^[6]. Among these, specific issues included:

• Facial volume loss: 10.9% ^[6]
• Sagging: 8.3% ^[6]
• Jowling: 7.7% ^[6]

Another 2026 study focused on individuals who had lost 10% to 20% of their body weight. This study found that 44% reported skin sagging ^[7]. This same group reported other concerns:

• Decreased facial volume: 37% ^[7]
• Hair loss: 30% ^[7]
• Reduced strength: 19% ^[7]

These figures highlight that GLP-1 patients do not just experience skin laxity. They also face issues like facial deflation, changes in hair, and a general feeling of reduced physical strength. These concerns suggest a need for a holistic approach to care ^[7].

Age, total weight lost, and speed of loss are factors that affect the likelihood of skin changes. Skin changes were more common in people over 55 and in those who lost more than 20 pounds. For patients who reported skin changes, over half (55.1%) noticed these changes within the first five months of treatment ^[6]. This means clinics need to consider baseline photography and skin assessment early in the weight loss process, before significant visible changes occur ^[6].

A Galderma report from 2025 indicated that 48% of more than 1,300 medication-assisted weight-loss patients reported significant facial changes. These changes typically appeared within three to six months ^[9]. The report also found that 77% of patients reported at least one negative change. These included sagging, wrinkles, or a tired appearance ^[9]. This shows that the first wave of aesthetic consultations can happen while patients are still actively losing weight. This is an important consideration for clinical planning.

8.1.1 Patient Satisfaction with Weight Loss Versus Aesthetic Outcomes

It is important to note that patients can be highly satisfied with their GLP-1 treatment even while having appearance concerns. In the 504-person study, 92% of patients were satisfied with their medication. Additionally, 84% reported improved body image, and 68.5% reported greater self-confidence ^[6]. This suggests that aesthetic care should support the health benefits already achieved. It should not frame weight loss as an aesthetic failure ^[6].

A clinic’s approach should acknowledge both the health success and the new aesthetic needs. This means offering solutions that complement the patient’s positive feelings about their weight loss. The goal is to help patients feel more aligned with their appearance after achieving their weight loss goals.

8.2 The Interconnected Nature of Aesthetic Concerns

Many GLP-1 aesthetic patients do not present with a single, isolated problem. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for several linked issues ^[10]. These included laxity, poor skin quality, and facial deflation. This data supports the need for assessments based on tissue problems rather than only by body part ^[10].

This interconnectedness means that a single treatment modality is often not enough. For instance, hyaluronic acid filler can replace lost facial volume. However, it cannot remove hanging skin. Energy treatments might improve mild laxity. But they will not restore a large missing fat compartment. Surgery can remove excess skin, but it involves recovery time and medical risks ^[6]. These distinct needs mean clinics must offer a range of solutions.

The patient’s desire for specific outcomes also varies. The McKinsey survey showed that 56% of patients wanted a natural result that resembled their appearance before weight loss. Meanwhile, 44% were open to a different look ^[10]. This shows that standard packages focusing on one device or one type of injection will not fit everyone. Clinics need flexible plans that can be customized to individual goals.

8.2.1 Poor Skin Quality as a Common Concern

Beyond laxity and volume loss, poor skin quality is a frequent concern. Weight loss can affect skin texture, hydration, and elasticity. These changes can make skin appear dull, crepey, or aged. Addressing skin quality often requires treatments such as chemical peels, topical retinoids, or certain energy-based devices that stimulate collagen and elastin production. These treatments are different from those used for laxity or volume loss but are equally important for overall patient satisfaction.

The research emphasizes assessing tissue problems. This means looking at the skin’s surface, its underlying structure, and its volume. This comprehensive view helps identify all issues that contribute to a patient’s aesthetic concerns after GLP-1 weight loss.

8.3 The Need for Comprehensive Assessment and Treatment Planning

Clinical directors must develop a comprehensive assessment process for GLP-1 patients. This process should capture all patient concerns, not just the most obvious ones. It should include factors such as age, percentage and speed of weight loss, medication stage, facial volume loss, affected body sites, skin quality, weight stability, nutrition, and muscle strength. Patient priorities are also critical. A simple three-level grading system (mild, moderate, or severe) for laxity can guide decisions on device care, combination treatments, or surgical referral ^[6].

The goal is to provide a phased treatment plan. This plan should start with a thorough assessment. Then, it should address structural volume correction carefully. Collagen and skin quality treatments would follow. Surface treatments would be the last step. It is important to reassess patients during active weight loss. Avoid large early corrections that might look overdone after further weight change ^[15].

The service line may need to connect with other health services. For example, hair loss is a reported issue for 30% of patients with 10% to 20% weight loss ^[7]. Reduced strength was reported by 19% ^[7]. This suggests that aesthetic clinics might need to link patients to nutritionists, resistance exercise programs, or hair care specialists. The approach should extend beyond skin treatment alone ^[7].

8.3.1 Combining Modalities for Better Outcomes

Combination treatment plans will likely become standard. A Galderma trial combined Sculptra (a biostimulator) with Restylane (a hyaluronic acid filler) ^[16]. After nine months, 85.7% of patients felt their face looked less gaunt. Also, 91.4% would recommend the regimen ^[16]. This study supports combined volume replacement and collagen stimulation. However, it was company-sponsored and did not separate the contribution of each product ^[16].

Clinicians surveyed considered hyaluronic acid filler the best facial treatment for an average of 47% of GLP-1 patients ^[8]. Biostimulators are also gaining interest. In Galderma’s research, 48% of patients were interested in biostimulators, and 41% considered hyaluronic acid injections ^[9]. Among clinics surveyed, 54% offered or were considering biostimulators, and 89% offered or were considering fillers ^[9].

A 10-expert Delphi panel suggested that some treatments could begin early. For example, 70% of the panel would start poly-L-lactic acid (a biostimulator) at the same time as medication-associated weight loss ^[15]. The panel was split on fat transfer. This expert opinion, though influenced by a Galderma grant, shows a leaning toward early intervention with certain modalities ^[15].

The practical treatment sequence should be:

1. Assessment
2. Conservative structural volume correction
3. Collagen and skin quality treatment
4. Surface treatment

This sequence allows for adjustments as weight loss continues. It helps avoid over-correction early on ^[15].

8.4 Modality Shifts and Budget Considerations

The demand from GLP-1 patients is causing a shift in treatment modalities. Clinics should reduce focus on fat reduction for patients who are already deflated. Instead, the service mix should include facial structure, skin quality, mild laxity, muscle support, and surgical referrals ^[8].

8.4.1 Non-Surgical Options Beyond Fat Reduction

Non-surgical skin tightening was one of the five most common non-surgical procedure groups globally in 2024. The total non-surgical market was 20.5 million procedures that year. This shows a large base of trained providers and consumers who are aware of these treatments ^[12].

External ultrasound and non-needle radiofrequency (RF) may become more popular for mild to moderate laxity. A Sofwave upper-arm study showed improvement in 93% of treated arms after two sessions ^[18]. However, this evidence comes from a manufacturer’s clinical summary. It should not be applied to older patients, severe laxity, or all body sites ^[18].

RF microneedling faces a different situation. The FDA issued a safety communication in October 2025. It listed burns, scars, unwanted fat loss, disfigurement, and nerve damage as reported serious harms from certain uses ^[13]. This might shift demand toward non-needle energy devices or providers with strong medical oversight. This shift is an inference, not a measured sales trend yet ^[13].

The FDA warning on RF microneedling does not apply to all RF platforms equally. Clinical directors must distinguish between needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices. These have different depths and risks. Marketing them all under one “RF tightening” label can hide these differences ^[13].

8.4.2 Surgical Referrals for Severe Cases

Surgery still has a clear role for severe laxity. In the U.S., abdominoplasty reached 171,064 procedures in 2024 ^[11]. Arm lifts rose 2%, thigh lifts 3%, and buttock lifts 3% from 2023 ^[11]. A Chinese study of post-bariatric patients found 78.2% reported excess skin, and 37.9% wanted body-contouring surgery ^[55]. While bariatric patients often lose more weight than GLP-1 users, this shows the need for surgical options ^[55].

Severe hanging skin should not be treated with a long series of device sessions with promises of surgical-level results. Clinics need firm surgical referral limits. This ensures patients receive the most appropriate care for their condition.

8.4.3 Budget Limitations and Patient Expectations

The commercial opportunity has budget limits. McKinsey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ^[10]. This is because patients also pay for medication, nutrition, fitness, and new clothing. Clinics should expect demand for staged plans, clear pricing, and high-value combinations rather than unlimited spending ^[10].

This means clinics need to offer financing options and clear estimates of benefits per treatment. Transparent pricing and staged care can help manage patient expectations and budget constraints ^[10].

Bio2 Laser Studio, for example, lists pricing for external RF body and facial contouring. They offer a $440 single session, a $1,980 six-session package, and a $175 monthly option ^[18]. This type of clear pricing and package structure can help reduce buying friction for patients ^[18].

8.5 Importance of Safety, Timing, and Referrals

Safety and timing are becoming more important decision factors. The FDA’s 2025 safety communication on RF microneedling highlights the need for licensed providers with device-specific training. Providers are also advised to report complications ^[13].

Timing of treatments also matters. ISAPS guidance suggests delaying elective surgery during GLP-1 dose escalation and while patients have active gastrointestinal symptoms (nausea, vomiting, abdominal pain, constipation) ^[14]. This means coordinating with the medication prescriber is part of surgical planning ^[14].

A 2026 West Virginia University study looked at 373 panniculectomy patients. It found possible differences in wound healing for those taking GLP-1 medicines before surgery. However, it found no clear rise in overall surgical risk ^[57]. This shows that broad assumptions about GLP-1 patients and surgery are not always accurate. Individual assessment is key ^[57].

8.5.1 The Value of Formal Referral Paths

The patient pool for GLP-1 weight loss is large and varied. ASPS members reported 837,485 patients using prescribed weight-loss medicine in 2024 ^[11]. Of these, 41% were considering non-surgical treatment, and 39% were considering surgery ^[11]. This shows that both non-surgical and surgical treatment tracks need capacity. A clinic offering only devices should establish a formal plastic surgery referral path ^[11].

This dual system is critical. Mild and moderate cases can stay within the clinic. Severe cases need a clear relationship with a surgeon and a smooth handover process. Building these referral networks ensures that patients receive the most appropriate care at every stage of their weight loss journey.

8.6 Operational Model for Post-GLP-1 Care

The most effective operating model for post-GLP-1 care will be staged, transparent, and built on referrals. Clinics need to track key data points:

• Consultation source
• Weight loss stage
• Type of concern
• Laxity grade
• Treatment selected
• Series completion
• Patient-reported improvement
• Photography grade
• Adverse events
• Refunds
• Repeat care
• Surgical referrals

These metrics help clinics make informed decisions about equipment purchases. They also help improve clinical protocols based on local utilization and measured results, rather than general growth figures ^[18].

Trust is an important business asset. The 2025 ASDS consumer survey found that 94% of people used ratings and review sites to choose a provider ^[16]. Clinics need consistent photographs, clear credentials, simple consent language, and outcomes reported by age, body site, and severity ^[16].

In summary, the aesthetic concerns of GLP-1 patients extend far beyond loose skin. They include facial deflation, poor skin quality, and other physical changes. A comprehensive assessment, a personalized and staged treatment plan, and clear referral pathways are crucial. This approach ensures that clinical directors can address the full scope of patient needs and provide effective, patient-centered care.

8.7 Key Takeaways for Clinical Directors

GLP-1 medications are changing the field of aesthetic medicine by creating a new patient population with specific and varied needs. Clinical directors must adapt their services to meet these demands effectively. Understanding the broad spectrum of concerns, from volume loss to skin quality changes, is essential for providing meaningful solutions.

• Broaden Assessment Criteria: Move beyond simple laxity. Evaluate for facial deflation, skin quality changes (texture, tone), and other related issues such as hair changes or perceived loss of muscle strength. This requires a thorough initial consultation that covers medical history, weight loss journey details, and patient-reported outcomes.
• Implement Comprehensive Treatment Plans: Recognize that single treatments are often insufficient. Develop combination therapy protocols that address multiple concerns simultaneously. This might involve combining injectables (fillers, biostimulators) with energy-based devices and topical skincare regimens.
• Adopt a Staged Approach: Plan treatments in phases, especially for patients still undergoing active weight loss. Prioritize structural concerns conservatively, then address collagen stimulation, skin quality, and surface issues. This minimizes the need for re-treatment due to ongoing body changes.
• Establish Strong Referral Networks: For moderate to severe laxity or other complex issues that fall outside the clinic’s non-surgical capabilities, establish clear and efficient referral pathways to plastic surgeons and other specialists (e.g., nutritionists, exercise physiologists).
• Focus on Transparency and Education: Clearly communicate treatment expectations, costs, and potential outcomes. Educate patients about the limitations of non-surgical treatments and the role of surgery for severe cases. Use consistent photography and patient testimonials to build trust.
• Monitor Outcomes Systematically: Track patient progress using standardized methods, including photography, patient-reported satisfaction scores, and objective measurements. This data will inform future treatment protocols and equipment purchase decisions.

By adopting these practices, clinics can position themselves to successfully serve the growing population of GLP-1 patients. This approach will improve patient satisfaction and ensure ethical, effective care in this evolving field of aesthetic medicine.

The next section will explore the expected modality shift from fat reduction to tissue support in further detail, examining how specific technologies are being adapted for GLP-1 patients.

---

Sources

• ¹ Gallup. (2026, July 7). In U.S., GLP-1 Usage Reaches New High. https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx?utm_source=openai
• ² World Health Organization. (2025, December 1). WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity?utm_source=openai
• ³ Novo Nordisk. (2026). Novo Nordisk Annual Report 2025. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-annual-report-2025.pdf.html?utm_source=openai
• ⁴ New England Journal of Medicine. (2021). Once-Weekly Semaglutide in Adults With Overweight or Obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183?utm_source=openai
• ⁵ New England Journal of Medicine. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• ⁶ Olivero and colleagues. (2026, August). Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss. Journal of Cosmetic Dermatology. https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.71145
• ⁷ PubMed. (2026, August). Skin Impacts and Tradeoffs of GLP-1 Therapy. https://pubmed.ncbi.nlm.nih.gov/42579223?utm_source=openai
• ⁸ Dermatologic Surgery. (2026). Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. https://pubmed.ncbi.nlm.nih.gov/42210883/
• ⁹ Galderma. (2025). Understanding the Aesthetic Impact of Medication-Driven Weight Loss. https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
• ¹⁰ McKinsey & Company. (2025). GLP-1s Are Boosting Demand for Medical Aesthetics. https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
• ¹¹ American Society of Plastic Surgeons. (2025, June 25). 2024 Plastic Surgery Statistics Report. https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
• ¹² International Society of Aesthetic Plastic Surgery. (2025, June 19). Global Survey 2024. https://www.isaps.org/discover/about-isaps/global-statistics/global-survey-2024-full-report-and-press-releases/
• ¹³ U.S. Food and Drug Administration. (2025, October 15). Potential Risks With Certain Uses of Radiofrequency Microneedling. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication?utm_source=openai
• ¹⁴ International Society of Aesthetic Plastic Surgery. (2026, May 22). Emerging Guidance on the Rise of GLP-1 Receptor Agonist Drugs. https://www.isaps.org/media/tw1j4oko/260522_isaps-ps-emerging-guidance_rise-of-glp-1-ra-drugs_final.pdf
• ¹⁵ Journal of Cosmetic Dermatology. (2025). Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients. https://www.galdermaaesthetics.com/ca/sites/default/files/2025-11/Consensus-Statements-on-Managing-Aesthetic-Needs-in-Prescription.pdf
• ¹⁶ Galderma. (2025, July 17). Final Nine-Month Data on Injectable Treatment After Medication-Driven Weight Loss. https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss?utm_source=openai
• ¹⁸ Bio2 Laser Studio. (Accessed 2026, August 29). Radiofrequency Body Contouring and Public Pricing. https://bio2laserstudio.com/radiofrequency-body-contouring-san-antonio
• ⁵⁵ PubMed. (2021). Experience of Excess Skin and Attitude to Body Contouring Surgery of a Chinese Post-Bariatric Population. https://pubmed.ncbi.nlm.nih.gov/34365452/?utm_source=openai
• ⁵⁷ American Society of Plastic Surgeons. (2026). Weight Loss Medications May Affect Some Complications After Panniculectomy. https://www.plasticsurgery.org/news/press-releases/weight-loss-medications-may-affect-some-complications-after-panniculectomy

10. Shifts in Treatment Modality Focus

The rise of GLP-1 (Glucagon-Like Peptide-1) medications for weight loss has significantly changed the patient profile seeking aesthetic treatments. Clinical directors must adapt their service offerings. The focus is moving away from fat reduction procedures toward interventions that support tissue, replace volume, and tighten skin. Surgical options will remain important for severe cases. This shift requires clinics to re-evaluate their equipment, training, and referral networks. Understanding these changes is important for clinical directors planning for the 2026 and beyond aesthetic market.

Before the widespread adoption of GLP-1 medicines, many aesthetic patients sought treatments primarily for fat reduction. These included procedures like cryolipolysis, liposuction, and certain energy-based devices. However, GLP-1 medications cause substantial weight loss, which can lead to new aesthetic concerns. These concerns often include facial volume loss, skin laxity, and sagging body skin ^[6]. The demand for solutions addressing these issues is growing rapidly, with a reported 137% increase in GLP-1 patients seen by aesthetic health professionals between 2023 and 2024 ^[8].

The patient pool for these aesthetic services is expanding quickly. In June 2026, 11% of U.S. adults were using a GLP-1 drug for weight loss. This is a significant rise from 3% in 2024. An additional 4% had used one at some point, bringing the total to 15% of U.S. adults with experience with these medications ^[1]. This expansion is global, though access varies. Novo Nordisk reported that its obesity medicines reached 3.6 million people in 2025. Wegovy was available in 52 countries in 2025, up from 17 countries in 2024 ^[3]. Despite this growth, the World Health Organization expects GLP-1 medicines to reach fewer than 10% of those who could benefit by 2030, indicating that demand will remain concentrated in regions with greater access and disposable income ^[2].

The term “Post-GLP-1” refers to the aesthetic changes that occur after major weight loss, not necessarily after stopping the medication. Obesity is often a chronic condition requiring long-term management, and the World Health Organization conditionally supports continuous GLP-1 therapy ^[2]. This means clinics must plan for ongoing care that addresses skin changes during active weight loss, stabilization, and maintenance phases. The patient journey is not a one-time event but a continuous process of managing the aesthetic effects of sustained weight reduction.

10.1 From Fat Reduction to Volume Restoration

One of the most noticeable aesthetic effects of GLP-1 induced weight loss is facial volume loss. Patients often describe a gaunt or hollowed appearance. In a 2026 survey of 504 GLP-1 users, 10.9% reported facial volume loss ^[6]. Another 2026 study found that 37% of people who lost 10% to 20% of body weight reported decreased facial volume ^[7]. This problem is particularly relevant as GLP-1 medications can lead to significant weight loss, with semaglutide averaging 14.9% and tirzepatide up to 20.9% in trials ^[4], ^[5]. Such changes affect facial fat compartments, neck contours, and other body areas ^[5].

The primary modality to address facial volume loss is the use of injectable fillers. Hyaluronic acid (HA) fillers are the main immediate tool for volume replacement. A survey of 406 aesthetic health professionals found that clinicians considered HA fillers the best facial treatment for an average of 47% of GLP-1 patients ^[8]. HA fillers are most useful when the main problem is midface or temple deflation, rather than excess skin ^[8]. This suggests a clear shift in focus from removing fat to strategically adding volume.

Biostimulators, which promote the body’s own collagen production over time, are also gaining interest. These products work differently from HA fillers, providing a more gradual and natural-looking restoration of tissue support. Galderma’s patient research showed that 48% of patients expressed interest in biostimulators, while 41% would consider HA injections ^[9]. Among surveyed clinics, 54% offered or were considering biostimulators, and 89% offered or were considering fillers ^[9]. This indicates a growing acceptance and demand for treatments that improve skin quality and structure from within, rather than just filling empty spaces.

A Galderma-sponsored trial highlighted the potential of combination therapies for facial deflation. The trial combined Sculptra (a poly-L-lactic acid biostimulator) with Restylane (a hyaluronic acid filler). At the nine-month mark, 85.7% of patients reported their face looked less gaunt, and 91.4% would recommend the regimen ^[17]. While this study was company-sponsored and did not isolate the effects of each product, it supports the idea that combining different modalities can provide better outcomes for patients with several facial concerns ^[17].

The timing of these treatments is also a subject of discussion among experts. A Delphi panel of 10 experts found that 70% would start poly-L-lactic acid treatment at the same time as medication-associated weight loss ^[15]. However, the panel was split on fat transfer. This suggests that while there is some consensus on early intervention with biostimulators, more data is needed for other volume restoration methods ^[15]. Clinics should prioritize a careful assessment, followed by conservative structural volume correction, then collagen and skin quality treatments, and finally surface treatments. It is important to reassess during active weight loss to avoid overly aggressive corrections that might look excessive with further weight change ^[15].

10.2 Addressing Skin Laxity and Sagging

Weight loss often leads to skin laxity and sagging, which are distinct from volume loss. A 2026 survey reported sagging in 8.3% of GLP-1 users and jowling in 7.7% ^[6]. Another study found skin sagging in 44% of people who lost 10% to 20% of body weight ^[7]. These figures, while different due to varying methodologies, underscore the widespread nature of skin laxity concerns among this patient group ^[6], ^[7].

For mild to moderate laxity, non-surgical skin tightening treatments are becoming increasingly popular. Non-surgical skin tightening was among the top five non-surgical procedures globally in 2024, with 20.5 million such procedures performed worldwide ^[14]. This indicates a large existing market and trained provider base ready to absorb the new demand from GLP-1 patients.

External ultrasound and non-needle radiofrequency (RF) devices are expected to gain market share due to their ability to provide tightening with minimal downtime. A study associated with SkinCeuticals found a 44% reduction in graded facial laxity at 12 weeks after one focused ultrasound treatment combined with a topical regimen ^[18]. A separate clinical study by Sofwave showed improvement in 93% of treated upper arms after two ultrasound sessions ^[18]. While these results show promise for mild to moderate cases, it is important to note that they do not prove energy treatments can replace surgery for severe skin excess ^[18].

RF microneedling, however, faces increased scrutiny. On October 15, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication regarding reported burns, scarring, fat loss, disfigurement, and nerve damage associated with certain uses of RF microneedling ^[13]. This warning specifically targets needle-based RF microneedling and not all forms of RF treatment ^[13]. This may cause a shift in demand toward non-needle energy devices or clinics with strong medical oversight and device-specific training ^[13]. Clinical directors need to differentiate between various RF platforms in their training and consent processes. Grouping all RF treatments under one general label can obscure important differences in depth and risk ^[13].

Clinics like Bio2 Laser Studio are already positioning non-invasive external RF for clients undergoing GLP-1 weight loss. Bio2 Laser Studio in San Antonio offers external RF body and facial contouring, with transparent pricing for single sessions, packages, and monthly options ^[18]. For example, a single body or facial contouring session costs $440, with a six-session package at $1,980. Monthly options include $175 for one treatment or $350 for two ^[18]. While their public pages do not present peer-reviewed post-GLP-1 outcome data, this approach demonstrates how clinics are adapting their service packaging to meet the specific needs of this patient group ^[18]. To strengthen future claims, internal tracking of standardized photography, patient-reported scores, treatment completion, and adverse-event data would be valuable ^[18].

10.3 The Enduring Role of Surgery

Despite the growth in non-surgical options, surgery will retain a critical role for patients with severe skin excess. This is particularly true for those who have experienced substantial weight loss, whether through GLP-1 medications or bariatric surgery. Among GLP-1 patients tracked by American Society of Plastic Surgeons (ASPS) members in 2024, 20% had already undergone plastic surgery related to weight loss. Another 39% were considering surgery, and 41% were considering non-surgical procedures ^[12]. This clearly shows a split in demand, with a significant portion of patients requiring or considering surgical intervention.

In the U.S., abdominoplasty procedures reached 171,064 in 2024 ^[13]. Other skin-removing procedures also showed increases, with arm lifts up 2%, thigh lifts up 3%, and buttock lifts up 3% from 2023 ^[13]. These numbers were rising even before the full impact of GLP-1 usage in 2025 and 2026 became evident ^[13]. A Chinese study of post-bariatric patients found that 78.2% reported excess skin, and 37.9% wanted body-contouring surgery ^[5]. While bariatric patients typically experience more weight loss than GLP-1 users, this study highlights the global unmet need for skin excision ^[5].

For clinical directors, this means building strong referral paths to plastic surgeons is important. A clinic that offers only devices should have a formal plastic-surgery referral process ^[12]. Severe hanging skin should not be treated with a long series of device-based procedures that promise surgical-level results. Realistic expectations and clear communication about what each modality can achieve are essential.

Coordination with the patient’s medication prescriber is also important for surgical planning. The International Society of Aesthetic Plastic Surgery (ISAPS) recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms like nausea, vomiting, abdominal pain, or constipation are active ^[14]. A 2026 study from West Virginia University found that 21.7% of panniculectomy patients from 2013 to 2023 were taking GLP-1 medicines before surgery ^[5]. The study indicated possible differences in wound healing but no clear rise in overall surgical risk ^[5]. This suggests that while GLP-1 use requires careful consideration in surgical planning, it does not necessarily create a blanket contraindication for all patients ^[5].

10.4 The Importance of Combination Therapies

The aesthetic concerns arising from GLP-1 induced weight loss are often complex and complex. Patients frequently present with several linked issues, such as laxity, poor skin quality, and facial deflation ^[10]. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for multiple concerns ^[10]. This means that single-treatment plans based on one device or one injection type will only meet the needs of a fraction of the market ^[10].

Combination plans, integrating various modalities, will likely become the standard of care. These plans can involve a sequence of treatments designed to address different aspects of the patient’s concerns. For example, volume replacement with fillers can be combined with biostimulators for long-term collagen production, and energy-based devices for skin tightening. This holistic approach is supported by trials such as the Galderma study, which found high patient satisfaction with a combination of Sculptra and Restylane ^[17].

A practical sequence for combination care could involve an initial assessment to identify specific problems. This would be followed by conservative structural volume correction using fillers. Then, treatments to improve collagen and skin quality, such as biostimulators or certain energy devices, would be introduced. Finally, surface treatments like chemical peels or microdermabrasion could address skin texture. This staged approach allows for adjustments as the patient continues their weight loss journey and stabilizes. It also avoids large early corrections that might look disproportionate after further changes in body weight ^[15].

The table below summarizes the anticipated shifts in treatment modalities for post-GLP-1 aesthetic patients:

Treatment Focus	Previous Emphasis (Pre-GLP-1)	Anticipated Shift (Post-GLP-1)	Key Modalities	Patient Profile
Fat Reduction	High demand for localized fat removal (e.g., cryolipolysis, liposuction).	Reduced demand, as GLP-1s address overall fat. Focus on remaining stubborn pockets only.	Minimally invasive fat removal methods, if any.	Patients seeking fine-tuning after significant weight loss.
Volume Replacement	Primarily for age-related volume loss.	Significant increase in demand for replacing volume lost due to rapid weight loss.	Hyaluronic acid fillers, fat grafting.	Patients with facial hollowing, gaunt appearance.
Tissue Support & Collagen Stimulation	Moderate demand for general anti-aging.	Increased demand for rebuilding structural support and improving skin elasticity.	Biostimulators (e.g., Sculptra, Radiesse), polynucleotides.	Patients with overall skin thinning, loss of firmness.
Skin Tightening	For mild to moderate laxity, often as an adjunct.	High demand for addressing widespread mild to moderate skin laxity.	External ultrasound (e.g., Sofwave), non-needle RF devices.	Patients with loose skin on face, neck, arms, abdomen.
Surgical Excision	For severe laxity, often post-bariatric surgery or significant lifestyle weight loss.	Consistent or increased demand for severe excess skin not treatable non-surgically.	Abdominoplasty, arm lift, thigh lift, neck lift, facelift.	Patients with hanging skin folds, significant skin redundancy.
Combination Therapies	Used for complex age-related concerns.	Standard approach for most GLP-1 patients due to multiple, interconnected issues.	custom plans integrating injectables, energy devices, and topical care.	Most GLP-1 aesthetic patients.

10.5 Considerations for Clinical Directors

The changing treatment field presents several important considerations for clinical directors:

10.5.1 Budget Limitations and Staged Plans

While the demand for aesthetic treatments among GLP-1 patients is high, their overall aesthetic spending may not always increase. A McKinsey survey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it ^[11]. This is because patients are also paying for the medication itself, nutrition counseling, fitness programs, and new clothing ^[11]. Clinics must offer staged plans that allow patients to address their highest-priority concerns first, with options for additional care after weight stabilization. Clear pricing, financing options, and transparent estimates of likely benefits per treatment will be critical for conversion ^[11].

10.5.2 Safety and Regulatory Compliance

The FDA’s safety communication regarding RF microneedling highlights the growing importance of safety and regulatory compliance ^[13]. Clinical directors must ensure their staff are properly trained and that consent processes clearly explain risks and benefits for each specific device and treatment. Comprehensive written rules for medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse-event reporting, and surgical referrals are essential ^[5]. Claims should accurately describe expected degrees of improvement rather than promising to prevent or remove loose skin ^[5].

10.5.3 Data Tracking and Outcome Measurement

Given the relative novelty of post-GLP-1 aesthetic concerns, there is a lack of audited global revenue figures or large-scale direct studies on laxity care ^[5]. Many existing studies are small, observational, or funded by treatment companies, which can limit broad claims ^[5]. Clinical directors should expand their services in phases, carefully track their own outcomes, and maintain firm surgical referral limits ^[5].

Effective data tracking should include:

• Consultation source.
• Patient’s weight loss stage (active loss, stabilization, maintenance).
• Type of aesthetic concern (e.g., volume loss, laxity, skin quality).
• Laxity grade (mild, moderate, severe).
• Treatment selected and completion of series.
• Patient-reported improvement.
• Standardized photography.
• Adverse events.
• Refunds.
• Repeat care.
• Surgical referrals.

This data will provide valuable insights into the effectiveness of different modalities for this specific patient population, supporting informed purchase decisions for new equipment and services ^[18].

10.5.4 Trust and Transparency

Building trust is a key business asset. A 2025 consumer survey by the American Society for Dermatologic Surgery found that 94% of consumers used ratings and review sites when selecting a provider ^[16]. Nearly half said a provider’s social media presence influenced their decisions ^[16]. Clinics should maintain consistent before-and-after photographs, clearly display staff credentials, use plain language in consent forms, and publish outcomes segmented by age, body site, and severity ^[16].

The changes brought by GLP-1 medications are reshaping the aesthetic industry. The focus is shifting from general fat reduction to targeted treatments for tissue support, volume restoration, and skin tightening. Clinical directors who understand and adapt to these shifts will be well-positioned to meet the growing and evolving needs of post-GLP-1 patients.

The next section will explore the impact of GLP-1 medications on patient expectations and how clinics can manage them effectively.

11. Benefits of Combination Treatment Plans

The rise of GLP-1 (Glucagon-Like Peptide-1) agonist medications for weight loss has brought a new set of aesthetic challenges for patients and clinical directors. Significant weight loss, whether rapid or gradual, often results in skin laxity, volume loss, and changes in skin quality. Addressing these issues effectively requires more than a single approach. Clinical research and growing practice experience show that combination treatment plans offer a comprehensive solution for patients seeking to restore a more youthful and natural appearance after major weight reduction. These plans combine different aesthetic modalities to target various concerns, leading to better patient satisfaction and more complete outcomes. The effects of GLP-1 related weight loss often present as several linked issues, such as overall laxity, poor skin quality, and facial deflation. A McKinsey survey found that 63% of GLP-1 aesthetic patients requested care for multiple, linked issues^[10]. This supports a broader assessment by tissue problem rather than by body part alone.

The shift in demand is moving from fat reduction to tissue support^[8]. For instance, hyaluronic acid filler can replace lost facial volume. Biostimulators can encourage collagen formation over time. External radiofrequency (RF) and ultrasound treatments can provide mild tightening for mild to moderate skin laxity. However, surgery remains the primary referral path for significant hanging or excess skin^[8]. This complex presentation often requires a layered approach, integrating injectables, energy-based devices, and sometimes even surgical referrals, to achieve the best possible results. The adoption of GLP-1 medications is rapidly increasing, with 11% of U.S. adults taking a GLP-1 drug for weight loss in June 2026, up from 3% in 2024^[1]. This means a larger patient pool will seek aesthetic care for post-weight-loss changes, making comprehensive treatment strategies even more important.

The prevalence of skin changes among GLP-1 users is notable. A 2026 survey of 504 users reported skin changes in 38.7% of respondents^[6]. Facial volume loss affected 10.9%, sagging affected 8.3%, and jowling affected 7.7%^[6]. Another 2026 study found that 44% of people who lost 10% to 20% of body weight reported skin sagging^[7]. These statistics highlight the widespread need for effective aesthetic interventions. Clinics are already seeing this demand, with a mean increase of 137% in GLP-1 patients from 2023 to 2024, according to a survey of 406 aesthetic health professionals^[8]. The leading concerns reported were midface volume loss, face and neck laxity, and loose body skin^[8]. Such a wide array of concerns means that single-treatment options are unlikely to satisfy most patients.

The commercial opportunity for aesthetic clinics has a budget limit, as McKinsey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it^[11]. This suggests that clinics should offer staged plans, clear pricing, and high-value combinations. These factors will be key for patients managing medication costs, nutrition, fitness, and clothing changes alongside aesthetic treatments^[11]. Combination treatment plans, when structured thoughtfully, can address multiple concerns within a patient’s budget and desired timeline, providing value and clear progress over time.

Addressing Multiple Aesthetic Concerns with Combined Modalities

Patients who experience significant weight loss often present with a range of aesthetic concerns that cannot be fully addressed by a single treatment type. The problem is often not just loose skin, but a combination of issues including lost facial volume, poor skin quality, texture changes, and localized laxity across different body areas^[10]. For example, average trial weight loss with GLP-1 drugs like semaglutide (14.9% at 68 weeks) and tirzepatide (up to 20.9% at 72 weeks) can profoundly change facial fat compartments, neck contours, breasts, arms, abdomen, thighs, and buttocks^[5]. This level of weight loss commonly leads to changes in multiple areas, meaning that clinical directors should expect patients with several affected regions rather than an isolated complaint^[5].

To meet these varied needs, combination therapy proves to be effective. For instance, volume loss in the midface or temples may be best addressed with hyaluronic acid (HA) fillers. Clinicians in a 406-provider survey considered HA filler the best facial treatment for an average of 47% of GLP-1 patients^[8]. However, HA fillers do not improve skin quality or texture. This is where biostimulators, such as poly-L-lactic acid (PLLA), become important. Biostimulators encourage the body’s natural collagen production over time, which can improve skin thickness, elasticity, and firmness^[8]. A Galderma patient research study showed that 48% of patients expressed interest in biostimulators, and 41% would consider HA injections^[9]. Among surveyed clinics, 54% offered or were considering biostimulators, and 89% offered or were considering fillers^[9].

A practical sequence for these combined treatments often starts with assessment, followed by conservative structural volume correction, then collagen and skin quality treatments, and finally surface treatments. This approach allows for adjustments as the patient’s weight stabilizes. Early, large corrections should be avoided, as further weight change could make them look excessive^[15].

For mild to moderate skin laxity, energy-based devices can be combined with injectables. External ultrasound and non-needle radiofrequency (RF) technologies can offer modest tightening effects without significant downtime^[8]. A focused-ultrasound and topical study reported a 44% reduction in graded laxity at 12 weeks^[17]. Another clinical study found improvement in 93% of treated upper arms after two ultrasound sessions^[18]. While these devices are effective for certain levels of laxity, they are not a substitute for surgery in cases of severe skin excess^[8].

Therefore, a truly comprehensive plan often involves a mix of these modalities:

• Injectables (Fillers): To restore lost volume and correct contours.
• Biostimulators: To stimulate natural collagen production for improved skin quality and firmness.
• Energy-based devices (Ultrasound, RF): To provide non-surgical tightening for mild to moderate laxity.
• Topical Skincare: To improve skin health, texture, and support other treatments.
• Surgical Referrals: For severe skin excess that non-surgical methods cannot address.

This layered approach allows clinical directors to tailor treatments to the specific and evolving needs of each patient, ensuring more balanced and natural-looking results.

Clinical Evidence for Combination Treatments

Clinical studies and expert opinions increasingly support the benefits of combination treatment plans, especially in the context of GLP-1 related weight loss. One notable example is a Galderma-sponsored phase IV study that combined Sculptra (a biostimulator) with Restylane (a hyaluronic acid filler) to address facial changes after medication-driven weight loss^[16]. The treatment regimen involved Sculptra plus Restylane at the first visit, another Sculptra session with an optional filler adjustment at week four, and an optional third Sculptra session at week eight^[16].

The results of this study were encouraging. At nine months, 85.7% of patients reported that their face looked less gaunt, and 88.6% felt they looked better than before treatment^[16]. Crucially, 91.4% of patients would recommend the regimen^[16]. No treatment-related adverse events were reported, suggesting a favorable safety profile for this combination^[16]. While the study supports combination care, it is important to note that it was company-sponsored and did not isolate the contribution of each product. This means it cannot definitively state how much benefit came from Sculptra alone versus Restylane alone^[16]. However, the high patient satisfaction and positive outcomes strongly suggest that combining volume replacement with collagen stimulation is an effective strategy for this patient group.

Another study associated with SkinCeuticals explored the combination of topical care with focused ultrasound for facial changes in GLP-1 users^[17]. Participants used a topical regimen for four weeks, received one ultrasound treatment, and continued topical care for another eight weeks^[17]. At week 12, graded laxity improved by 44% from baseline, and marionette lines improved by 34%^[17]. Ninety-four percent of participants reported moderate to significant improvement, compared to only 30% in a placebo group^[17]. This study indicates that a multi-modal approach, integrating skincare with energy-based treatments, can produce noticeable improvements. Similar to the Galderma study, the combined design means it is difficult to determine the exact contribution of the topical products versus the ultrasound treatment alone. Two study authors were SkinCeuticals employees, which is also a factor to consider^[17].

Beyond specific studies, a consensus among experts points to the value of combined approaches. A 10-expert Delphi panel discussed the timing of treatments during GLP-1 associated weight loss^[15]. Seventy percent of the panelists agreed that poly-L-lactic acid (PLLA) could be started at the same time as medication-associated weight loss^[15]. This suggests that early intervention with biostimulators, even during active weight loss, is considered reasonable by many experts. The panel, however, was evenly split on the timing of fat transfer, indicating ongoing debate about certain modalities^[15]. This study, funded by a Galderma grant, reflects expert opinion rather than definitive proof, but it still informs clinical practice regarding combination therapies^[15].

The International Society of Aesthetic Plastic Surgery (ISAPS) reported nearly 38 million aesthetic procedures globally in 2024, with 20.5 million being non-surgical^[14]. This large market already relies on a range of devices and injectables. The growing patient population undergoing GLP-1 weight loss will likely further drive the adoption of combined non-surgical treatments, as these patients often seek to address both volume deficits and skin quality issues. The trend of combining various non-surgical methods is already established in broader aesthetic practice, and its application to post-GLP-1 patients is a natural extension of this practice.

Strategic Implementation of Combination Treatment Plans

Clinical directors must consider several factors when integrating combination treatment plans into their practices for post-GLP-1 patients. These factors include patient assessment, timing of treatments, managing patient expectations, and structuring pricing. The goal is to provide value, achieve patient satisfaction, and ensure safe outcomes.

Patient Assessment and Staging of Care

A detailed initial assessment is crucial for GLP-1 patients. This assessment should cover:

• Age, current weight, and target weight
• Percentage and speed of weight loss
• GLP-1 medication stage (active loss, stabilization, maintenance)
• Specific aesthetic concerns, including facial volume loss, body sites affected, and skin quality
• Presence of any related health conditions or symptoms
• Patient priorities and budget constraints

A three-level laxity grade (mild, moderate, or severe) can guide decisions regarding device care, combination care, or surgical referral^[15]. For patients still actively losing weight, a conservative approach is best. Avoid large early corrections that might look disproportionate after further weight reduction^[15]. Instead, treatments can be staged, beginning with the most pressing concerns and gradually adding more extensive care as weight stabilizes^[11].

Regular reassessment is key throughout the treatment journey, especially during active weight loss. This allows clinical directors to adjust the plan as the patient’s body changes, ensuring that treatments remain appropriate and effective. Baseline photography and skin assessment should occur early, before extensive appearance changes are established^[6]. This creates a clear reference point for tracking progress.

Choosing the Right Combination Modalities

The choice of combination modalities depends heavily on the specific concerns of the patient:

• Facial Volume Loss: For areas like the midface or temples where fat pads have diminished, hyaluronic acid fillers are often the first choice. They provide immediate volume restoration and contouring.
• Skin Quality and Firmness: Biostimulators like Sculptra or Radiesse are excellent for stimulating natural collagen production over time. These can be combined with fillers to address both volume and skin texture simultaneously.
• Mild to Moderate Laxity: Energy-based devices such as external ultrasound (e.g., Ultherapy, Sofwave) or non-ablative radiofrequency are suitable for tightening skin with mild to moderate laxity. These can be used on the face, neck, and certain body areas. The SkinCeuticals-associated study highlighted the benefit of combining focused ultrasound with topical regimens for improved facial laxity and marionette lines^[17].
• Severe Laxity or Hanging Skin: For significant excess skin, particularly on the body (e.g., abdomen, arms, thighs), non-surgical treatments are often insufficient. In these cases, a clear surgical referral path to a plastic surgeon is essential. The American Society of Plastic Surgeons (ASPS) data shows that among GLP-1 patients, 20% had undergone plastic surgery, 39% were considering surgery, and 41% were considering non-surgical procedures^[8]. Clinics should be ready to offer both non-surgical and surgical referral options.
• Adjunctive Therapies: Medical-grade skincare products can support and enhance the results of in-clinic treatments by improving skin health and barrier function.

Pricing and Patient Budget Considerations

As noted earlier, a significant portion of GLP-1 patients (60%) reduced their overall aesthetic spending, while 40% increased it^[11]. This highlights the need for clear pricing, financing options, and staged treatment plans. Clinics should:

• Offer clear estimates of likely benefits per treatment.
• Provide package deals for combination treatments or series of treatments, offering cost savings compared to individual sessions.
• Consider financing plans to make comprehensive care more accessible.
• Emphasize the value of combination treatments in achieving more complete and satisfying results within budget constraints.

Bio2 Laser Studio, for example, lists clear package pricing for its external RF body and facial contouring services, offering single sessions, multi-session packages, and monthly options^[18]. This transparency helps reduce buying friction for patients. Bio2 Laser Studio links these treatments to GLP-1 weight loss patients. While their public pages do not provide peer-reviewed post-GLP-1 outcome data, internal tracking of patient-reported outcomes and standardized photography would strengthen future claims^[18].

Safety and Timing Considerations

Safety is a primary concern, especially with energy-based devices. The U.S. Food and Drug Administration (FDA) issued a safety communication in October 2025 regarding potential risks with certain uses of radiofrequency (RF) microneedling, including burns, scarring, fat loss, disfigurement, and nerve damage^[13]. This warning applies specifically to needle-based RF microneedling, not all forms of RF treatment^[13]. Clinical directors must distinguish between different RF technologies (needle-based, external, minimally invasive subdermal) in staff training, consent forms, and patient discussions to manage risks effectively^[15]. This FDA warning may shift demand toward non-needle energy devices or providers with stronger medical oversight^[15].

Timing of treatments in relation to GLP-1 use also requires careful consideration. ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and if gastrointestinal symptoms like nausea or abdominal pain are active^[14]. This necessitates coordination with the prescribing physician. While a 2026 study on panniculectomy patients taking GLP-1 medicines found possible differences in wound healing but no clear rise in overall surgical risk, blanket assumptions about safety are unsafe^[15]. For non-surgical treatments, close monitoring and phased interventions are advisable. Each service line needs written rules for medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse event reporting, and referral^[15].

Benefits for Clinical Directors and Patients

Implementing comprehensive combination treatment plans offers substantial benefits for both clinical directors and their patients.

Benefits for Clinical Directors:

• Enhanced Patient Satisfaction: Addressing multiple concerns leads to more complete and natural-looking results, increasing patient satisfaction and loyalty. High patient satisfaction, such as the 91.4% recommendation rate in the Galderma study, translates to positive word-of-mouth and practice growth^[16].
• Increased Service Revenue: Combination plans often involve multiple procedures or devices over time, leading to higher average revenue per patient compared to single-treatment approaches.
• Stronger Competitive Position: Clinics offering comprehensive, custom solutions are better positioned in a market where patients have complex needs and varying budgets. McKinsey found that 63% of GLP-1 aesthetic patients requested care for several linked issues^[10], indicating a market demand for multi-faceted solutions.
• Improved Clinical Outcomes: By strategically combining modalities, clinical directors can achieve results that are not possible with single treatments alone, particularly for patients with extensive skin laxity and volume loss.
• Better Patient Retention and Referrals: Satisfied patients are more likely to return for maintenance treatments and refer others, creating a sustainable patient base. Trust is a significant business asset, with 94% of consumers using ratings and review sites to choose a provider, and clear outcomes separated by age, body site, and severity can build this trust^[16].
• Reduced Risk of Patient Dissatisfaction: Properly managed expectations and staged care reduce the likelihood of patients feeling that their concerns were not fully addressed by a single, limited treatment.
• improved Resource Utilization: A clear strategy for combining devices and injectables allows for better planning and utilization of clinic equipment and staff expertise.

Benefits for Patients:

• Comprehensive and Natural Results: Patients achieve more harmonious and natural-looking outcomes as various aspects of post-weight-loss changes (volume, laxity, skin quality) are addressed concurrently or sequentially. The Galderma study showed 85.7% of patients felt their face looked less gaunt and 88.6% felt better than before treatment^[16].
• custom Treatment Plans: Combination approaches allow for individualized treatment plans that directly match the patient’s unique anatomy and concerns, rather than a one-size-fits-all approach.
• Cost-Effectiveness Over Time: While initial investment may be higher, a comprehensive plan can lead to more lasting results, potentially reducing the need for frequent, less effective single treatments in the long run. Staged plans can begin with high-priority concerns and add later care after weight stabilizes^[11].
• Managed Expectations: Clear communication about what each modality can achieve, and the synergistic effects of combinations, helps patients understand realistic outcomes.
• Reduced Downtime (for non-surgical combinations): Many non-surgical combination treatments offer significant aesthetic improvement with minimal downtime compared to surgical alternatives, which is appealing to many patients. A focused-ultrasound study, for example, showed a 44% reduction in laxity at 12 weeks with low downtime^[17].
• Improved Self-Confidence and Quality of Life: Addressing aesthetic concerns after weight loss can significantly improve a patient’s body image and overall quality of life. In a 504-person study, 84% reported improved body image and 68.5% reported greater self-confidence after GLP-1 use, despite appearance concerns^[6]. Aesthetic care should support these health gains.

The success of combination treatment plans for post-GLP-1 patients relies on careful assessment, thoughtful treatment design, clear communication, and a commitment to patient safety and satisfaction. As the demand for aesthetic care among GLP-1 users continues to grow, clinics that master these comprehensive approaches will be well-prepared to meet the evolving needs of this patient population.

Transition to Next Section

While combination treatment plans offer significant advantages for addressing the diverse needs of post-GLP-1 patients, the field of non-surgical options is constantly shifting. The efficacy of specific energy-based devices and injectables continues to be refined through research and clinical experience. The next section will specifically explore the use of non-invasive ultrasound and radiofrequency (RF) technologies, evaluating their role in tightening skin and improving contours for this patient group, and considering the specific safety and consent pressures now associated with certain RF microneedling applications.

12. Role of Non-Invasive Energy-Based Devices

The rise of GLP-1 (glucagon-like peptide-1) weight-loss medicines has created a growing demand for aesthetic treatments to address skin laxity. Patients who experience significant weight reduction often face concerns such as facial volume loss, sagging skin, and jowling^[6]. While surgical options offer definitive solutions for severe excess skin, a substantial portion of patients seeks non-surgical alternatives due to preferences for lower downtime, reduced risk, and less invasive procedures^[12]. Non-invasive energy-based devices, particularly external ultrasound and radiofrequency (RF) systems, are positioned to play a key role in addressing mild to moderate skin laxity in this patient population. These devices stimulate collagen production and tighten tissues, offering a middle ground between injectables and surgery. The market for non-surgical aesthetic procedures is already substantial, with 20.5 million procedures performed globally in 2024^[14]. This established market provides a foundation of trained providers and consumer acceptance for these technologies. Clinical directors must understand the capabilities, limitations, and safety considerations of these devices to effectively integrate them into comprehensive post-GLP-1 aesthetic treatment plans.

The increase in GLP-1 users is significant. In June 2026, 11% of U.S. adults were taking a GLP-1 drug for weight loss, a substantial rise from 3% in 2024^[1]. This expansion translates into a larger patient pool seeking aesthetic solutions. Patient-reported skin changes are common. A 2026 survey of 504 GLP-1 users found that 38.7% reported skin changes. Specifically, 10.9% reported facial volume loss, 8.3% reported sagging, and 7.7% reported jowling^[6]. Another 2026 study indicated that 44% of people who lost 10% to 20% of body weight reported skin sagging^[7]. These numbers highlight a clear need for treatments that can address these concerns. Non-invasive energy-based devices, by stimulating collagen and elastin, offer a potential solution for some of these issues, particularly for mild to moderate laxity.

The demand for non-surgical care is evident. Among GLP-1 patients tracked by American Society of Plastic Surgeons (ASPS) members in 2024, 41% were considering a non-surgical procedure, while 39% were considering surgery^[12]. This suggests a strong preference or need for non-invasive options. The shift in modality focus from fat reduction to tissue support is also notable. While GLP-1 patients have reduced fat, their primary aesthetic concerns often relate to skin laxity and volume loss, making tightening and structural support treatments more relevant^[8]. External radiofrequency and ultrasound are specifically mentioned as offering modest tightening for mild to moderate laxity^[8]. This section will explore the specific types of non-invasive energy-based devices, their mechanisms of action, clinical evidence, safety considerations, and their practical application in managing post-GLP-1 skin laxity.

Understanding Non-Invasive Ultrasound for Skin Laxity

Non-invasive ultrasound devices use focused acoustic energy to create thermal coagulation points at specific depths within the skin and subcutaneous tissue. This controlled heating stimulates a wound-healing response, leading to neocollagenesis (new collagen formation) and elastin remodeling, which in turn results in tissue tightening and lifting over several months. The key advantage of focused ultrasound is its ability to precisely deliver energy to deep tissue layers, including the superficial musculoaponeurotic system (SMAS), without damaging the superficial skin layer. This precision allows for effective tightening with minimal downtime, aligning well with patient demand for low-downtime options^[11].

Clinical evidence supports the use of ultrasound for mild to moderate laxity. One study reported a 44% reduction in graded facial laxity at 12 weeks when focused ultrasound was combined with a topical regimen. In this study, participants used a topical regimen for four weeks before one ultrasound treatment, and continued topical care for another eight weeks. The results showed that 94% reported moderate to significant improvement, compared with 30% using a placebo. Only three mild, self-resolving adverse events were reported^[18]. This specific study, though associated with SkinCeuticals and involving employees as authors, points to the potential of ultrasound in improving facial changes in GLP-1 users when combined with supportive skincare.

Another manufacturer clinical study, specifically from Sofwave, reported improvement in 93% of treated upper arms after two ultrasound sessions^[18]. The upper-arm protocol involved two sessions spaced one to three weeks apart. While promising, this evidence comes from a manufacturer summary and should be considered with caution. It does not automatically apply to older patients, cases of severe laxity, or every body site. However, it indicates a high rate of positive outcomes for certain body areas and degrees of laxity. These findings suggest that ultrasound can be a valuable tool for targeting specific areas of concern that commonly arise after weight loss, such as sagging in the arms or submental region.

The appeal of non-invasive ultrasound for post-GLP-1 patients lies in its ability to provide measurable tightening without incisions, anesthesia, or a lengthy recovery period. Patients undergoing GLP-1 weight loss often experience a gradual reduction in body fat, which can lead to progressive skin laxity. Early intervention with ultrasound might help to mitigate this laxity as weight loss progresses, or address it once weight has stabilized. The typical treatment course involves one to two sessions, with results appearing over several months as collagen rebuilds. This gradual improvement can align with a patient’s desire for natural-looking changes.

Despite its benefits, it is important to manage patient expectations. Non-invasive ultrasound is generally most effective for mild to moderate skin laxity. It is not a substitute for surgical procedures for patients with significant skin excess or hanging skin^[18]. Clinical directors must conduct thorough assessments to determine if a patient’s laxity falls within the treatable range for ultrasound or if surgical referral is more appropriate. Intake should record age, percentage and speed of weight loss, medication stage, and a three-level laxity grade (mild, moderate, or severe) to guide treatment decisions^[20].

Exploring External Radiofrequency (RF) Treatments for Skin Tightening

External radiofrequency devices deliver energy to the skin through electrodes on the skin surface. This energy heats the dermal and subcutaneous layers, causing collagen fibers to contract and stimulating the production of new collagen. The controlled heating aims to improve skin firmness and reduce the appearance of laxity. Unlike focused ultrasound, external RF generally has a broader heating pattern and may not reach the same depths. However, it is a proven method for non-invasive skin tightening, offering a comfortable treatment experience with no downtime.

External RF treatments are considered a safe and effective option for mild to moderate skin laxity. The demand for low-downtime care positions these devices favorably in the post-GLP-1 aesthetic market^[11]. The mechanism of action, primarily neocollagenesis and remodeling of existing collagen, makes RF suitable for improving skin quality and firmness in areas affected by weight loss, such as the face, neck, and certain body areas. The professional literature indicates that non-surgical skin tightening was among the five most common non-surgical procedure groups worldwide in 2024^[23]. This reflects a broad acceptance and utilization of these technologies.

One example of an independent clinic, Bio2 Laser Studio in San Antonio, Texas, explicitly links external RF body and facial contouring to GLP-1 weight loss on its public pages^[30]. The studio offers specific pricing structures, including single sessions, packages of multiple sessions, and monthly options. For example, a single body or facial contouring session is listed at $440, a six-session package at $1,980, and a $175 monthly option for one treatment^[30]. This demonstrates how smaller providers are adapting their service offerings and pricing to cater to the emerging GLP-1 patient demographic. The clear pricing and repeat-session structures can help reduce buying friction for patients. However, the absence of published peer-reviewed post-GLP-1 outcome data from such clinics highlights the need for strong internal tracking of results to support stronger efficacy claims.

The FDA’s safety communication on RF microneedling, issued in October 2025, differentiates between various RF applications^[13]. The warning listed reported burns, scarring, fat loss, disfigurement, and nerve damage with certain aesthetic uses of RF microneedling^[13]. This warning applies specifically to needle-based RF, not every form of RF treatment. This distinction is important for clinical directors. External RF treatments, which do not involve needles, are generally considered to carry a lower risk profile compared to RF microneedling. The FDA communication may move demand toward non-needle energy devices, or to providers with stronger medical oversight^[25]. This potential shift implies an increased focus on the safety and efficacy of external RF devices that avoid needle-based delivery.

When considering external RF, clinical directors must ensure staff training is current and comprehensive, and consent processes clearly explain the specific type of RF treatment being offered. Marketing should differentiate between needle-based RF, external RF, and other heat devices to avoid confusion and misrepresentation. This transparency builds trust, which is a critical factor for patients choosing a provider^[29]. Clear claims about the likely degree of improvement, rather than promises of complete prevention or removal of loose skin, are also essential.

Comparing Non-Invasive Ultrasound and External RF

Both non-invasive ultrasound and external radiofrequency treatments address mild to moderate skin laxity by stimulating neocollagenesis. However, they differ in their energy delivery mechanisms, depth of penetration, and typical treatment protocols. Understanding these differences is essential for selecting the most appropriate device for each patient and their specific concerns after GLP-1 induced weight loss.

Energy Delivery and Depth of Action

• Non-invasive Ultrasound: Uses focused acoustic waves to create thermal coagulation points at precise depths. Devices like those used in the SkinCeuticals-associated study and the Sofwave clinical study can target specific tissue layers, including the SMAS (superficial musculoaponeurotic system), which is a deeper structural layer. This precision allows for lifting effects in addition to tightening^[18].
• External Radiofrequency: Delivers electromagnetic energy to heat the dermal and subcutaneous layers through surface electrodes. The heating is generally broader and less precise in depth control compared to focused ultrasound. It primarily works on stimulating collagen contraction and new collagen formation within the dermis and upper subcutaneous tissue, leading to skin tightening and improved texture.

Treatment Protocol and Downtime

• Non-invasive Ultrasound: Often requires fewer sessions, sometimes as few as one or two, with results gradually appearing over several months. Downtime is typically minimal, often involving only transient redness or swelling. The SkinCeuticals-associated study, for instance, used a single focused-ultrasound treatment^[18].
• External Radiofrequency: May require a series of multiple sessions (e.g., 6-8 sessions) to achieve optimal results, with maintenance treatments possibly needed. Downtime is usually negligible, making it a very appealing option for patients seeking zero recovery time.

Suitability for Post-GLP-1 Patients

• Both modalities are well-suited for patients with mild to moderate skin laxity resulting from GLP-1 weight loss.
• For patients primarily concerned with a noticeable lift, especially in areas like the brow, jawline, or neck, focused ultrasound might be preferred due to its deeper action on structural tissues.
• For overall skin tightening, improved skin quality, and reduction of fine lines and wrinkles on the face or body, external RF can be a very effective choice.

The choice between ultrasound and external RF, or even a combination, depends on the individual patient’s specific presentation of laxity, their aesthetic goals, budget, and tolerance for treatment intensity and number of sessions. A comprehensive assessment of the patient’s skin quality, degree of laxity, and underlying tissue loss is essential for making an informed recommendation.

Safety Considerations and Regulatory Environment

The aesthetic industry is subject to regulatory oversight, and clinical directors must stay informed about safety communications and guidelines. The U.S. Food and Drug Administration (FDA) plays a key role in regulating medical devices, including those used for non-invasive skin tightening.

FDA Safety Communication on RF Microneedling

On October 15, 2025, the FDA issued a safety communication regarding potential risks with certain uses of radiofrequency (RF) microneedling^[13]. This communication warned of reported adverse events such as burns, scarring, unwanted fat loss, disfigurement, and nerve damage^[13]. The FDA stressed that RF microneedling is a medical procedure and advised patients to seek licensed providers with device-specific training. It also urged providers to report complications^[26].

It is critical to understand that this warning specifically applies to RF microneedling devices, which combine microneedling with RF energy delivery. It does not apply equally to every RF platform. Clinical directors should differentiate between:

• Needle-based RF (RF Microneedling): Involves needles penetrating the skin to deliver RF energy, carrying risks associated with both needle insertion and thermal energy.
• External RF: Energy is delivered via electrodes on the skin surface without penetration. These devices are generally considered less invasive and carry a different risk profile.
• Minimally invasive subdermal RF: Involves a probe inserted under the skin to deliver RF energy. This also has a different risk profile.

Marketing all these under a single broad “RF tightening” label can mask significant differences in depth of action, invasiveness, and potential risks^[27]. The FDA’s focus on RF microneedling may lead to a shift in demand toward non-needle energy devices, or toward providers who demonstrate stronger medical oversight and clearer consent processes for all RF modalities^[25].

General Safety Practices for Energy-Based Devices

Beyond specific warnings, general safety practices are paramount for all energy-based devices:

• Provider Training and Certification: Ensure all staff operating devices are properly trained, certified, and competent in their use. This includes understanding device parameters, skin types, and potential contraindications.
• Patient Selection: Carefully screen patients for suitability. Factors like skin type, medical history, medications, and the presence of implants can affect treatment safety and outcomes.
• Informed Consent: Provide detailed, plain language explanations of the procedure, expected outcomes, potential risks, and alternative treatments. Patients should understand that non-invasive treatments offer modest improvement, not surgical-level results.
• Photography and Documentation: Standardized before-and-after photography is essential for tracking progress, managing expectations, and providing evidence in case of complications.
• Adverse Event Reporting: Establish clear protocols for recognizing, managing, and reporting any adverse events to the appropriate regulatory bodies and device manufacturers.

The overall context for post-GLP-1 patients also requires consideration. GLP-1 medications themselves can have side effects, and their interaction with aesthetic treatments needs to be monitored. While the ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms are active, similar caution may be prudent for certain energy-based procedures, especially those that involve deeper tissue or potential for systemic effects^[27]. Clinics should establish clear rules regarding medication stage, active symptoms, weight stability, and nutrition screening as part of their service protocols^[28].

Clinical Application and Patient Management

Effective integration of non-invasive energy-based devices into post-GLP-1 aesthetic care requires a systematic approach to patient assessment, treatment planning, and outcome monitoring. The goal is to provide high-value care that addresses patient concerns while managing expectations realistically.

Patient Assessment and Treatment Planning

Patients undergoing GLP-1 mediated weight loss present with a unique set of aesthetic concerns. The assessment should be holistic:

• Weight Loss Profile: Document the total weight lost, the speed of loss, and the current phase of weight management (active loss, stabilization, maintenance). Skin changes are associated with weight loss above 20 pounds and tend to appear within five months for over half of affected individuals^[6].
• Laxity Grading: Implement a standardized, three-level laxity grade (mild, moderate, severe) for each body area. This guides whether device care, combination care, or surgical referral is appropriate^[20].
• Tissue Assessment: Beyond laxity, evaluate skin quality (texture, elasticity, tone), volume loss (especially facial deflation), and overall contour irregularities. Sixty-three percent of GLP-1 aesthetic patients in a McKinsey survey requested care for several linked issues, such as laxity, poor skin quality, and facial deflation^[10].
• Patient Goals and Budget: Understand what the patient hopes to achieve and their financial constraints. McKinsey found that about 60% of GLP-1 patients reduced total aesthetic spending, while 40% increased it^[11]. This suggests a need for staged plans and clear pricing.
• Medication Status: Understand the patient’s GLP-1 medication regimen, including dosage, duration, and any side effects.

Based on this assessment, clinical directors can develop custom treatment plans. For mild to moderate laxity, non-invasive ultrasound or external RF can be primary modalities. For more complex cases, combination approaches are often indicated. A practical sequence for facial treatment could be assessment first, conservative structural volume correction second (e.g., with hyaluronic acid fillers), collagen and skin-quality treatment third (which includes energy-based devices and biostimulators), and surface treatment last^[22]. Reassessment during active weight loss is critical to avoid overcorrection.

Combination Therapies

Single treatments may not address the multiple concerns of GLP-1 patients, as 63% request care for several linked issues^[10]. Combination therapies often yield superior results. For example, a Galderma trial combining Sculptra (a biostimulator) with Restylane (a hyaluronic acid filler) reported that 85.7% of patients felt their face looked less gaunt after nine months, and 91.4% would recommend the regimen^[17]. While this study was company-sponsored and did not isolate the contribution of each product, it supports the concept of combining volume replacement with collagen stimulation. Non-invasive energy devices can be integrated into such protocols to address skin laxity while injectables restore volume. The SkinCeuticals-associated study also showed improved results when focused ultrasound was combined with a topical regimen, suggesting that adjunctive skincare can enhance the effects of energy-based treatments^[18].

Managing Expectations and Referrals

One of the most important aspects of patient management is setting realistic expectations. Non-invasive energy-based devices provide improvement for mild to moderate laxity but cannot replicate the results of surgery for severe skin excess. Severe hanging skin should not be treated with a long series of device treatments under the promise of surgical-level results^[25]. Clinical directors must establish clear referral pathways to plastic surgeons for patients who present with severe laxity, extensive skin folds, or ptosis that is beyond the scope of non-invasive treatment. The ASPS data from 2024 shows that 20% of GLP-1 patients had already undergone plastic surgery, and another 39% were considering it^[12]. This indicates a significant surgical need that devices alone cannot meet. Clinics that offer only devices should therefore build formal plastic-surgery referral relationships^[12]. Clear claims describing likely degrees of improvement, rather than promising complete prevention or removal of loose skin, are critical for ethical practice and patient satisfaction^[28].

Operational and Financial Considerations

For clinical directors, investing in non-invasive energy-based devices must be data-driven. Purchase decisions should be based on local utilization, patient demand, and measured results, not solely on broad GLP-1 growth headlines^[30]. Key operational metrics to track include:

• Consultation source and conversion rates for GLP-1 patients.
• Laxity grade distribution among GLP-1 patients.
• Treatment selected, series completion rates, and patient-reported improvement scores.
• Photography grades and any adverse events.
• Repeat care rates and surgical referral patterns.

McKinsey’s research indicates that 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it, suggesting that cost-effectiveness and clear pricing models are important^[11]. Offering staged plans, financing options, and transparent pricing can help clinics cater to varying patient budgets and increase treatment accessibility^[11]. The example of Bio2 Laser Studio’s pricing structure for RF body contouring demonstrates how clear, package-based pricing can reduce friction for patients^[30]. Trust signals, such as strong before-and-after portfolios, positive reviews, and clear staff credentials, also play a significant role in patient conversion for this patient group, as 94% of consumers use ratings and review sites to choose a provider^[16].

Conclusion

Non-invasive ultrasound and external radiofrequency devices are ready to be significant modalities in addressing the aesthetic concerns of post-GLP-1 weight-loss patients. Their ability to deliver mild to moderate skin tightening with low downtime aligns well with patient preferences. Clinical evidence, while sometimes from manufacturer-sponsored studies, suggests measurable improvements in laxity for appropriate candidates. However, it is important to clearly distinguish these treatments from surgical solutions for severe skin excess. The FDA’s safety communication regarding RF microneedling highlights the need for precise understanding of different RF technologies and strong safety protocols. Clinical directors must adopt a comprehensive approach, including thorough patient assessment, custom combination treatment plans, realistic expectation management, and clear surgical referral pathways. By integrating these practices with transparent pricing and diligent outcome tracking, clinics can effectively serve the expanding population of GLP-1 patients seeking aesthetic improvements. This strategic focus ensures that non-invasive energy-based devices are utilized responsibly and effectively, contributing to patient satisfaction and clinic growth in this evolving aesthetic market segment.

The increasing patient pool and the shift toward tissue support treatments mean that the role of non-invasive energy-based devices will continue to grow. Understanding their capabilities and limitations, combined with a commitment to patient safety and education, will be crucial for clinical directors as they navigate the post-GLP-1 aesthetic field. The next section will focus on the role of injectable biostimulators and fillers, which often complement these energy-based devices in comprehensive treatment plans.

13. Safety Considerations for RF Microneedling

Radiofrequency (RF) microneedling has gained popularity in aesthetic practices for addressing skin concerns like laxity and texture. However, its use now carries increased scrutiny due to an official communication from the U.S. Food and Drug Administration (FDA) in October 2025^[13]. This communication highlighted potential risks associated with certain applications of the technology. Clinical directors must understand these safety concerns and their implications for treatment selection, patient consent, and practice operations, especially in the context of a growing patient population experiencing skin changes after GLP-1 medication-associated weight loss. The warning from the FDA signals a shift in the regulatory and clinical perception of RF microneedling, moving it from a broadly applied aesthetic tool to a procedure requiring more careful consideration of device type, operator skill, and patient selection. This shift affects how clinical directors should approach equipment purchases, staff training, and referral protocols.

The FDA’s safety communication specifically mentioned reported adverse events such as burns, scarring, unwanted fat loss, disfigurement, and nerve damage^[13]. It is important to note that this warning applies to “certain uses” of RF microneedling and not every form of radiofrequency treatment^[13]. This distinction is vital for clinical directors, as the RF technology spectrum includes non-needle external RF, minimally invasive subdermal RF, and other heat-based devices, each with different mechanisms of action, depth of penetration, and risk profiles. Marketing all these under a single “RF tightening” label can hide significant differences in potential effects and safety requirements^[27]. Clinical directors must separate these technologies in staff education and patient consent processes.

The post-GLP-1 patient group presents particular challenges and considerations for skin laxity treatments. These patients may experience significant changes in skin structure and volume due to rapid and substantial weight loss^[6]. The potential for unexpected tissue responses or heightened vulnerability to adverse events with certain procedures, including RF microneedling, warrants a cautious and evidence-based approach. The FDA communication, therefore, has substantial implications for how RF microneedling is integrated into treatment plans for this patient population.

This section will examine the specific risks outlined by the FDA, distinguish between different RF modalities, explore the impact on treatment choices and patient counseling, and discuss necessary adjustments to clinical protocols and staff training. It will also consider how the FDA’s guidance influences the competitive field for skin tightening technologies and the overall patient care strategy for individuals seeking aesthetic interventions after GLP-1-induced weight loss.

Understanding the FDA Safety Communication on RF Microneedling

On October 15, 2025, the U.S. Food and Drug Administration issued a safety communication addressing potential risks associated with specific applications of radiofrequency (RF) microneedling devices^[13]. This communication served as a significant alert for both patients and providers in the aesthetic field. The FDA stated that RF microneedling is a medical procedure and advised patients to seek treatment from licensed providers with device-specific training^[27]. Additionally, it urged providers to report complications, emphasizing that its review of the technology was ongoing^[27].

The core of the FDA’s concern revolved around reported serious harms. These included:

• Burns: Unintended thermal injury to the skin, which can range from mild to severe^[13].
• Scarring: Permanent tissue damage resulting from improper treatment, excessive energy, or individual patient factors^[13].
• Unwanted Fat Loss: A particularly troubling adverse event for some patients, especially when treating areas where volume preservation is important, such as the face. This risk is amplified in patients who have already experienced facial volume loss due to GLP-1 medicines^[13].
• Disfigurement: Severe and lasting alteration of appearance, potentially resulting from any of the above complications^[13].
• Nerve Damage: Injury to nerves, leading to altered sensation, weakness, or other neurological symptoms^[13].

It is important for clinical directors to understand that these adverse events are not inherent to all RF treatments, but rather to “certain uses” of RF microneedling. The FDA did not issue a blanket condemnation of all radiofrequency therapies. Instead, the focus was on devices that combine microneedling with RF energy, implying that the specific interaction of needles creating channels and delivering thermal energy below the skin surface introduces a unique set of risks when not properly managed.

The communication did not specify particular device brands or types, but rather the general modality. This places the burden on clinical directors to evaluate their own equipment, protocols, and staff competence. The phrase “certain uses” suggests that factors like treatment depth, energy settings, number of passes, operator technique, and patient selection are critical in determining safety outcomes. For instance, using RF microneedling at aggressive settings or in areas with superficial fat pads may elevate the risk of unwanted fat loss, which can be difficult to reverse.

The FDA’s statement that its review was “continuing” indicates that this is not a final ruling, but an ongoing process. This means that further guidance, restrictions, or even changes in device classifications could occur. Clinical directors should stay informed about any updates from regulatory bodies and adjust their practices accordingly. This continuous oversight requires practices to maintain thorough records, including detailed consent forms, pre- and post-treatment photography, and documentation of any adverse events, which could contribute to the collective understanding of RF microneedling safety.

The impact of this communication extends beyond immediate clinical practice. It influences patient perception, insurance coverage debates, and potentially the future development and marketing of RF microneedling devices. Patients, armed with this information, may ask more pointed questions about risks during consultations, necessitating more detailed and transparent discussions from providers.

Distinguishing RF Modalities and Risk Profiles

The term “radiofrequency treatment” encompasses a wide array of devices and techniques. The FDA’s safety communication specifically targets RF microneedling, a distinction that clinical directors must clearly understand and communicate. It is crucial to differentiate between needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices, as each has a distinct mechanism, depth of action, and associated risk profile^[27].

Table 13.1: Comparison of RF Modalities and Key Characteristics

Modality	Mechanism	Target Depth	Key Risks	Application for Post-GLP-1 Laxity
RF Microneedling	Needles create micro-channels; RF energy delivered through needles into dermis.	Deep dermis, sometimes superficial fat.	Burns, scarring, unwanted fat loss, disfigurement, nerve damage[13].	Deeper collagen stimulation, but heightened risk concerns with FDA warning. Potential for fat loss is significant for GLP-1 patients already experiencing volume loss.
External (Non-Needle) RF	RF energy delivered via external applicator on skin surface.	Superficial dermis.	Surface burns, transient redness. Generally lower risk profile compared to invasive methods.	Mild to moderate skin tightening, skin quality improvement. Considered safer for GLP-1 patients due to non-invasive nature. Bio2 Laser Studio uses external RF for body and facial contouring[30].
Minimally Invasive Subdermal RF	Cannulas inserted under skin to deliver RF energy directly to subdermal tissues.	Subdermal fat, fibrous septae.	Burns (internal and external), nerve damage, contour irregularities, infection.	More aggressive tightening and fat remodeling than external RF; often used for more significant laxity. Requires surgical expertise.
Focused Ultrasound (HIFU)	Ultrasound energy creates thermal coagulation points at precise depths.	Deep dermis, superficial musculoaponeurotic system (SMAS).	Pain during treatment, temporary numbness, nerve palsy (rare), contour irregularities. No fat loss risk if correctly used.	Significant lifting and tightening for mild to moderate laxity. Non-invasive with targeted depth control.

RF Microneedling: This category, the subject of the FDA’s warning, involves devices that combine physical microneedling with the delivery of radiofrequency energy^[13]. The needles penetrate the skin to a specific depth, and RF energy is emitted from the needle tips, heating the tissue around them. This dual action aims to stimulate collagen production and tighten the skin. The ability to deliver heat precisely at various depths, including into the superficial fat layer, contributes to its efficacy but also to its risks^[13]. For GLP-1 patients, who may already be experiencing facial volume loss, the risk of unwanted fat loss from RF microneedling is particularly concerning and must be explicitly discussed during consent^[13].

External (Non-Needle) RF: These devices apply RF energy to the skin’s surface without puncturing it. The energy penetrates through the epidermis to heat the dermis, promoting collagen contraction and new collagen formation. Examples include monopolar, bipolar, and multipolar RF devices. While the heating is less precise and generally more superficial than RF microneedling, the risk of serious complications like scarring or fat loss is significantly lower. For patients with mild to moderate laxity, especially those seeking a less invasive option post-GLP-1 weight loss, external RF can be a suitable choice. Bio2 Laser Studio, for instance, offers external RF body and facial contouring, positioning it as a service for clients losing weight or using GLP-1 medicines^[30]. Their public pages indicate a focus on this modality, offering single sessions and package pricing^[30].

Minimally Invasive Subdermal RF: This modality involves inserting fine cannulas or probes beneath the skin to deliver RF energy directly to the subdermal tissues and fat layer. These procedures are typically performed under local anesthesia and are more invasive than external RF but less so than surgical lifts. While they can achieve more significant tightening and contouring than external RF, they carry higher risks, including burns, nerve damage, and contour irregularities, and demand a higher level of medical training and expertise for safe operation.

Focused Ultrasound (HIFU): Although not RF technology, focused ultrasound devices are often considered alongside RF for non-surgical skin tightening. They use ultrasound energy to create precise thermal coagulation points at specific depths in the deep dermis and superficial muscular aponeurotic system (SMAS) layer. These devices do not use needles or general bulk heating. While focused ultrasound can induce significant lifting and tightening for mild to moderate laxity, it presents different risks, such as temporary nerve palsy or numbness, but generally not unwanted fat loss if correctly used. A SkinCeuticals-associated study in 2026 reported a 44% improvement in graded laxity at 12 weeks after one focused-ultrasound treatment combined with a topical regimen^[18].

The critical takeaway for clinical directors is that “RF tightening” is not a single, homogeneous treatment. Marketing strategies that group all RF technologies under one umbrella term can be misleading and obscure the differences in risk and patient suitability. Practices must be careful in their staff training, ensuring that all personnel understand the specific indications, contraindications, and potential complications of each device they operate. Patient consent forms must also clearly distinguish the modality being used and detail its particular risks, especially concerning RF microneedling in light of the FDA’s warning. This clear differentiation supports informed patient choice and helps practices manage potential liabilities.

Impact on Treatment Choices and Patient Counseling for GLP-1 Patients

The FDA’s safety communication on RF microneedling has direct and significant consequences for treatment choices and patient counseling, particularly for the growing number of individuals experiencing skin laxity after GLP-1 medication-associated weight loss. This communication should prompt clinical directors to re-evaluate their offerings and patient education strategies.

Re-evaluation of Treatment Protocols: The core implication is that RF microneedling, while still a viable option for some, must be approached with greater caution. Clinical directors may find themselves moving demand toward non-needle energy devices or toward providers with stronger medical oversight for RF microneedling treatments^[26]. This shift is an inference based on the FDA’s warning, and actual sales trends confirming this shift are still being monitored^[26].

For GLP-1 patients, the concern about unwanted fat loss is particularly salient. These patients are often presenting with facial volume loss and generalized skin laxity as a direct result of their weight reduction^[6]. Introducing a treatment that carries a risk of further fat reduction, even if localized, can exacerbate their aesthetic concerns and undermine the desired outcome of volume restoration and tightening. Therefore, in cases where facial volume loss is a primary concern, RF microneedling should be carefully considered, and perhaps alternative modalities should be prioritized.

Non-invasive ultrasound and external RF devices are likely to benefit from this increased scrutiny on RF microneedling^[26]. These technologies offer modest tightening for mild to moderate laxity with lower associated risks of fat loss or scarring. A Sofwave upper-arm study, for instance, found improvement in 93% of treated arms after two sessions of focused ultrasound^[18]. While this evidence comes from a manufacturer’s clinical summary and should not be broadly applied to all patients or body sites, it illustrates the potential of non-needle energy devices for tissue support^[18]. For clinical directors seeking to mitigate risks and address patient concerns about fat loss, these modalities offer a compelling alternative.

Enhanced Patient Counseling and Informed Consent: The FDA warning demands a more detailed and explicit discussion of risks during patient consultations. Providers must go beyond general statements about energy-based devices and specifically address the potential for burns, scarring, fat loss, disfigurement, and nerve damage associated with RF microneedling^[13]. This is especially important for GLP-1 patients, who may have unique physiological responses or heightened skin sensitivity.

Key elements for patient counseling should include:

• Clear Risk Disclosure: A direct and understandable explanation of all reported adverse events from the FDA communication, custom to the specific device being considered.
• Discussion of Fat Loss Risk: An explicit conversation about the potential for unwanted fat loss, particularly for facial treatments, and how this relates to the patient’s existing volume concerns from GLP-1 weight loss.
• Alternative Treatment Options: Presentation of alternative modalities for skin tightening, such as external RF, focused ultrasound, biostimulators, or surgical options, along with their respective benefits and risks. This allows for informed decision-making based on a comprehensive understanding of available choices.
• Operator Training and Experience: Transparency about the provider’s and staff’s training and experience with the specific RF microneedling device. The FDA advised seeking licensed providers with device-specific training^[27].
• Realistic Expectations: Setting clear, realistic expectations about the degree of improvement possible, especially for mild to moderate laxity treated with non-surgical methods. It is crucial to manage expectations and avoid promising surgical-level results from non-surgical devices, particularly for patients with severe hanging skin^[26].
• Pre- and Post-Treatment Care: Detailed instructions on preparing the skin before treatment and managing post-treatment recovery, including any signs of complications to look out for.

Informed consent forms must be updated to reflect the FDA’s specific concerns. Generic consent forms that do not explicitly mention the risks outlined by the FDA may be insufficient. The consent process should also emphasize that RF microneedling is a medical procedure, underscoring the seriousness of the treatment^[27].

For clinical directors, this means investing more time in each consultation to ensure patients fully grasp the information. It also implies a responsibility to ensure that all front-line staff involved in patient education are well-versed in these distinctions and can answer patient questions accurately and responsibly. This approach builds trust and helps mitigate potential legal or reputational issues arising from adverse events.

Adjustments to Clinical Protocols and Staff Training

The FDA’s safety communication mandates a thorough review and adjustment of clinical protocols and staff training for any practice offering RF microneedling. This is not merely a suggestion but a necessity for patient safety, legal compliance, and the reputation of the practice.

Revised Clinical Protocols: Every service line offering RF microneedling needs written rules that cover a range of critical operational aspects. These rules should be specific and actionable, ensuring consistency and accountability across all treatments.

• Medication Stage and Patient Stability: For GLP-1 patients, protocols must consider the patient’s weight loss stage, active symptoms, and weight stability^[28]. The ISAPS guidance, for example, recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms remain active^[28]. While this guidance specifically refers to surgery, the principle of patient stability applies to energy-based treatments as well, especially given their potential for tissue response variations.
• Nutrition Screening: Given that GLP-1 patients are undergoing significant body changes, including potential changes in nutritional status, screening for nutritional deficiencies or specific dietary needs can help predict and manage healing responses.
• Device Settings and Parameters: Strict guidelines for device settings (e.g., energy levels, pulse duration, needle depth, number of passes) must be established and adhered to, based on the specific device model, treated area, and patient skin type and concerns. Aggressive settings, particularly in areas prone to fat loss or with delicate skin, should be avoided or used with extreme caution.
• Skin Assessment and Patient Selection: Pre-treatment skin assessment should be thorough, identifying areas of concern like pre-existing volume loss, thinning skin, or prior scarring. Patients with certain medical conditions, skin types, or expectations may be poor candidates for RF microneedling. A three-level laxity grade (mild, moderate, or severe) can help guide appropriate treatment selection, steering severe cases toward surgical referral rather than aggressive device usage^[24].
• Photography: Standardized before-and-after photography is essential, also for tracking treatment progress but also for documenting baseline conditions and any adverse events. This provides objective evidence for both patient and provider.
• Adverse Event Reporting: A clear, documented process for reporting and managing adverse events is critical. This includes internal reporting for quality improvement and external reporting to the FDA as advised in their safety communication^[27].
• Referral Guidelines: Establishing firm surgical referral limits is important. Severe hanging skin should not be treated with a long series of device treatments that promise surgical-level results. Clinics should have formal referral paths to plastic surgeons for appropriate cases^[26]. This helps manage patient expectations and ensures the most suitable treatment for their needs.

Enhanced Staff Training and Competency: The FDA’s emphasis on device-specific training underscores the need for continuous education and rigorous competency assessment for all staff involved in RF microneedling.

• Device-Specific Expertise: Training must go beyond general RF principles to cover the unique operating characteristics, safety features, and potential complications of each specific RF microneedling device used in the practice. This includes understanding the nuances of needle insulation, energy delivery patterns, and cooling mechanisms.
• Anatomy and Physiology: A deep understanding of facial and body anatomy, including the distribution of fat pads, nerve pathways, and vascular structures, is crucial to minimize risks like nerve damage or unwanted fat loss. This knowledge allows operators to adjust treatment depths and energy settings appropriately.
• Patient Assessment Skills: Staff must be proficient in assessing skin quality, laxity, and potential contraindications. They need to understand how GLP-1-induced weight loss might alter tissue characteristics and adjust their assessment accordingly.
• Adverse Event Recognition and Management: All personnel must be trained to recognize early signs of complications (e.g., unusual redness, swelling, pain, blistering) and know the immediate steps to take to manage them. This includes protocols for cooling, topical treatments, and physician consultation.
• Consent Process Mastery: Staff responsible for the consent process must be fully educated on all risks, benefits, and alternatives, and be able to communicate this information clearly and empathetically to patients. They should be able to answer questions thoroughly and ensure patients understand the gravity of the FDA warning regarding RF microneedling.
• Continuous Education and Recertification: Given the evolving nature of aesthetic technology and regulatory guidance, regular refreshers and recertification programs are vital to maintain high standards of practice.

By implementing these rigorous protocols and comprehensive training programs, clinical directors can better ensure patient safety, reduce the incidence of adverse events, and build patient trust. This proactive approach also protects patients but also safeguards the practice from potential liabilities and maintains its professional standing in a competitive market.

The Competitive field and Modality Shifts

The FDA’s safety communication on RF microneedling introduces a significant factor into the competitive field for aesthetic skin tightening treatments. It is likely to accelerate a modality shift, moving patient demand and provider preference away from higher-risk options and toward those perceived as safer, especially for patients with post-GLP-1 laxity.

Increased Scrutiny and Demand Shift: RF microneedling now carries greater safety and consent pressure^[26]. This pressure is expected to influence patient decisions. When presented with the risks of burns, scarring, fat loss, and nerve damage explicitly outlined by the FDA, patients, particularly those already managing the changes from GLP-1 weight loss, may opt for alternatives. This anticipated shift means that non-needle energy devices, such as external radiofrequency and focused ultrasound, are positioned to benefit^[26]. These technologies offer tightening for mild to moderate laxity with a generally lower risk profile, particularly regarding fat loss, which is a major concern for GLP-1 patients.

Bio2 Laser Studio provides an example of a small clinic that has explicitly linked external RF body and facial contouring to GLP-1 weight loss^[30]. By focusing on non-invasive external RF, they naturally mitigate the specific risks highlighted by the FDA for microneedling RF. This strategic positioning could prove advantageous in attracting patients who are seeking skin tightening but are risk-aaverse, or who want to avoid further volume reduction. The studio’s pricing structure, offering single sessions, packages, and monthly options, aims to reduce buying friction for patients^[30].

Impact on Device Manufacturers: The FDA warning could prompt device manufacturers of RF microneedling technologies to refine their devices, provide more extensive training, or clearly define specific indications and contraindications to address the safety concerns. It may also spur the development of new safety features or real-time monitoring systems to reduce risks. Manufacturers of external RF and focused ultrasound devices, meanwhile, may emphasize their relative safety advantages in their marketing efforts, capitalizing on the concerns raised by the FDA.

Role of Surgical Referral: Despite the advancements in non-surgical options, surgery will retain a clear and critical role, especially for patients with severe skin excess after substantial weight loss^[26]. For example, in the U.S., abdominoplasty procedures reached 171,064 in 2024, with arm, thigh, and buttock lifts also seeing increases^[13]. These surgical procedures are essential for removing truly hanging skin, an outcome that no non-surgical device, including RF microneedling, can replicate. Clinical directors must ensure strong referral relationships with plastic surgeons to serve patients whose needs exceed the capabilities of non-surgical treatments. A clinic that offers only devices should build a formal plastic-surgery referral path^[29].

Need for Evidence and Transparency: The evolving field also underscores the importance of evidence-based practice and transparency. Practices offering non-surgical treatments for GLP-1 related laxity, such as Bio2 Laser Studio, should focus on internal tracking of outcomes, including standardized photography, patient-reported scores, treatment completion rates, and adverse event data^[30]. Such data would strengthen future claims and build confidence in their chosen modalities. In a market where safety is under heightened scrutiny, clear evidence of efficacy and a low complication rate will become a significant competitive differentiator.

Ultimately, the FDA’s safety communication serves as a reminder that the aesthetic field, while driven by innovation, must prioritize patient safety above all. Clinical directors who proactively adjust their protocols, enhance staff training, and transparently counsel patients about risks and benefits for each modality will be better positioned to navigate this shifting competitive environment and provide appropriate care for the post-GLP-1 patient population.

Conclusion and Transition

The U.S. FDA’s safety communication regarding radiofrequency (RF) microneedling marks a pivotal moment for aesthetic practices, particularly in the context of the expanding post-GLP-1 patient population. The explicit mention of risks such as burns, scarring, unwanted fat loss, disfigurement, and nerve damage necessitates a thorough re-evaluation of treatment protocols, patient counseling, and staff training for any clinic offering this modality^[13]. Clinical directors must recognize that RF microneedling is a medical procedure requiring licensed providers and device-specific training, and they must actively report complications^[27].

This increased scrutiny is expected to influence treatment choices, potentially shifting demand toward non-needle energy devices like external RF and focused ultrasound for mild to moderate laxity^[26]. These alternatives often present a lower risk profile for severe complications, particularly unwanted fat loss, which is a major concern for GLP-1 patients already experiencing volume depletion. Practices like Bio2 Laser Studio, focusing on external RF for GLP-1 patients, exemplify a strategic alignment with this evolving safety-conscious market^[30]. However, clinical directors should always remember that non-surgical methods have limitations and cannot replace surgery for severe hanging skin^[26]. strong surgical referral pathways remain critical for a comprehensive service offering.

Moving forward, clinical directors must implement stringent clinical protocols, including detailed patient assessment, appropriate device settings, and careful adverse event reporting. Comprehensive, device-specific staff training is not optional but essential for safe and effective care. Furthermore, patient counseling must become even more transparent, explicitly detailing the specific risks of RF microneedling and presenting alternative options clearly. This commitment to safety, transparency, and evidence-based practice will be crucial for building trust and maintaining a strong reputation in this dynamic market segment.

The implications of the FDA’s communication extend beyond RF microneedling itself, setting a higher standard for all energy-based devices and invasive aesthetic procedures. As clinical directors adapt to these changes, the focus will undoubtedly turn to optimizing patient outcomes across the entire spectrum of aesthetic interventions. The next section will explore the integration of a patient’s overall health and wellness into aesthetic treatment plans, considering the systemic effects of GLP-1 medications and the importance of a holistic approach to care.

14. Commercial Considerations and Patient Budgeting

The increasing use of GLP-1 medications for weight loss presents both a growing patient population and new commercial considerations for aesthetic clinics. Clinical directors must understand the financial habits of this patient group. This includes varied spending patterns, the importance of staged treatment plans, and the need for clear pricing. The post-GLP-1 aesthetic market is substantial, but it also features specific budget limitations and patient expectations. Clinics that adapt their commercial strategies to these factors will be better positioned for success. The market is not characterized by unlimited spending. Instead, it demands careful planning, transparent costs, and treatment options that provide good value.

The core commercial opportunity involves addressing skin laxity and volume loss that can result from rapid or significant weight reduction. However, patients on GLP-1 therapy often have other financial commitments, including the cost of their medication, nutritional support, and fitness programs. These factors influence their aesthetic spending. Clinics need to offer flexible approaches, including various financing options and precise estimates of treatment benefits. Understanding the patient journey-from initial weight loss to stabilization and maintenance-is crucial for developing effective and financially viable care plans.

14.1. The Expanding Patient Population and Global Market Dynamics

The patient pool for post-GLP-1 aesthetic treatments is growing rapidly, indicating a significant commercial opportunity. In June 2026, 11% of U.S. adults were taking a GLP-1 drug for weight loss, a substantial increase from 3% in 2024. Overall, 15% of U.S. adults had used a GLP-1 medication at some point^[1]. This near fourfold increase in current users over two years means that even if a small fraction of these individuals seek aesthetic care, the potential patient base is much larger than it was in 2024^[1].

This expansion is not limited to the United States. Novo Nordisk reported that its obesity medicines reached 3.6 million people in 2025. Wegovy, a key GLP-1 medication, became available in 52 countries in 2025, up from 17 countries in 2024^[3]. The global branded GLP-1 obesity medicine market grew by 104% in volume through November 2025^[8]. This expansion suggests that aesthetic demand will appear in more markets globally, although typically with a delay. Patients usually seek aesthetic treatments after experiencing visible facial and body volume loss^[3].

Despite this global growth, access to GLP-1 medicines is uneven. The World Health Organization (WHO) expects that fewer than 10% of people who could benefit from GLP-1 therapies will receive them by 2030^[2]. This uneven access is due to factors like manufacturing capacity, pricing, insurance coverage, and health system capabilities^[2]. Consequently, post-weight-loss aesthetic demand will remain concentrated in countries and cities where GLP-1 access is greater and disposable income allows for elective treatments^[2].

Clinical directors should recognize that the first wave of aesthetic consultations can begin while patients are still losing weight. Galderma’s international research showed that significant facial changes often appear within three to six months after GLP-1 treatment starts^[9]. This timing means clinics in new GLP-1 markets should anticipate aesthetic inquiries shortly after prescription growth^[9].

For larger aesthetic chains, country and city prescription data can help guide expansion strategies. Independent clinics, however, should rely more on their own consultation volume and relationships with local GLP-1 prescribers before investing in additional equipment. Device manufacturers should avoid assuming that global obesity prevalence directly translates to the size of the aesthetic market, as access and affordability remain significant barriers to treatment^[9].

14.2. Understanding Patient Spending Habits and Budget Limits

A critical commercial consideration is that greater concern about appearance after weight loss does not always lead to a larger aesthetic budget. A McKinsey survey found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it^[10]. This trend is likely because patients are also managing other costs associated with their weight loss journey, such as medication expenses, nutrition programs, fitness memberships, and new clothing^[10]. Clinics must recognize these financial constraints and offer solutions that align with patient budgets.

This finding highlights the need for clinics to provide staged treatment plans. These plans allow patients to address their most pressing concerns first and add further treatments as their weight stabilizes and financial capacity permits^[10]. Offering clear pricing, financing options, and transparent estimates of the likely benefits for each treatment will be crucial for conversion. Patients want to understand the value they are receiving for their investment.

The American Society of Plastic Surgeons (ASPS) reported that its members treated 837,485 patients using prescribed weight-loss medicine in 2024. Among these patients, 41% were considering non-surgical treatment, and 39% were considering surgery^[12]. This demonstrates a split in demand between surgical and non-surgical care, reinforcing the need for clinics to offer a range of services or establish clear referral paths.

For clinics, this means moving away from a strategy of pushing expensive, single-treatment solutions. Instead, a more effective approach involves building long-term relationships with patients through phased care. For example, a patient might start with non-surgical options to address early signs of laxity and volume loss. Later, if weight loss continues or stabilizes, they might consider more extensive surgical interventions or combination therapies.

The global aesthetic procedure volume in 2024 was nearly 38 million, with 17.4 million surgical and 20.5 million non-surgical procedures^[14]. This shows a large existing market for aesthetic treatments. Post-weight-loss care is entering an environment with established patient acceptance and provider capacity^[14]. However, the unique financial pressures on GLP-1 patients require a custom commercial approach.

14.3. The Commercial Value of Staged Plans and Clear Pricing

Given the varied spending habits of GLP-1 patients, clinics should prioritize staged plans, clear pricing, and high-value combinations rather than anticipating unlimited spending^[10]. A staged approach allows patients to manage costs over time and to see incremental improvements, which can build trust and commitment to further treatments.

14.3.1. Implementation of Staged Treatment Plans

Staged treatment plans can be structured to address immediate concerns first, with follow-up treatments scheduled as the patient’s weight stabilizes. For instance, initial treatments might focus on facial volume restoration with hyaluronic acid fillers or early collagen stimulation with biostimulators. As weight loss progresses or plateaus, further treatments for skin laxity on the body or more involved surgical referrals can be discussed.

One practical sequence for treatment is:

1. Assessment of patient concerns, weight-loss stage, laxity grade, and overall health^[23].
2. Conservative structural volume correction for areas like the midface or temples^[23].
3. Treatment for collagen production and skin quality improvement^[23].
4. Surface treatments for texture and tone^[23].

It is important to reassess patients during active weight loss to avoid large, early corrections that might appear excessive after further weight changes^[23]. This phased approach offers flexibility and allows patients to observe results before committing to more extensive procedures.

14.3.2. Importance of Clear and Transparent Pricing

Transparency in pricing is a significant factor in patient conversion. The McKinsey study indicated that patients need clear estimates of likely benefits per treatment^[11]. Clinics should publish straightforward pricing for individual sessions, packages, and membership options where applicable. This helps patients budget and reduces perceived buying friction.

For example, Bio2 Laser Studio in San Antonio explicitly links external radiofrequency (RF) body and facial contouring to GLP-1 weight loss. The studio publishes specific prices: $440 for a single body or facial contouring session, $1,980 for a six-session package, and a $175 monthly option^[18]. This clear, upfront pricing strategy allows patients to understand the cost structure and choose options that fit their financial situation.

Beyond pricing, clinics need to provide financing options. These can include payment plans, third-party medical financing, or membership models that spread costs over time. Such options can make treatments more accessible for patients who might otherwise delay or forgo care due to upfront costs.

14.4. The Role of Combination Treatments and Modality Shifts

The post-GLP-1 aesthetic market is shifting away from single treatments toward combination plans. This shift is driven by the complex nature of skin changes, which often involve both volume loss and laxity. Patients frequently request care for several linked issues, such as laxity, poor skin quality, and facial deflation, rather than a single complaint^[10]. A McKinsey survey found that 63% of GLP-1 aesthetic patients sought treatment for multiple concerns^[10]. This means standard packages based on one device or one injection type will only appeal to a portion of the market^[10].

Combination therapies can address these multiple concerns more effectively. For instance, a Galderma trial combined Sculptra (a biostimulator for collagen formation) with Restylane (a hyaluronic acid filler for volume replacement). After nine months, 85.7% of patients felt their face looked less gaunt, and 91.4% would recommend the regimen^[17]. While this study was company-sponsored and did not isolate the contribution of each product, it supports the effectiveness of combined approaches^[17].

The modality mix is also moving from fat reduction to tissue support, tightening, and surgical excision. Hyaluronic acid fillers remain the primary tool for immediate facial volume replacement, especially for midface or temple deflation^[22]. Biostimulators are gaining interest, with 48% of patients expressing interest in them, and 54% of clinics offering or considering them^[22].

Non-invasive energy-based treatments like external radiofrequency (RF) and focused ultrasound are also benefiting from the demand for low-downtime care. A SkinCeuticals-associated study reported a 44% reduction in graded laxity at 12 weeks when combining a topical regimen with one focused-ultrasound treatment^[18]. A Sofwave clinical study found improvement in 93% of treated upper arms after two ultrasound sessions^[24]. These technologies can offer modest tightening for mild to moderate laxity.

However, it is important to manage patient expectations regarding non-surgical methods. These treatments may not produce the same results as surgery for severe post-weight-loss skin. Surgery remains the main referral path for significant hanging or severe excess skin^[25]. Clinics should reduce reliance on fat-reduction messaging for patients who are already experiencing deflation and instead focus on facial structure, skin quality, mild laxity, and muscle support, alongside clear surgical referral guidelines^[25].

14.5. Safety, Timing, and Referral Pathways

Safety and timing are becoming increasingly important buying criteria for GLP-1 patients. The U.S. Food and Drug Administration (FDA) issued a warning in October 2025 about potential risks, including burns, scarring, fat loss, disfigurement, and nerve damage, associated with certain uses of RF microneedling^[13]. This warning underscores the need for clinics to ensure device-specific training, licensed providers, and clear consent processes. It may also shift demand toward non-needle energy devices or clinics with strong medical oversight^[26].

The timing of aesthetic treatments, particularly surgical procedures, also requires careful consideration. The International Society of Aesthetic Plastic Surgery (ISAPS) recommends delaying elective surgery during GLP-1 dose escalation and while patients experience active gastrointestinal symptoms such as nausea or vomiting^[14]. This highlights the need for coordination between aesthetic providers and the medication prescriber.

Clinics need a dual system to serve the GLP-1 patient population. Mild and moderate cases of skin laxity and volume loss may be managed within the clinic using non-surgical methods. However, severe cases, especially those with significant hanging skin, require a formal plastic surgery referral path and a clear handoff process^[29]. This is supported by ASPS data, which showed that 20% of GLP-1 patients under their members’ care had already undergone plastic surgery, while 39% were considering it^[12].

For example, a 2026 study on panniculectomy patients found possible differences in wound healing for those taking GLP-1 medicines before surgery, though it did not show a clear rise in overall surgical risk^[28]. This research emphasizes that blanket assumptions about GLP-1 patients and surgery are unsafe, requiring individualized assessment and careful patient management.

Every service line addressing GLP-1 patients should have written rules. These rules must cover medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent procedures, photography protocols, adverse-event reporting, and referral guidelines. Marketing claims should focus on likely degrees of improvement rather than promising complete prevention or removal of loose skin, ensuring realistic patient expectations^[28].

14.6. Building a Sustainable Service Line

To build a sustainable post-weight-loss service line, clinical directors need an operating model that is staged, transparent, and referral-based. The commercial funnel is large, but it is divided between surgical and non-surgical paths^[29]. A successful service line will support both paths rather than attempting to force every patient into the clinic’s existing equipment^[29].

Trust is a valuable business asset in this market. The 2025 American Society for Dermatologic Surgery (ASDS) consumer survey revealed that 94% of consumers used ratings and review sites when choosing a provider^[16]. Nearly half also reported that a provider’s social media presence influenced their appointment decisions^[16]. Clinics need to cultivate this trust through consistent photography, clear staff credentials, easy-to-understand consent forms, and outcomes data separated by age, body site, and severity^[30].

Bio2 Laser Studio serves as an example of a small clinic packaging its services for GLP-1 patients. It uses public pages to link non-invasive external RF body and facial contouring to GLP-1 weight loss. The studio also publishes package and membership pricing. For instance, a single body or facial contouring session costs $440, a six-session package is $1,980, and monthly options are available at $175 for one treatment or $350 for two^[18]. While Bio2 Laser Studio’s public pages do not provide peer-reviewed post-GLP-1 outcome data, its clear pricing and session structures reduce buying friction for patients. To strengthen future claims, the studio would need to track internal data such as standardized photography, patient-reported improvement scores, treatment completion rates, and adverse event data^[31].

Effective internal tracking is crucial. Clinical directors should track the source of consultations, the patient’s weight-loss stage, the type of concern (e.g., volume loss, laxity), the grade of laxity, the specific treatment selected, series completion rates, patient-reported improvement, photography grades, adverse events, refunds, repeat care, and surgical referrals. These metrics will inform future purchase decisions and help clinics base their growth strategies on local utilization and measured results, rather than solely on broad GLP-1 growth headlines^[31].

The post-GLP-1 aesthetic market, while substantial, demands a thoughtful and patient-centric commercial approach. Clinics that prioritize clear communication, flexible treatment plans, transparent pricing, and strong referral networks will be best equipped to serve this growing population and build a sustainable service line.

14.7. Key Data Points for Commercial Planning

The following table summarizes key commercial and patient budgeting data relevant to GLP-1 related aesthetic treatments:

Data Point	Details	Source and Significance
U.S. GLP-1 Use (Current)	11% of adults in June 2026, up from 3% in 2024. 15% had used at some point.	Gallup, July 2026[1]. Significant expansion of potential patient base.
Novo Nordisk Obesity Reach	3.6 million people in 2025. Wegovy availability increased from 17 to 52 countries.	Novo Nordisk Annual Report 2025[3]. Indicates global spread of demand, with aesthetic interest to follow.
GLP-1 Volume Growth	104% increase in global branded GLP-1 obesity medicine volume through November 2025.	Novo Nordisk, 2026 reporting[8]. Sustained growth in the underlying patient population.
Patient-Reported Skin Changes	38.7% of 504 GLP-1 users reported skin changes. 55.1% of those noted changes within five months.	Olivero and colleagues, J Cosm Dermatol, August 2026[6]. Highlights early onset of aesthetic concerns.
Growth in GLP-1 Aesthetic Patients	Mean increase of 137% from 2023 to 2024 among surveyed aesthetic professionals.	Dermatologic Surgery, 2026[7]. Strong demand signal for aesthetic care.
Patients with Multiple Concerns	63% of GLP-1 aesthetic patients requested care for several linked issues (e.g., laxity, poor skin quality, facial deflation).	McKinsey, 2025[10]. Standard single-treatment packages are insufficient.
Aesthetic Budget Split	About 60% reduced overall aesthetic spending, while 40% increased it.	McKinsey, 2025[11]. Emphasizes need for staged plans, clear pricing, and financing options.
ASPS Patient Data	837,485 GLP-1 patients under ASPS member care in 2024. 41% considered non-surgical, 39% considered surgical care.	ASPS, June 2025[12]. Confirms dual demand for both non-surgical and surgical options.
Global Aesthetic Procedures	Nearly 38 million procedures in 2024 (17.4M surgical, 20.5M non-surgical).	ISAPS, June 2025[14]. Post-GLP-1 care enters a large, established market.
Combination Injectable Satisfaction	91.4% would recommend Galderma’s Sculptra + Restylane regimen. 85.7% felt less gaunt after nine months.	Galderma, July 2025[17]. Supports the value of combination treatments for facial concerns.
RF Microneedling Safety Warning	FDA warning (October 2025) on burns, scarring, fat loss, disfigurement, nerve damage with certain uses.	FDA, October 2025[13]. Increases safety scrutiny and demands licensed, trained providers.
Consumer Trust Factors	94% use ratings/reviews; nearly half influenced by social media presence.	ASDS Consumer Survey, 2025[16]. Highlights need for strong online reputation and transparent results.

The commercial environment for post-GLP-1 aesthetic treatments is complex. It requires clinics to be agile in their pricing, treatment packaging, and patient communication. By understanding patient budgeting patterns and prioritizing transparency and value, clinical directors can effectively serve this growing market segment.

The next section will discuss specific marketing and communication strategies that clinical directors can use to reach and engage GLP-1 patients effectively.

References

• ^[1] Gallup. (2026, July 7). In U.S., GLP-1 Usage Reaches New High. Retrieved from https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
• ^[2] World Health Organization. (2025, December 1). WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. Retrieved from https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
• ^[3] Novo Nordisk. (2026). Novo Nordisk Annual Report 2025: Commercial Execution. Retrieved from https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-annual-report-2025.pdf.html
• ^[6] Olivero and colleagues. (2026, August). Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss. Journal of Cosmetic Dermatology. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.71145
• ^[7] Dermatologic Surgery. (2026). Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Retrieved from https://pubmed.ncbi.nlm.nih.gov/42210883/
• ^[8] Novo Nordisk. (2026). Financial performance – Novo Nordisk Annual Report 2025. Retrieved from https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html
• ^[9] Galderma. (2025). Understanding the Aesthetic Impact of Medication-Driven Weight Loss. Retrieved from https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
• ^[10] McKinsey & Company. (2025). GLP-1s Are Boosting Demand for Medical Aesthetics. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
• ^[11] McKinsey & Company. (2025). GLP-1s Are Boosting Demand for Medical Aesthetics. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
• ^[12] American Society of Plastic Surgeons. (2025, June 25). Interest in Aesthetic Health Remained Consistent Despite Economic Uncertainty in 2024, According to New Report from American Society of Plastic Surgeons. Retrieved from https://www.plasticsurgery.org/news/press-releases/interest-in-aesthetic-health-remained-consistent-despite-economic-uncertainty-in-2024-according-to-new-report-from-american-society-of-plastic-surgeons
• ^[13] U.S. Food and Drug Administration. (2025, October 15). Potential Risks With Certain Uses of Radiofrequency Microneedling. Retrieved from https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
• ^[14] International Society of Aesthetic Plastic Surgery. (2025, June 19). Global Survey 2024. Retrieved from https://www.isaps.org/discover/about-isaps/global-statistics/global-survey-2024-full-report-and-press-releases/
• ^[16] American Society for Dermatologic Surgery. (2025). 2025 Consumer Survey. Retrieved from https://www.asds.net/medical-professionals/practice-resources/consumer-survey-on-cosmetic-dermatologic-procedures?referrer_id=815894%3Freferrer_id%3D815894
• ^[17] Galderma. (2025, July 17). Galderma Unveils Final Nine-Month Data on Injectable Treatment After Medication-Driven Weight Loss. Retrieved from https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss
• ^[18] SkinCeuticals-associated study. (2026). Clinical Efficacy of a Topical Regimen Before and After Ultrasound in GLP-1 Users. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41781778/
• ^[22] Galderma. (2025). Understanding the Aesthetic Impact of Medication-Driven Weight Loss. Retrieved from https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
• ^[23] Galderma Aesthetics. (2025). Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients. Journal of Cosmetic Dermatology. Retrieved from https://www.galdermaaesthetics.com/ca/sites/default/files/2025-11/Consensus-Statements-on-Managing-Aesthetic-Needs-in-Prescription.pdf
• ^[24] Sofwave. (2024). Clinical Study Summary. Retrieved from https://api.sofwave.com/app/uploads/2024/12/MK00105_E-Upper-Arm-Lax-Skin-Lifting_Clinical-Study-Summary.pdf
• ^[25] American Society of Plastic Surgeons. (2025). 2024 Plastic Surgery Statistics Report. Retrieved from https://www.plasticsurgery.org/plastic-surgery-statistics
• ^[26] U.S. Food and Drug Administration. (2025, October 15). Potential Risks With Certain Uses of Radiofrequency Microneedling. Retrieved from https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
• ^[28] American Society of Plastic Surgeons. (2026). Weight Loss Medications May Affect Some Complications After Panniculectomy. Retrieved from https://www.plasticsurgery.org/news/press-releases/weight-loss-medications-may-affect-some-complications-after-panniculectomy
• ^[29] American Society of Plastic Surgeons. (2025). 2024 Plastic Surgery Statistics Report. Retrieved from https://www.plasticsurgery.org/documents/News/Statistics/2024/plastic-surgery-statistics-report-2024.pdf
• ^[30] American Society for Dermatologic Surgery. (2025). 2025 Consumer Survey. Retrieved from https://www.asds.net/medical-professionals/practice-resources/consumer-survey-on-cosmetic-dermatologic-procedures?referrer_id=815894%3Freferrer_id%3D815894
• ^[31] Bio2 Laser Studio. (Accessed 2026, August 29). Radiofrequency Body Contouring and Public Pricing. Retrieved from https://bio2laserstudio.com/radiofrequency-body-contouring-san-antonio

15. Recommended Operating Model for Clinics

The rise of GLP-1 medications for weight loss presents a significant shift in the aesthetic market. Clinical directors must adapt their operating models to meet the specific needs of this growing patient population. This adaptation requires a focus on staged care, clear communication, and strong referral networks. The “post-GLP-1” phase often refers to the period after significant weight loss, not necessarily after stopping treatment, as the World Health Organization (WHO) supports long-term GLP-1 therapy for chronic obesity management ^[3]. Therefore, clinics need to plan for care during active weight loss, stabilization, and maintenance phases. This section outlines a recommended operating model for clinics to effectively serve post-GLP-1 patients, integrating assessment, treatment strategies, safety protocols, and commercial considerations.

Understanding the Post-GLP-1 Patient Profile

The patient pool for GLP-1 medications is expanding quickly. In June 2026, 11% of U.S. adults were using a GLP-1 drug for weight loss, a substantial increase from 3% in 2024 ^[1]. This expansion is global, with Wegovy becoming available in 52 countries in 2025, up from 17 in 2024 ^[2]. Novo Nordisk reported that its obesity medicines reached 3.6 million people in 2025 ^[2], and branded GLP-1 obesity medicine volume grew by 104% through November 2025 ^[5]. This means a larger potential patient base for aesthetic care. However, the World Health Organization expects that GLP-1 medicines will reach fewer than 10% of people who could benefit by 2030 due to issues like manufacturing, price, coverage, and health system capacity ^[3]. This suggests that aesthetic demand will remain concentrated in areas with greater GLP-1 access and higher disposable income ^[3].

The primary concern for these patients is often skin changes. A 2026 survey of 504 GLP-1 users found that 38.7% reported skin changes ^[6]. Specific issues included facial volume loss (10.9%), sagging (8.3%), and jowling (7.7%) ^[6]. Another 2026 study reported skin sagging in 44% of people who lost 10% to 20% of body weight ^[7]. These skin changes are more common in individuals over 55 and those who lose more than 20 pounds ^[6]. Over half of affected individuals noticed changes within the first five months of treatment ^[6].

It is important to note that these patients often have several related concerns, not just loose skin. A McKinsey survey found that 63% of GLP-1 aesthetic patients sought care for multiple issues, such as laxity, poor skin quality, and facial deflation ^[9]. This requires clinics to move beyond single-device or single-injection approaches and consider broader treatment plans.

Despite appearance concerns, most GLP-1 users express satisfaction with their medication and improved body image. In the 504-person study, 92% were satisfied with the medication, 84% reported improved body image, and 68.5% reported greater self-confidence ^[6]. Aesthetic care should support these health gains rather than frame weight loss as a cosmetic failure ^[6].

This patient group represents a significant demand. A survey of 406 aesthetic health professionals reported a mean 137% increase in GLP-1 patients from 2023 to 2024 ^[8]. This indicates a strong signal for aesthetic consultation growth.

Comprehensive Intake and Assessment

A crucial first step in the recommended operating model is a comprehensive intake and assessment process. Given the diverse and specific needs of GLP-1 patients, a standard aesthetic consultation may not be sufficient. Clinical directors should implement a detailed intake protocol that gathers all relevant information to guide treatment decisions and set realistic expectations.

Key Information to Collect During Intake:

• Weight-Loss History: Document the patient’s starting weight, current weight, total weight lost, and the rate of weight loss. Faster and greater weight loss is associated with a higher risk of skin changes ^[6].
  • For example, average trial weight loss with semaglutide was 14.9% at 68 weeks, and up to 20.9% with tirzepatide at 72 weeks ^[4]. Such substantial losses can affect multiple body areas ^[4].
• GLP-1 Medication Stage: Understand if the patient is in an active weight-loss phase, weight stabilization, or maintenance. The World Health Organization conditionally supports long-term GLP-1 therapy ^[3], meaning patients may be on these medications indefinitely. Treatment timing should align with their medication journey.
  • Early treatment is debated. A Delphi panel of experts was split on starting poly-L-lactic acid simultaneously with medication-associated weight loss ^[15]. However, Galderma’s research indicated that significant facial changes often appear within three to six months of starting treatment ^[10], suggesting the first major consultation wave can occur while patients are still losing weight.
  • Baseline photography and skin assessment should ideally occur early, before large appearance changes become established ^[6].
• Specific Concerns: Go beyond general “loose skin.” Ask about facial volume loss, sagging, jowling, skin quality, and changes in specific body areas such as the neck, arms, abdomen, or thighs. Patients often present with multiple linked issues ^[9].
  • In a survey of aesthetic professionals, midface volume loss, face and neck laxity, and loose body skin were the leading concerns ^[8].
  • Facial deflation, skin laxity, texture change, and severe skin excess are distinct problems requiring different approaches ^[6].
• Age: Age over 55 is a factor associated with increased risk of skin changes ^[6].
• Weight Stability: Assess if the patient’s weight has stabilized. This is a critical factor for planning aesthetic procedures. The International Society of Aesthetic Plastic Surgery (ISAPS) recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms are active ^[14].
• Overall Health and Lifestyle: Inquire about nutrition, resistance exercise, hair care, and other medical management. The aesthetic service line may need to link to these areas, as patients reported hair loss (30%) and reduced strength (19%) in one study ^[7].
• Patient Priorities and Expectations: Understand what the patient hopes to achieve. Many patients (56%) desire a natural result similar to their prior appearance, while others (44%) are open to a different look ^[9]. Managing expectations is key, especially given budget constraints.

Laxity Grading System:

To standardize assessment and guide treatment, clinical directors should implement a three-level laxity grading system:

• Mild Laxity: Suitable for non-invasive devices (e.g., external radiofrequency, focused ultrasound), topical treatments, or minor injectable support.
• Moderate Laxity: May benefit from combination non-surgical treatments, biostimulators, or minimally invasive procedures.
• Severe Laxity (Hanging Skin): Primarily requires surgical referral. Non-surgical methods cannot effectively address significant skin excess ^[11].

This grading system helps ensure that patients are offered appropriate treatments and prevents overselling non-surgical options for conditions that require surgery ^[11].

Treatment Planning: Staged Care and Combination Approaches

The operating model should prioritize staged care and combination treatments over single-treatment plans. This approach addresses the varied and evolving needs of post-GLP-1 patients, who often have multiple concerns and budget considerations.

Staged Care Approach:

A practical sequence for treatment planning is:

1. Assessment: As detailed above, a comprehensive assessment is the first step.
2. Conservative Structural Volume Correction: Address volume loss using hyaluronic acid fillers or fat grafting.
   • Hyaluronic acid filler remains a primary tool for immediate volume replacement, especially for midface or temple deflation ^[8]. In the 406-provider survey, clinicians considered it the best facial treatment for an average of 47% of GLP-1 patients ^[8].
   • Global facial fat grafting procedures increased by 19.2% in 2024 compared to 2023, reaching about 0.9 million procedures ^[12]. This suggests a growing acceptance for fat transfer as a volume replacement option.
   • It is important to avoid large early corrections, as further weight loss could make them appear excessive ^[15].
3. Collagen and Skin Quality Treatment: Incorporate biostimulators or energy-based devices to improve skin quality and promote collagen formation over time.
   • Biostimulators, which stimulate collagen production, are gaining interest. Galderma’s research showed 48% of patients were interested in biostimulators, and 54% of surveyed clinics offered or considered them ^[10].
   • Energy-based treatments like external ultrasound and non-needle radiofrequency (RF) can address mild to moderate laxity ^[11]. A Sofwave upper-arm study reported improvement in 93% of treated arms after two sessions ^[18].
4. Surface Treatment: Address superficial concerns like texture, tone, and fine lines.

This staged approach allows for adjustments as the patient’s weight stabilizes and their skin adapts. It also helps manage patient budgets, as 60% of GLP-1 patients reduced aesthetic spending, while 40% increased it ^[10]. Staged plans allow patients to prioritize concerns and spread costs over time ^[10].

Combination Treatment Modalities:

Combination plans are likely to become standard for post-GLP-1 patients, who often present with multiple, linked issues like laxity, poor skin quality, and facial deflation ^[9].

• Injectable Combinations: The Galderma phase IV trial combined Sculptra (a biostimulator) with Restylane (a hyaluronic acid filler) ^[16]. At nine months, 85.7% of patients felt their face looked less gaunt, and 91.4% would recommend the regimen ^[16]. This supports the benefit of combined volume replacement and collagen stimulation.
• Energy-Based and Topical Combinations: A study associated with SkinCeuticals showed a topical regimen combined with one focused-ultrasound treatment resulted in a 44% reduction in graded laxity and 34% improvement in marionette lines at 12 weeks ^[17]. This indicates the potential for combining different modalities for improved outcomes.

Clinical directors should develop treatment protocols that combine modalities to address the multi-faceted nature of GLP-1 related skin changes. Standard packages based on a single device or injection type will only cater to a fraction of the market ^[9].

Safety, Timing, and Referral Systems

Safety and proper timing are paramount. The operating model must incorporate clear guidelines for medication stage, active symptoms, weight stability, and nutrition screening. Strong referral systems are also critical, particularly for severe cases requiring surgery.

Safety Considerations:

• RF Microneedling Safety: The U.S. Food and Drug Administration (FDA) issued a safety communication on October 15, 2025, regarding potential risks with certain uses of RF microneedling ^[13]. Reported harms included burns, scarring, fat loss, disfigurement, and nerve damage ^[13].
  • This FDA warning applies to RF microneedling, not all forms of RF treatment ^[13]. Clinical directors must differentiate between needle-based RF, external RF, minimally invasive subdermal RF, and other heat devices in training, consent, and marketing ^[13].
  • Clinics should ensure staff are properly trained and licensed for device-specific treatments, and that complication reporting is standard practice ^[13]. This may lead to a shift in demand toward non-needle energy devices or clinics with strong medical oversight.
• General Procedure Safety: Every service line needs written rules for device settings, staff credentials, consent, photography, adverse-event reporting, and referral ^[15]. Claims should describe likely degrees of improvement rather than promising prevention or removal of loose skin ^[15].

Timing of Procedures:

Coordination with the patient’s medication prescriber is essential.

• During Active Weight Loss: ISAPS guidance recommends delaying elective surgery during GLP-1 dose escalation and while gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, constipation) are active ^[14].
• Weight Stability: It is generally advisable to wait until a patient’s weight has stabilized before performing significant aesthetic procedures. This helps ensure more predictable and lasting results.
• A West Virginia University study examined 373 panniculectomy patients, 21.7% of whom were taking GLP-1 medicines before surgery. It found possible differences in wound healing but no clear rise in overall surgical risk ^[14], highlighting that blanket assumptions about timing without specific evidence are unwise.

Effective Referral Systems:

A dual system is necessary to cater to both non-surgical and surgical needs.

• Plastic Surgery Referrals: For patients with severe laxity or hanging skin, surgical intervention is the only effective solution ^[11].
  • Among GLP-1 patients tracked by American Society of Plastic Surgeons (ASPS) members in 2024, 20% had already undergone plastic surgery, 39% were considering surgery, and 41% were considering a non-surgical procedure ^[11].
  • This indicates a clear demand for both treatment paths. Clinics focusing solely on devices must establish formal, transparent surgical referral paths.
  • Body contouring procedures like abdominoplasty (171,064 procedures in the U.S. in 2024), arm lifts (+2%), thigh lifts (+3%), and buttock lifts (+3%) were already increasing before the full impact of GLP-1s was seen ^[11], showing a pre-existing need for skin removal surgery.
• Interdisciplinary Referrals: As mentioned, GLP-1 patients may have other needs such as nutrition counseling, resistance exercise programs, or hair care ^[7]. Partnering with other health professionals can provide comprehensive care and enhance patient satisfaction.

Commercial and Operational Considerations

The commercial opportunity is significant, but it comes with budget limits and a need for transparency. Clinics need a strong operating model to manage these aspects effectively.

Budget Sensitivity and Clear Pricing:

The McKinsey survey revealed that about 60% of GLP-1 patients reduced their overall aesthetic spending, while 40% increased it ^[10]. This indicates a diverse financial field among these patients.

• Staged Plans: Offer staged treatment plans that begin with the highest-priority concerns and allow for additional care after weight stabilization ^[10]. This helps patients manage costs while still addressing their aesthetic needs.
• Clear Pricing and Financing: Provide clear, upfront pricing for treatments and packages. Consider offering financing options to make treatments more accessible. Bio2 Laser Studio, for example, lists external RF body or facial contouring at $440 for a single session, $1,980 for a six-session package, and $175 for a monthly option ^[19]. This clear pricing helps reduce buying friction.
• High-Value Combinations: Focus on combinations that deliver noticeable results rather than promoting unlimited spending ^[10].

Building Trust and Managing Expectations:

Trust is a critical business asset in aesthetics. The 2025 ASDS consumer survey found that 94% of consumers used ratings and review sites when choosing a provider ^[16].

• Consistent Photography: Implement standardized clinical photography before, during, and after treatments. This provides objective evidence of results and helps manage patient expectations.
• Clear Credentials: Clearly display staff qualifications and device certifications.
• Plain Consent Language: Ensure all consent forms use clear, easy-to-understand language about risks, benefits, and expected outcomes.
• Outcome Tracking: Systematically track patient-reported outcomes, objective photographic grades, adverse events, refunds, and repeat care. This data is vital for validating treatment efficacy and improving protocols. Bio2 Laser Studio, for instance, could strengthen its claims by publishing standardized photography and patient-reported scores for its post-GLP-1 patients ^[19].
• Realistic Claims: Be realistic about what non-surgical treatments can achieve, especially for severe laxity. Avoid language that promises surgical-level results from device series ^[11].

Internal Tracking and Data Collection:

Clinical directors should establish strong internal tracking systems to monitor the effectiveness and demand for their post-GLP-1 service line.

• Track Consultation Sources: Understand how GLP-1 patients are finding the clinic.
• Monitor Concern Types and Laxity Grades: Analyze the prevalence of different concerns and severity levels to tailor service offerings.
• Treatment Selection and Completion Rates: Track which treatments are chosen and how often patients complete recommended series.
• Patient-Reported Improvement and Photography Grades: Collect systematic feedback and objective visual data on results.
• Adverse Events and Refunds: Closely monitor for complications and patient dissatisfaction.
• Surgical Referrals: Track the number of patients referred for surgery and the outcomes of those referrals.

This data should inform purchasing decisions, ensuring that new equipment or services are based on local utilization and measured results, not just broad market trends ^[15].

Building a Collaborative Network

Effective management of post-GLP-1 patients often requires collaboration with other medical professionals.

• Primary Care Physicians and Endocrinologists: Maintain communication with the patient’s GLP-1 prescribing doctor to understand their medication schedule, dosage, and any ongoing health issues. This ensures that aesthetic treatments align with the patient’s overall health plan.
• Dietitians and Nutritionists: Refer patients to nutrition experts, as diet plays a role in skin health and overall well-being during and after weight loss.
• Physical Therapists or Exercise Specialists: Encourage patients to incorporate resistance exercise, which can help with muscle strength that may be reduced after weight loss ^[7] and improve body contour.
• Dermatologists and Hair Specialists: For issues like hair loss (reported by 30% of patients in one study ^[7]) or other dermatological concerns, referrals to specialized professionals can be beneficial.

This collaborative network positions the clinic as part of a comprehensive care team, enhancing patient trust and satisfaction.

Marketing and Messaging

The marketing strategy for a post-GLP-1 service line should be carefully crafted to be supportive and informative, not exploitative.

• Focus on Solutions, Not Problems: Frame messaging around supporting patients through their weight loss journey and helping them feel confident in their new body, rather than highlighting “Ozempic face” or other negative terms.
• Educational Content: Provide educational materials about the types of skin changes that can occur, the range of available treatments (non-surgical and surgical), and the importance of staged care.
• Testimonials and Before-and-Afters: Use patient testimonials and ethical, standardized before-and-after photos (with consent) to showcase realistic results. The American Society for Dermatologic Surgery (ASDS) consumer survey found that nearly half of consumers said a provider’s social media presence influenced appointment decisions ^[16].
• Transparency: Be transparent about limitations of treatments, especially concerning severe laxity. This builds long-term trust.
• Incorporate GLP-1 Language: Small clinics like Bio2 Laser Studio have already integrated GLP-1 language into their public pages for services like external RF body and facial contouring ^[19]. This helps patients identify relevant services.

Example Operating Model Components:

To illustrate, consider the following components that a clinical director might implement:

Operating Model Component	Key Actions for Clinical Directors	Rationale/Evidence
Comprehensive Patient Intake	Develop a detailed questionnaire covering GLP-1 use, weight loss history, co-morbidities. Implement a standardized skin laxity grading system (mild, moderate, severe). Conduct baseline clinical photography and 3D imaging for objective assessment. Discuss patient expectations and budget limitations openly.	Risk factors include age >55, weight loss >20 lbs, rapid loss [6]. 44% of patients with 10-20% weight loss report sagging [7]. 63% of patients have multiple concerns [9].
Staged Treatment Planning	Prioritize volume restoration (fillers/fat grafting), then collagen stimulation (biostimulators, energy devices), then surface quality. Offer phased treatment plans to manage patient budgets and allow for adjustments during active weight loss. Reassess regularly, especially during active weight loss.	Average GLP-1 weight loss is 14.9-20.9% [4], requiring careful staging. 60% of patients reduce aesthetic spending [10]. Early significant corrections may look excessive with further weight loss [15].
Combination Modality Protocols	Develop protocols combining injectables (HA fillers + biostimulators). Integrate energy-based devices (external RF, focused ultrasound) with topical regimens. Train staff on safe and effective combination use.	Galderma trial: 85.7% reported less gaunt face with Sculptra + Restylane combination [16]. SkinCeuticals study: 44% reduction in laxity with topical + ultrasound [17].
strong Safety and Consent Procedures	Strict adherence to FDA guidelines, especially for RF microneedling risks. Clear differentiation between various RF technologies. Comprehensive patient consent forms detailing risks, benefits, and expected outcomes. Systematic adverse event reporting and internal review.	FDA warning on RF microneedling (Oct 2025) lists burns, scarring, fat loss [13]. ISAPS recommends delaying elective surgery during active GLP-1 symptoms [14].
Effective Referral Network	Establish formal referral pathways with plastic surgeons for severe laxity. Network with GLP-1 prescribers, dietitians, and exercise specialists. Provide clear criteria for surgical referral to patients and staff.	20% of GLP-1 patients had surgery, 39% considering surgery [11]. Body contouring surgeries are increasing [11]. 78.2% of post-bariatric patients reported excess skin [19].
Transparent Pricing & Budget Management	Offer clear, itemized pricing for treatments and packages. Explore financing options for patients. Provide realistic cost estimates for staged plans.	60% of GLP-1 patients reduced aesthetic spending [10]. Clear pricing reduces buying friction (e.g., Bio2 Laser Studio) [19].
Data-Driven Decision Making	Track patient acquisition channels, treatment mix, completion rates, patient satisfaction, and outcomes. Use internal data to inform equipment purchases and service expansions. Regularly review and adapt protocols based on measured results.	Forecasts are directional, direct studies are small [15], making internal tracking essential. 94% of consumers use ratings and reviews [16], requiring verifiable outcomes.

By adopting this comprehensive operating model, clinics can effectively meet the complex needs of the post-GLP-1 patient population. This approach balances clinical excellence with commercial viability, ensuring patient safety, satisfaction, and sustainable business growth.

The next section will discuss specific marketing strategies custom to attract and retain these patients, focusing on ethical communication and building trust.

16. Frequently Asked Questions

The rapid adoption of GLP-1 (glucagon-like peptide-1) medications for weight loss has introduced new considerations for aesthetic clinics and their patients. As individuals achieve significant weight reduction, many experience changes in skin laxity, facial volume, and body contours. Clinical directors and aesthetic professionals face increasing demand for treatments to address these concerns. This section answers common questions about post-GLP-1 skin changes, available treatments, and clinical management strategies, drawing on recent research and expert insights to provide a clear understanding of this evolving area of aesthetic medicine.

What are GLP-1 Medications and Why are They Relevant to Aesthetic Practices?

GLP-1 medications are a class of drugs primarily used for treating type 2 diabetes and, more recently, for weight management in individuals with obesity or overweight conditions. These medications work by mimicking natural hormones that regulate appetite and blood sugar. They lead to significant and sustained weight loss. For example, semaglutide trials showed an average weight loss of 14.9% over 68 weeks, and tirzepatide trials showed up to 20.9% weight loss over 72 weeks^[4],^[5]. Such substantial weight reduction can alter the body’s fat compartments and skin structure, leading to aesthetic concerns.

The relevance to aesthetic practices stems from the growing number of people using these drugs. In June 2026, 11% of U.S. adults were taking a GLP-1 drug for weight loss, a notable increase from 3% in 2024. Furthermore, 15% of U.S. adults had used one at some point^[1]. This expansion is not limited to the U.S.; Novo Nordisk, a key manufacturer, expanded Wegovy availability from 17 countries in 2024 to 52 countries in 2025, reaching 3.6 million people with its obesity medicines in 2025^[3],^[18]. This increase in users means a larger potential patient pool for aesthetic treatments addressing post-weight loss changes. Clinics are already seeing this demand; a survey of 406 aesthetic health professionals reported a mean 137% increase in GLP-1 patients from 2023 to 2024^[8]. These patients often seek help for midface volume loss, face and neck laxity, and loose body skin^[8].

The term “Post-GLP-1” refers to the period after major weight loss, which does not necessarily mean stopping the medication. The World Health Organization (WHO) considers obesity a chronic, relapsing disease and supports long-term GLP-1 therapy^[2]. Therefore, clinics need to plan care for patients during active weight loss, stabilization, and maintenance phases^[2].

How Common Are Skin Changes After GLP-1 Weight Loss?

Skin changes are a common consequence of significant weight loss, including that achieved with GLP-1 medications. However, reported rates can vary due to different study methodologies and patient groups. A 2026 survey of 504 GLP-1 users found that 38.7% reported skin changes^[6]. Specific concerns included facial volume loss (10.9%), sagging (8.3%), and jowling (7.7%)^[6]. A separate 2026 study noted skin sagging in 44% of individuals who had lost 10% to 20% of their body weight^[7]. This study also found decreased facial volume in 37% and hair loss in 30% of the subgroup^[7].

The speed and amount of weight loss, along with patient age, play a role in the development of skin changes. The 2026 survey observed higher risk for individuals over 55 and those who lost more than 20 pounds. More than half of affected respondents (55.1%) noticed skin changes within the first five months of treatment^[6]. Galderma’s international patient research in 2025 similarly indicated that significant facial changes often appear within three to six months after starting treatment^[9]. Seventy-seven percent of these patients reported at least one negative change, such as sagging, wrinkles, or a tired appearance^[9].

These findings suggest that while many patients are satisfied with their weight loss (92% satisfaction with medication, 84% improved body image in one study), aesthetic concerns can still arise^[6]. Clinics should perform baseline photography and skin assessment early in the patient’s journey, even before major appearance changes occur^[6].

What Specific Aesthetic Concerns Arise from GLP-1 Weight Loss?

GLP-1-associated weight loss can lead to several aesthetic concerns, primarily related to volume loss and skin laxity. These issues are often interconnected and can affect multiple body areas. According to a McKinsey survey, 63% of GLP-1 aesthetic patients requested care for several linked issues, such as laxity, poor skin quality, and facial deflation^[10]. This supports an assessment approach based on tissue problems rather than individual body parts.

Common concerns include:

• Facial Volume Loss: As facial fat reduces, patients may experience a “gaunt” or “hollowed-out” appearance, particularly in the midface and temples. This was reported by 10.9% of users in one survey and 37% in another^[6],^[7].
• Skin Sagging and Laxity: The skin, which stretched to accommodate a larger body mass, may not retract fully after weight loss, leading to loose or sagging skin. This affects various areas, including the face (8.3% reported sagging, 7.7% jowling)^[6], neck, arms, abdomen, thighs, and buttocks^[5].
• Poor Skin Quality: Weight loss can sometimes impact overall skin quality, affecting texture and elasticity.
• Body Contour Changes: Beyond facial changes, significant weight loss can alter the contours of the body. Procedures like abdominoplasty, arm lifts, thigh lifts, and buttock lifts, which address excess skin, were already seeing increases before the full impact of GLP-1 treatments was felt^[13]. A Chinese post-bariatric study found 78.2% of patients had excess skin, with 37.9% wanting body-contouring surgery^[23].

It is important for clinicians to recognize that these issues are distinct. For example, hyaluronic acid filler can replace facial volume but cannot remove hanging skin. Energy treatments might improve mild laxity but will not restore large missing fat compartments. Surgery remains the primary option for removing severe excess skin^[6].

What are the Main Treatment Modalities for Post-GLP-1 Skin Laxity and Volume Loss?

The main treatment modalities for post-GLP-1 aesthetic changes span both non-surgical and surgical options, with a growing emphasis on combination approaches and tissue support rather than fat reduction. The goal shifts from removing fat to restoring volume, supporting tissue, and excising severe excess skin.

Non-Surgical Treatments

• Hyaluronic Acid Fillers: These are primarily used to replace lost facial volume. In a survey of 406 providers, hyaluronic acid filler was considered the best facial treatment for an average of 47% of GLP-1 patients^[8]. It is most effective for midface or temple deflation^[8].
• Biostimulators: Products like Sculptra stimulate the body’s own collagen production over time, addressing skin quality and firmness. Interest in biostimulators is growing, with 48% of patients expressing interest in Galderma’s research, and 54% of clinics offering or considering them^[19]. A Galderma phase IV study combining Sculptra with Restylane showed 85.7% of patients felt their face looked less gaunt after nine months, and 91.4% would recommend the regimen^[17].
• External Radiofrequency (RF) and Ultrasound: These energy-based devices can offer modest tightening for mild to moderate skin laxity. Non-invasive ultrasound and external RF devices are likely to benefit from the demand for low-downtime care. For example, a focused-ultrasound and topical study reported a 44% reduction in graded laxity at 12 weeks^[17]. A separate manufacturer study found improvement in 93% of treated upper arms after two ultrasound sessions^[21]. It is important to note that these results may not apply to severe post-weight-loss skin^[17].
• RF Microneedling: This combines microneedling with radiofrequency energy to stimulate collagen. However, the U.S. Food and Drug Administration (FDA) issued a safety communication in October 2025 regarding potential risks such as burns, scarring, fat loss, disfigurement, and nerve damage with certain uses^[13]. This warning applies specifically to RF microneedling and not all forms of RF treatment. The safety concerns may lead to a shift in demand toward non-needle energy devices or clinics with strong medical oversight^[13].

Surgical Treatments

Surgery remains the main referral path for significant hanging or severe excess skin that cannot be addressed non-surgically. In 2024, 20% of GLP-1 patients tracked by American Society of Plastic Surgeons members had already undergone plastic surgery, with another 39% considering it^[12]. Common surgical procedures include:

• Abdominoplasty (Tummy Tuck): To remove excess skin and tighten abdominal muscles. In the U.S., 171,064 abdominoplasties were performed in 2024^[13].
• Arm Lifts (Brachioplasty): To remove loose skin from the upper arms. These rose 2% from 2023 to 2024^[13].
• Thigh Lifts: To address sagging skin on the thighs. These rose 3% from 2023 to 2024^[13].
• Buttock Lifts: To reshape the buttocks by removing excess skin. These also rose 3% from 2023 to 2024^[13].

It is crucial for clinics offering non-surgical options to have a clear surgical referral pathway for patients with severe skin excess^[12].

Why are Combination Treatments Gaining Popularity?

Combination treatment plans are gaining popularity because GLP-1 weight loss often leads to several interconnected aesthetic concerns rather than a single isolated issue. As noted, 63% of GLP-1 aesthetic patients in a McKinsey survey requested care for several linked problems, such as laxity, poor skin quality, and facial deflation^[10]. Standard packages based on one device or one injection type may not fully address these complex needs^[10].

The rationale for combination therapy is to address multiple aspects of skin and volume changes concurrently. For example, a patient might experience both facial volume loss and skin laxity. Treating only one issue would yield an incomplete result. Combining hyaluronic acid fillers for immediate volume replacement with biostimulators for long-term collagen production can offer a more comprehensive and natural-looking outcome^[17]. A Galderma phase IV trial combining Sculptra with Restylane reported that 85.7% of patients felt their face looked less gaunt after nine months, and 91.4% would recommend the regimen^[17]. While this study was company-sponsored and did not isolate the contribution of each product, it supports the benefit of combined volume replacement and collagen stimulation^[17].

A practical sequence for combination care could involve:

1. Assessment: Thorough evaluation of the patient’s specific concerns, including age, weight lost, speed of loss, medication stage, and skin quality.
2. Conservative Structural Volume Correction: Addressing immediate volume deficits, especially in the face, with fillers.
3. Collagen and Skin Quality Treatment: Incorporating biostimulators or energy-based devices to improve skin firmness and texture over time.
4. Surface Treatments: Addressing superficial skin concerns as a final step.

Reassessment should occur during active weight loss, and large early corrections should be avoided, as further weight changes could alter the result^[15].

What is the FDA Warning About RF Microneedling and How Does it Affect Treatment Choices?

On October 15, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication concerning potential risks associated with certain uses of radiofrequency (RF) microneedling devices. The warning highlighted reported adverse events, including burns, scarring, unwanted fat loss, disfigurement, and nerve damage^[13]. The FDA clarified that RF microneedling is a medical procedure and advised patients to seek licensed providers with device-specific training. Providers were encouraged to report complications^[13].

This warning is significant for aesthetic practices for several reasons:

• Increased Safety and Consent Pressure: Clinics offering RF microneedling must ensure comprehensive patient consent, clearly outlining the risks. Staff must have proper training and adhere to device-specific protocols to minimize adverse events.
• Differentiation of RF Technologies: The FDA warning specifically targets RF microneedling. It does not apply to every form of RF treatment. Clinical directors should educate their staff and patients about the distinctions between needle-based RF, external RF, minimally invasive subdermal RF, and other heat-based devices. Marketing all these technologies under a single “RF tightening” label can obscure important differences in depth of action and potential risks^[14].
• Potential Shift in Demand: The safety communication may cause a shift in patient and provider preference toward non-needle energy devices (such as external ultrasound or non-needle RF) or toward providers with stronger medical oversight. This is an inference based on the warning, not yet a measured sales trend^[14].
• Need for strong Protocols: Every service line involving energy-based devices needs written rules covering medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse-event reporting, and referral pathways^[14].

Ultimately, the FDA’s communication underscores the importance of patient safety, provider training, and transparent communication regarding medical aesthetic procedures, particularly as new technologies and patient populations emerge.

What are the Financial Considerations for Patients Seeking Post-GLP-1 Aesthetic Treatments?

The financial aspect is a significant factor for patients considering aesthetic treatments after GLP-1-induced weight loss. While weight loss may increase appearance concerns, it does not always translate into an unlimited budget for aesthetic care. A McKinsey study found that about 60% of GLP-1 patients reduced their total aesthetic spending, while 40% increased it^[11]. This suggests that many patients are also allocating funds to other aspects of their weight loss journey, such as medication costs, nutrition, fitness, and new clothing^[11].

For clinics, this means understanding the patient’s budget limitations and offering solutions that provide clear value. Key financial considerations and strategies include:

• Staged Treatment Plans: Offering treatment plans that can be phased over time allows patients to manage costs. Clinics can begin with the highest-priority concern and add subsequent treatments as the patient’s weight stabilizes and their budget allows^[11].
• Clear Pricing: Transparency in pricing for individual treatments and packages is crucial. Patients need to understand the costs involved and the expected benefits. Bio2 Laser Studio, for instance, publishes clear pricing for its external RF body and facial contouring services, offering single sessions, multi-session packages, and monthly options^[24].
• Financing Options: Providing third-party financing options can make treatments more accessible for patients who might not be able to pay upfront for comprehensive care^[11].
• High-Value Combinations: Focusing on combination treatments that offer good value and address multiple concerns can be more appealing than single, expensive treatments with limited scope. The goal is to provide clear estimates of likely benefit per treatment and overall treatment plan^[11].

Clinics should expect demand for thoughtful, budget-conscious approaches rather than patients with unlimited spending capacity. Successful practices will be those that can adapt their offerings and financial models to meet these patient needs.

When is the Best Time to Start Aesthetic Treatments During or After GLP-1 Therapy?

The timing of aesthetic treatments for GLP-1 patients is a subject of ongoing discussion among experts. The “Post-GLP-1” designation usually refers to the period after major weight loss, not necessarily after stopping the medication, as many patients remain on GLP-1 drugs long-term^[2]. Since skin changes can appear relatively early in the weight loss process, timing becomes a critical consideration.

Some key points regarding treatment timing:

• Early Onset of Changes: Significant facial changes can appear within three to six months of starting GLP-1 treatment^[9]. More than half of those reporting skin changes in one survey noticed them within the first five months^[6]. This suggests that aesthetic concerns can begin while patients are still actively losing weight.
• Debate on Early Treatment: There is some debate about starting aesthetic treatments, particularly injectables, during active weight loss. A 10-expert Delphi panel, supported by a Galderma grant, found that 70% of experts would start poly-L-lactic acid (a biostimulator) at the same time as medication-associated weight loss. However, the panel was split evenly on the timing of fat transfer procedures^[15]. This highlights that expert opinions can differ, especially for more invasive procedures.
• Conservative Approach During Active Loss: A consensus often favors a conservative approach during active weight loss. The recommendation is to conduct an initial assessment, followed by conservative structural volume correction, then collagen and skin quality treatments, and finally surface treatments. It is generally advised to avoid large early corrections, as further weight changes could make these corrections appear excessive or unbalanced later^[15].
• Delaying Elective Surgery: For surgical interventions, the International Society of Aesthetic Plastic Surgery (ISAPS) guidance recommends delaying elective surgery during GLP-1 dose escalation and while patients experience active gastrointestinal symptoms such as nausea, vomiting, abdominal pain, or constipation^[14]. This necessitates coordination with the patient’s medication prescriber.
• Weight Stability for Optimal Surgical Outcomes: For extensive body contouring surgeries, achieving weight stability is generally preferred to ensure optimal, lasting results. A 2026 study from West Virginia University examining panniculectomy patients found possible differences in wound healing for those taking GLP-1 medicines before surgery, but no clear rise in overall surgical risk, indicating that blanket assumptions should be avoided^[14].

In summary, early baseline photography and skin assessment are beneficial. Non-surgical treatments can begin cautiously during active weight loss, with a focus on conservative and staged approaches. Surgical interventions are typically best performed after weight stabilization and resolution of medication-related side effects.

How Should Clinical Directors Prepare Their Practices for the Growing Demand?

Clinical directors must strategically prepare their practices to effectively address the growing demand for post-GLP-1 aesthetic treatments. The patient pool is expanding rapidly; U.S. GLP-1 use for weight loss increased from 3% in 2024 to 11% in June 2026^[1]. Clinics reported a mean 137% increase in GLP-1 patients from 2023 to 2024^[8]. This requires a thoughtful approach to service offerings, staffing, and patient management.

Key Preparatory Steps:

1. Understand the Evolving Patient Profile:
   • Broad Concerns: Expect patients with multiple, linked aesthetic issues, including laxity, poor skin quality, and facial deflation^[10]. Treatments should address the underlying tissue problems, not just isolated body parts.
   • Varying Needs: Recognize that while 41% of GLP-1 patients under ASPS member care were considering non-surgical options, 39% were considering surgery^[12]. A clinic’s service line should support both pathways.
   • Budget Sensitivity: Acknowledge that about 60% of GLP-1 patients reduced their overall aesthetic spending^[11]. Offer staged plans, clear pricing, and high-value combinations.
2. Diversify Treatment Modalities:
   • Shift Focus: Move from fat reduction messaging to an emphasis on tissue support, volume restoration, and skin tightening.
   • Injectables: Ensure expertise in hyaluronic acid fillers for volume replacement and biostimulators for collagen production^[8],^[19].
   • Energy-Based Devices: Invest in or utilize external ultrasound and non-needle radiofrequency devices for mild to moderate laxity^[21]. Be aware of and address the FDA warning regarding RF microneedling by providing clear distinctions and strong medical oversight^[13].
   • Surgical Referrals: Establish strong, formal referral relationships with plastic surgeons for patients with severe excess skin, as energy treatments cannot replace surgery in these cases^[14].
3. Implement strong Clinical Protocols:
   • Comprehensive Intake: Gather information on age, percentage and speed of weight loss, medication stage, facial volume loss, affected body sites, skin quality, weight stability, nutrition, strength, and patient priorities^[6].
   • Laxity Grading: Use a three-level laxity grade (mild, moderate, severe) to guide device selection, combination therapy, or surgical referral^[6].
   • Staged Care Plans: Develop phased treatment strategies, avoiding large early corrections during active weight loss to prevent suboptimal outcomes after further changes^[15].
   • Safety Measures: Ensure strict protocols for medication stage, active symptoms, weight stability, nutrition screening, device settings, staff credentials, consent, photography, adverse-event reporting, and referral^[14].
4. Focus on Transparency and Trust:
   • Clear Communication: Manage patient expectations by describing likely degrees of improvement rather than promising prevention or complete removal of loose skin^[14].
   • Digital Presence: Recognize that 94% of consumers use ratings and review sites and nearly half are influenced by a provider’s social media when choosing a clinic^[16].
   • Outcome Tracking: Implement rigorous internal tracking of consultation source, weight-loss stage, concern type, laxity grade, selected treatment, series completion, patient-reported improvement, photography grades, adverse events, refunds, repeat care, and surgical referrals. This data will strengthen future claims and support evidence-based practice^[24]. Bio2 Laser Studio, for example, provides clear pricing and packages, but would benefit from publishing controlled outcome data to support stronger efficacy claims^[24].
5. Staff Training and Education:
   • Continuous Learning: Keep staff updated on the latest research regarding GLP-1 medications and their aesthetic effects.
   • Interdisciplinary Knowledge: Train staff to understand the medical context of GLP-1 therapy, including potential side effects and the importance of coordination with prescribing physicians.

By adopting these strategies, clinical directors can build a strong, patient-centered, and financially sustainable post-weight loss service line that meets the unique needs of this growing patient population.

What is the Difference Between Weight Loss in Clinical Trials and Real-World Patient Outcomes?

The weight loss figures reported in GLP-1 clinical trials, while impressive, represent optimal conditions and may not perfectly reflect real-world patient outcomes. Understanding this difference is important for managing patient expectations in an aesthetic practice.

Clinical Trial Results:

• Controlled Environments: Clinical trials, such as the STEP 1 trial for semaglutide and SURMOUNT-1 trial for tirzepatide, are conducted under highly controlled conditions. Participants adhere strictly to medication regimens, often receive close medical supervision, and may have additional support for diet and exercise^[4],^[5].
• Significant Averages: These trials report substantial average weight loss: 14.9% with semaglutide over 68 weeks and up to 20.9% with tirzepatide over 72 weeks^[4],^[5]. These figures demonstrate the medication’s potential for significant body transformation.

Real-World Patient Outcomes:

• Variability: In real-world settings, patient adherence to medication, diet, and exercise can vary. Factors like cost, insurance coverage, access to healthcare, and personal lifestyle choices influence actual weight loss results.
• Concentrated Demand: Despite global expansion, the World Health Organization (WHO) expects GLP-1 medicines to reach fewer than 10% of those who could benefit by 2030, primarily due to manufacturing, price, coverage, and health system capacity issues^[2]. This means aesthetic demand will likely remain concentrated in areas with greater access and disposable income^[2].
• Psychological and Financial Factors: While GLP-1 usage is rising (11% of U.S. adults in June 2026)^[1], a significant portion (60%) of these patients reduce overall aesthetic spending, even if concerns about appearance increase^[11]. This indicates that financial constraints or other priorities can affect a patient’s pursuit of aesthetic care.

For clinical directors, the “real world” involves managing a diverse patient population with varied weight loss results, aesthetic concerns, and financial limitations. While trial data highlight the potential for body changes, individual patient consultations must consider the actual weight loss achieved and the patient’s readiness for aesthetic intervention.

What Role Does Patient Satisfaction Play in Post-GLP-1 Aesthetic Care?

Patient satisfaction is a central aspect of post-GLP-1 aesthetic care, influencing treatment choices, adherence, and clinic reputation. While patients may be satisfied with their weight loss, appearance concerns can still impact their overall well-being. A 2026 study found that 92% of GLP-1 users were satisfied with their medication, 84% reported improved body image, and 68.5% reported greater self-confidence^[6]. However, 38.7% still reported skin changes^[6].

This suggests that aesthetic care should aim to enhance the positive outcomes of weight loss rather than framing the weight loss as an aesthetic failure. The goal is to support the patient’s improved health and self-image by addressing specific appearance concerns. For instance, in a Galderma study, 85.7% of patients felt their face looked less gaunt after a combination injectable treatment, and 91.4% would recommend the regimen^[17]. This indicates high satisfaction with interventions that restore volume and improve skin quality.

Factors Contributing to Patient Satisfaction:

• Realistic Expectations: Clear and honest communication about what treatments can achieve is crucial. Claims should describe likely degrees of improvement, not promise prevention or complete removal of loose skin^[14].
• Customized Treatment Plans: Since 63% of patients have several concerns^[10], personalized plans that address multiple issues will lead to better satisfaction than one-size-fits-all approaches.
• Transparent Pricing: As many patients are budget-conscious, clear pricing and staged payment options can reduce anxiety and increase satisfaction^[11].
• Positive Patient Experience: This includes professional staff, clear credentials, comfortable clinic environments, and easy access to information. Given that 94% of consumers use ratings and review sites, and nearly half are influenced by social media, trust signals are paramount^[16].
• Visible Results: Standardized photography and patient-reported outcome measures help track progress and demonstrate improvements, which contributes to patient satisfaction and supports the clinic’s claims^[24].

By focusing on these elements, clinics can ensure that aesthetic interventions for GLP-1 patients contribute positively to their overall weight loss journey and satisfaction.

What are the Ethical Considerations for Marketing Aesthetic Treatments to GLP-1 Patients?

Marketing aesthetic treatments to GLP-1 patients carries several ethical considerations. Clinics must balance the commercial opportunity with patient well-being and responsible communication. The commercial market is large, with GLP-1 usage rising, and patient concern about appearance changes growing^[1],^[8]. However, this demographic also faces financial constraints and unique physiological changes.

Ethical Marketing Practices:

1. Avoid Exploitation: Do not exploit body image insecurities that may arise from rapid weight loss. Frame aesthetic treatments as supporting the patient’s health and confidence journey, rather than fixing a “problem” created by GLP-1 use^[6].
2. Realistic Expectations: Marketing materials must set realistic expectations. Avoid exaggerated claims about what treatments can achieve. Clearly communicate potential results, downtime, and risks. This is especially important given the FDA’s warning about RF microneedling and the need for careful consent^[13].
3. Transparency in Pricing: Be clear about costs, including packages, follow-up treatments, and potential need for maintenance. Given that 60% of GLP-1 patients reduce aesthetic spending, transparency helps patients make informed financial decisions^[11].
4. Scientific Accuracy: Base marketing claims on sound scientific evidence and clinical data. Avoid generalizations, especially when discussing energy-based devices. Differentiate between needle-based RF, external RF, and other technologies, as their risks and benefits are not interchangeable^[14].
5. Integration with Medical Journey: Acknowledge that GLP-1 therapy is a medical journey. Position aesthetic treatments as complementary to, and integrated with, their ongoing health management.
6. Referral Clarity: For cases of severe skin laxity requiring surgery, marketing should clearly indicate the need for surgical referral and not over-promise non-surgical solutions. This includes being transparent about the limitations of energy devices for significant skin excess^[14].
7. Data Protection and Privacy: Handle patient data, including before-and-after photos, with strict adherence to privacy regulations and ethical consent practices.

Clinics like Bio2 Laser Studio are already linking external RF body and facial contouring to GLP-1 weight loss in their public messaging, offering clear pricing structures^[24]. To enhance ethical positioning, such practices would benefit from publishing controlled outcomes data specific to GLP-1 patients, alongside transparent pricing and clear disclaimers about individual results. Ethical marketing builds trust, which is a valuable asset in attracting and retaining patients in this evolving market^[16].

How Does the Global field Affect Demand for Post-GLP-1 Aesthetic Treatments?

The global expansion of GLP-1 medications is influencing the demand for associated aesthetic treatments, but access and demand are uneven across regions. Novo Nordisk’s Wegovy, for example, expanded from 17 countries in 2024 to 52 in 2025, reaching 3.6 million people globally^[3],^[18]. This suggests a widening market for aesthetic procedures related to weight loss.

Uneven Access and Demand:

• Concentration in Certain Markets: The World Health Organization (WHO) estimates that fewer than 10% of those who could benefit from GLP-1 medicines will receive them by 2030^[2]. Factors like manufacturing capacity, price, insurance coverage, and local prescribing rules limit access. Therefore, post-weight-loss aesthetic demand will likely remain concentrated in countries and cities with better GLP-1 access and higher disposable income^[2].
• Lag Effect: Aesthetic inquiries will typically follow a delay after prescription growth, as it takes time for patients to achieve significant weight loss and notice skin changes. Galderma’s research points to significant facial changes appearing three to six months after treatment initiation^[9]. Clinics in newly opened GLP-1 markets should anticipate this lag.
• Cultural and Regulatory Differences: Aesthetic preferences and regulatory environments vary globally. What is popular or approved in one region may not be in another. For instance, a Chinese post-bariatric study showed high rates of excess skin (78.2%) and interest in body contouring surgery (37.9%), but cost and concerns about risks were barriers^[23].

Global Aesthetic Market Context:

• Large Existing Market: Post-weight-loss care is entering an already large and established global aesthetic market. In 2024, nearly 38 million aesthetic procedures were performed worldwide, including over 17.4 million surgical and 20.5 million non-surgical procedures, representing a 42.5% increase since 2020^[14]. This indicates a pre-existing capacity and patient acceptance for aesthetic treatments.
• Early Indicators: In 2024, global facial fat grafting procedures rose by 19.2%, while overall face and head procedures increased by 4.3%^[14]. This suggests that the early commercial effects of GLP-1 weight loss might first appear in facial volume and skin services.

Clinical directors with international operations or those planning expansion should use country and city prescription data to guide their strategies. Independent clinics should rely on local consultation volume and relationships with prescribers rather than assuming uniform global demand^[18]. Device manufacturers, similarly, should avoid equating global obesity prevalence directly with aesthetic market size, as access and affordability remain significant barriers in many parts of the world^[18].

The information presented in this section provides a foundational understanding of the frequently asked questions surrounding post-GLP-1 skin laxity. The next section will explore specific case studies and successful clinical approaches in greater detail, building upon these insights to offer practical examples for implementation.

References

1. Home | ISAPS
2. In U.S., GLP-1 Usage Reaches New High
3. Novo Nordisk Annual Report 2025
4. WHO issues global guideline on the use of GLP-1 medicines in treating obesity
5. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
6. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
7. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss – PubMed
8. GLP-1s are boosting demand for medical aesthetics | McKinsey
9. Interest in Aesthetic Health Remained Consistent Despite Economic Uncertainty in 2024, According to New Report from American Society of Plastic Surgeons | ASPS
10. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss – PubMed
11. Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss | Galderma
12. Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy – PubMed
13. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication | FDA
14. GLP-1s are boosting demand for medical aesthetics | McKinsey
15. Consensus Statements on Managing Aesthetic Needs in Prescription Medication‐Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study
16. In U.S., GLP-1 Usage Reaches New High
17. WHO issues global guideline on the use of GLP-1 medicines in treating obesity
18. Novo Nordisk Annual Report 2025
19. Financial performance – Novo Nordisk Annual Report 2025
20. Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine
21. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
22. Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face” – PubMed
23. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss – PubMed
24. https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
25. GLP-1s are boosting demand for medical aesthetics | McKinsey
26. GLP-1s are boosting demand for medical aesthetics | McKinsey
27. Interest in Aesthetic Health Remained Consistent Despite Economic Uncertainty in 2024, According to New Report from American Society of Plastic Surgeons | ASPS
28. Plastic Surgery Statistics | American Society of Plastic Surgeons
29. Global Survey 2024: Full Report and Press Releases | ISAPS
30. Global Survey 2024: Full Report and Press Releases | ISAPS
31. Consumer Survey on Cosmetic Dermatologic Procedures
32. Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss | Galderma
33. Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy – PubMed
34. In U.S., GLP-1 Usage Reaches New High
35. 2025 at a glance – Novo Nordisk Annual Report 2025
36. https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
37. WHO issues global guideline on the use of GLP-1 medicines in treating obesity
38. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
39. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
40. Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey – Olivero – 2026 – Journal of Cosmetic Dermatology – Wiley Online Library
41. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss – PubMed
42. https://www.galderma.com/sites/default/files/2025-07/Galderma_MDWL_Report_12.pdf
43. Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss | Galderma
44. Consensus Statements on Managing Aesthetic Needs in Prescription Medication‐Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study
45. Global Survey 2024: Full Report and Press Releases | ISAPS
46. https://api.sofwave.com/app/uploads/2024/12/MK00105_E-Upper-Arm-Lax-Skin-Lifting_Clinical-Study-Summary.pdf
47. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication | FDA
48. Plastic Surgery Statistics | American Society of Plastic Surgeons
49. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication | FDA
50. https://www.isaps.org/media/tw1j4oko/260522_isaps-ps-emerging-guidance_rise-of-glp-1-ra-drugs_final.pdf
51. Weight Loss Medications May Affect Some Complications After Panniculectomy | ASPS
52. 2024 Plastic Surgery Statistics Report
53. GLP-1s are boosting demand for medical aesthetics | McKinsey
54. Consumer Survey on Cosmetic Dermatologic Procedures
55. Radiofrequency Body Contouring – Body Sculpting
56. Novo Nordisk Annual Report 2025
57. Interest in Aesthetic Health Remained Consistent Despite Economic Uncertainty in 2024, According to New Report from American Society of Plastic Surgeons | ASPS
58. Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss | Galderma
59. Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy – PubMed
60. Experience of Excess Skin and Attitude to Body Contouring Surgery of a Chinese Post-Bariatric Population – PubMed
61. Radiofrequency Body Contouring – Body Sculpting